
<html lang="en"     class="pb-page"  data-request-id="66450701-5965-46c3-83bf-85af1a7c8cc4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2019.62.issue-13;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.9b00280"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors" /></meta><meta name="dc.Creator" content="Yun  Wu" /></meta><meta name="dc.Creator" content="Beilei  Wang" /></meta><meta name="dc.Creator" content="Junjie  Wang" /></meta><meta name="dc.Creator" content="Shuang  Qi" /></meta><meta name="dc.Creator" content="Fengming  Zou" /></meta><meta name="dc.Creator" content="Ziping  Qi" /></meta><meta name="dc.Creator" content="Feiyang  Liu" /></meta><meta name="dc.Creator" content="Qingwang  Liu" /></meta><meta name="dc.Creator" content="Cheng  Chen" /></meta><meta name="dc.Creator" content="Chen  Hu" /></meta><meta name="dc.Creator" content="Zhenquan  Hu" /></meta><meta name="dc.Creator" content="Aoli  Wang" /></meta><meta name="dc.Creator" content="Li  Wang" /></meta><meta name="dc.Creator" content="Wenchao  Wang" /></meta><meta name="dc.Creator" content="Tao  Ren" /></meta><meta name="dc.Creator" content="Yujiao  Cai" /></meta><meta name="dc.Creator" content="Mingfeng  Bai" /></meta><meta name="dc.Creator" content="Qingsong  Liu" /></meta><meta name="dc.Creator" content="Jing  Liu" /></meta><meta name="dc.Description" content="Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor..." /></meta><meta name="Description" content="Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="June 17, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00280" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright Â© 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00280" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00280" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00280" /></link>
        
    
    

<title>Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00280" /></meta><meta property="og:title" content="Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0019.jpeg" /></meta><meta property="og:description" content="Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor compound 18 (CHMFL-KIT-64), which is potent against c-KIT wt and a broad spectrum of drug-resistant mutants with improved bioavailability. 18 exhibits single-digit nM potency against c-KIT kinase and c-KIT T670I mutants in the biochemical assay and displays great potencies against most of the gain-of-function mutations in the juxtamembrane domain, drug-resistant mutations in the ATP binding pocket (except V654A), and activation loops (except D816V). In addition, 18 exhibits a good in vivo pharmacokinetic (PK) profile in different species including mice, rats, and dogs. It also displays good in vivo antitumor efficacy in the c-KIT T670I, D820G, and Y823D mutant-mediated mice models as well as in the c-KIT wt patient primary cells which are known to be imatinib-resistant. The potent activity against a broad spectrum of clinically important c-KIT mutants combining the good in vivo PK/pharmacodynamic properties of 18 indicates that it might be a new potential therapeutic candidate for gastrointestinal stromal tumors." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00280"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00280">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-13/achre4.2021.54.issue-13/20210706/achre4.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-26/aamick.2021.13.issue-26/20210707/aamick.2021.13.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-13/accacs.2021.11.issue-13/20210702/accacs.2021.11.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-13/acncdm.2021.12.issue-13/20210707/acncdm.2021.12.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-27/acsodf.2021.6.issue-27/20210713/acsodf.2021.6.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-27/ascecg.2021.9.issue-27/20210712/ascecg.2021.9.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-27/ancham.2021.93.issue-27/20210713/ancham.2021.93.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-27/bichaw.2021.60.issue-27/20210713/bichaw.2021.60.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-13/cmatex.2021.33.issue-13/20210713/cmatex.2021.33.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-13/enfuem.2021.35.issue-13/20210701/enfuem.2021.35.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-13/esthag.2021.55.issue-13/20210706/esthag.2021.55.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-26/iecred.2021.60.issue-26/20210707/iecred.2021.60.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-13/inocaj.2021.60.issue-13/20210705/inocaj.2021.60.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-26/jafcau.2021.69.issue-26/20210707/jafcau.2021.69.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-13/jmcmar.2021.64.issue-13/20210708/jmcmar.2021.64.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-13/joceah.2021.86.issue-13/20210702/joceah.2021.86.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-26/jpcafh.2021.125.issue-26/20210708/jpcafh.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-26/jpcbfk.2021.125.issue-26/20210708/jpcbfk.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-26/jpccck.2021.125.issue-26/20210708/jpccck.2021.125.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-26/jpclcd.2021.12.issue-26/20210708/jpclcd.2021.12.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-26/jacsat.2021.143.issue-26/20210707/jacsat.2021.143.issue-26.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-27/langd5.2021.37.issue-27/20210713/langd5.2021.37.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-13/mamobx.2021.54.issue-13/20210713/mamobx.2021.54.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-13/orlef7.2021.23.issue-13/20210702/orlef7.2021.23.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-13/orgnd7.2021.40.issue-13/20210712/orgnd7.2021.40.issue-13.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00280&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00280&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00280&amp;href=/doi/10.1021/acs.jmedchem.9b00280" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 13</span><span class="cit-fg-pageRange">, 6083-6101</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/13" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00270" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00355" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Yun Wu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yun Wu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yun++Wu">Yun Wu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Beilei Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Beilei Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Beilei++Wang">Beilei Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Junjie Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Junjie Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Junjie++Wang">Junjie Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Shuang Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuang Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuang++Qi">Shuang Qi</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Fengming Zou</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fengming Zou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fengming++Zou">Fengming Zou</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Ziping Qi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ziping Qi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ziping++Qi">Ziping Qi</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Feiyang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Feiyang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Feiyang++Liu">Feiyang Liu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Qingwang Liu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingwang Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingwang++Liu">Qingwang Liu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Cheng Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Chen">Cheng Chen</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Chen Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chen Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chen++Hu">Chen Hu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Zhenquan Hu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Zhenquan Hu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Zhenquan++Hu">Zhenquan Hu</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Aoli Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Aoli Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Aoli++Wang">Aoli Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Li Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Li Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Li++Wang">Li Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Wenchao Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenchao Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenchao++Wang">Wenchao Wang</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Tao Ren</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tao Ren</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precedo Pharmaceuticals Inc, Hefei, Anhui 230088, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Ren">Tao Ren</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Yujiao Cai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yujiao Cai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of General Surgery, Second Hospital Affiliated to Army Medical University, Xinqiao Road, Chongqing 400037, P. R. China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yujiao++Cai">Yujiao Cai</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Mingfeng Bai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingfeng Bai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Molecular Imaging Laboratory, Department of Radiology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingfeng++Bai">Mingfeng Bai</a></span></div></div></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor">Qingsong Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qingsong Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">University of Science and Technology of China, Hefei, Anhui 230026, P. R. China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Institutes of Physical Science and Information Technology, Anhui University, Hefei, Anhui 230601, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#7706041b1e024e40371f1a111b591614591419"><span class="__cf_email__" data-cfemail="cfbebca3a6baf6f88fa7a2a9a3e1aeace1aca1">[emailÂ protected]</span></a>. Phone: 86-551-65595161 (Q.L.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qingsong++Liu">Qingsong Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link">http://orcid.org/0000-0002-7829-2547</a></div></div></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor">Jing Liu</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jing Liu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">High Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</div><div class="loa-info-affiliations-info">Precision Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</div><div class="loa-info-affiliations-info">Precision Targeted Therapy Discovery Center, Institute of Technology Innovation, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230088, P. R. China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#afc5c6c1c8c3c6daefc7c2c9c381cecc81ccc1"><span class="__cf_email__" data-cfemail="0a6063646d66637f4a62676c66246b69246964">[emailÂ protected]</span></a>. Phone: 86-551-65593186 (J.L.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jing++Liu">Jing Liu</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link">http://orcid.org/0000-0001-9513-3591</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00280&amp;href=/doi/10.1021%2Facs.jmedchem.9b00280" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 13</span><span class="cit-pageRange">, 6083â6101</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">June 17, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>12 February 2019</li><li><span class="item_label"><b>Published</b> online</span>17 June 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 July 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00280" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00280</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D6083%26pageCount%3D19%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DYun%2BWu%252C%2BBeilei%2BWang%252C%2BJunjie%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D13%26contentID%3Dacs.jmedchem.9b00280%26title%3DDiscovery%2Bof%2B2-%25284-Chloro-3-%2528trifluoromethyl%2529phenyl%2529-N-%25284-%2528%25286%252C7-dimethoxyquinolin-4-yl%2529oxy%2529phenyl%2529acetamide%2B%2528CHMFL-KIT-64%2529%2Bas%2Ba%2BNovel%2BOrally%2BAvailable%2BPotent%2BInhibitor%2Bagainst%2BBroad-Spectrum%2BMutants%2Bof%2Bc-KIT%2BKinase%2Bfor%2BGastrointestinal%2BStromal%2BTumors%26numPages%3D19%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D6101%26publicationDate%3DJuly%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00280"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1683</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">7</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00280" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)-N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Yun&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Beilei&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Junjie&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Shuang&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Fengming&quot;,&quot;last_name&quot;:&quot;Zou&quot;},{&quot;first_name&quot;:&quot;Ziping&quot;,&quot;last_name&quot;:&quot;Qi&quot;},{&quot;first_name&quot;:&quot;Feiyang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Qingwang&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Chen&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Zhenquan&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Aoli&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Li&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Wenchao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Yujiao&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Mingfeng&quot;,&quot;last_name&quot;:&quot;Bai&quot;},{&quot;first_name&quot;:&quot;Qingsong&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jing&quot;,&quot;last_name&quot;:&quot;Liu&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;06&quot;,&quot;day&quot;:&quot;17&quot;,&quot;issue&quot;:&quot;13&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;6083-6101&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00280&quot;},&quot;abstract&quot;:&quot;Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor compound 18 (CHMFL-KIT-64), which is potent against c-KIT wt and a broad spectrum of drug-resistant mutants with improved bioavailability. 18 exhibits single-digit nM potency against c-KIT kinase and c-KIT T670I mutants in the biochemical assay and displays great potencies against most of the gain-of-function mutations in the juxtamembrane domain, drug-resistant mutations in the ATP binding pocket (except V654A), and activation loops (except D816V). In addition, 18 exhibits a good in vivo pharmacokinetic (PK) profile in different species including mice, rats, and dogs. It also displays good in vivo antitumor efficacy in the c-KIT T670I, D820G, and Y823D mutant-mediated mice models as well as in the c-KIT wt patient primary cells which are known to be imatinib-resistant. The potent activity against a broad spectrum &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00280&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00280" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00280&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00280" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00280&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00280" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00280&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00280&amp;href=/doi/10.1021/acs.jmedchem.9b00280" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00280" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00280" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00280%26sid%3Dliteratum%253Aachs%26pmid%3D31250638%26genre%3Darticle%26aulast%3DWu%26date%3D2019%26atitle%3DDiscovery%2Bof%2B2-%25284-Chloro-3-%2528trifluoromethyl%2529phenyl%2529-N-%25284-%2528%25286%252C7-dimethoxyquinolin-4-yl%2529oxy%2529phenyl%2529acetamide%2B%2528CHMFL-KIT-64%2529%2Bas%2Ba%2BNovel%2BOrally%2BAvailable%2BPotent%2BInhibitor%2Bagainst%2BBroad-Spectrum%2BMutants%2Bof%2Bc-KIT%2BKinase%2Bfor%2BGastrointestinal%2BStromal%2BTumors%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D13%26spage%3D6083%26epage%3D6101%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/13" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/jmcmar.2019.62.issue-13/20190711/jmcmar.2019.62.issue-13.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor compound <b>18</b> (CHMFL-KIT-64), which is potent against c-KIT wt and a broad spectrum of drug-resistant mutants with improved bioavailability. <b>18</b> exhibits single-digit nM potency against c-KIT kinase and c-KIT T670I mutants in the biochemical assay and displays great potencies against most of the gain-of-function mutations in the juxtamembrane domain, drug-resistant mutations in the ATP binding pocket (except V654A), and activation loops (except D816V). In addition, <b>18</b> exhibits a good in vivo pharmacokinetic (PK) profile in different species including mice, rats, and dogs. It also displays good in vivo antitumor efficacy in the c-KIT T670I, D820G, and Y823D mutant-mediated mice models as well as in the c-KIT wt patient primary cells which are known to be imatinib-resistant. The potent activity against a broad spectrum of clinically important c-KIT mutants combining the good in vivo PK/pharmacodynamic properties of <b>18</b> indicates that it might be a new potential therapeutic candidate for gastrointestinal stromal tumors.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_17252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_17252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> Approximately 20 individuals in a million are diagnosed with this disease each year in the United States.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Identification of the c-KIT mutant was a major breakthrough in the pathology of GISTs, which provided a therapeutic target for the treatment of GISTs. 95% of GISTs express c-KIT, and 80â85% GISTs carry activation mutations such as V559A/D/G, V560D, L576P, and so forth, which are mainly located in the juxtamembrane region of c-KIT encoded by exon 11.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> c-KIT kinase belongs to type III receptor tyrosine kinase family which also includes FLT3, CSF1R, and PDGFRÎ±/Î².It plays critical roles in cell proliferation, migration, and survival upon activation in different physiological and pathological contexts. Drug discovery targeting c-KIT has attracted extensive attention in the past decades.</div><div class="NLM_p">Imatinib (<b>1</b>), an inhibitor of c-KIT, PDGFRs, and ABL kinases, was approved as the first-line treatment for advanced GISTs (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> However, with the exception of 20% of the patients with GISTs exhibiting primary resistance to <b>1</b>, most patients will eventually relapse due to secondary mutations upon chronic treatment.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Most of the secondary mutations include those that occurred in the ATP binding pocket such as T670I/E, V654A, outside the ATP binding pocket S709F, and activation loops such as D816E/H/V, D820E/G/Y, D822K, Y823D, A829P, and so forth. Multitargeted kinase inhibitor sunitinib (<b>2</b>) was then approved as the second line treatment for patients with GISTs who are refractory to or intolerant of imatinib therapy. Although <b>2</b> could overcome some of imatinib-resistant mutations such as V654A and T670I,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> certain imatinib-resistant mutants located in the activation loop remain resistant to it.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Later, multitargeted kinase inhibitor regorafenib (<b>3</b>) was approved as the third-line therapy for patients with GISTs who are not amenable to surgery and refractory to both <b>1</b> and <b>2</b>.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Similarly, <b>3</b> also could not overcome some of the secondary resistance mutations in the c-KIT activation loops. Furthermore, both <b>2</b> and <b>3</b> have limited overall clinical response and exhibit severe side effects.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> In addition, ponatinib (<b>4</b>), which was clinically approved for CML, could also potently inhibit KIT exon 11 primary mutants and a range of secondary mutants, including those within the activation loop.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, it was suspended by FDA due to serious side effects in 2013 and later was listed in black box warning status for clinical usage. Cabozantinib (<b>5</b>) (a TKI targeting c-KIT, MET, VEGFR2, and AXL) also displays potency against different c-KIT mutations in the patient-derived xenograft (PDX) models of GISTs.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> In addition, BLU285 (<b>6</b>) which is under clinical investigation is a potent and highly selective inhibitor of mutated c-KIT and PDGFRÎ±. It exhibits a good antitumor effect in the PDX models of GISTs,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> but it could not overcome the c-KIT T670I mutant.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Furthermore, DCC-2618 (<b>7</b>)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and AZD3229 (<b>8</b>), which are under clinical and preclinical development, respectively, exhibited different broad mutant inhibition profiles.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> However, given the fact that there are over a dozen of different c-KIT mutants emerged in the clinic, there is still a great demand to develop new therapeutics which bears different potency profiles against the broad spectrum of the c-KIT mutants.</div><div class="NLM_p last">Our previously developed quinolone-based type II c-KIT kinase inhibitor CHMFL-KIT-8140 (<b>9</b>)<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> could also overcome a variety of imatinib-resistant secondary mutants including T670I but with poor pharmacokinetic (PK) properties. Through the type II kinase inhibitor binding element hybrid drug design approach,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> we designed a series of compounds and screened them with transformed BaF3 cells which led to the discovery of a novel highly potent c-KIT kinase inhibitor CHMFL-KIT-64 (<b>18</b>) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). It was potent against a broad spectrum of c-KIT primary gain-of-function mutants, secondary mutants, and A-loop mutants. In addition, <b>18</b> also displayed good in vivo PK properties and antitumor efficacy in different preclinical mice models of GISTs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37188" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37188" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> StructureâActivity Relationship Exploration</h3><div class="NLM_p">Compound <b>9</b> is a highly potent type II c-KIT kinase inhibitor which is capable of overcoming the T670I gatekeeper mutant; however, the poor PK profiles limit its further development. In order to address this deficiency, we initiated a medicinal chemistry study that resulted in the identification of a highly potent inhibitor which could overcome a broad spectrum of c-KIT mutants. Using the type II kinase inhibitor binding element hybrid design approach,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> we started to explore the structureâactivity relationships (SAR) by varying the âheadâ, âlinkerâ, and âtailâ moieties. We first fixed the hinge-binding part as 6,7-dimethoxyquinolin and explored the âlinker2â (L2) and âtailâ (R<sup>1</sup>) moieties. The growth inhibition of IL-3-independent BaF3 cells (GI<sub>50</sub>) expressing the c-KIT wt (BaF3-tel-c-KIT) and c-KIT T670I (BaF3-tel-c-KIT-T670I), which has been used for the development of <b>9</b> and shows a correlation with biochemical IC<sub>50</sub>,<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> was used as the primary readout to evaluate the potency and selectivity of the new compounds (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Replacement of the urea of L2 in <b>9</b> with acetamide and the âtailâ moiety R<sup>1</sup> with the simple phenyl ring (<b>10</b>) or pyridine (<b>11</b>) resulted in great activity loss. Switching L2 in <b>10</b> to cyclopropanecarboxamide (<b>12</b>) did not achieve apparent potency. Interestingly, introduction of the CF<sub>3</sub> group in the para-position of R<sup>1</sup> (<b>13</b>) significantly increased the activity both to the c-KIT wt (GI<sub>50</sub> = 0.022 Î¼M) and the c-KIT T670I (GI<sub>50</sub> = 0.011 Î¼M); meanwhile, it showed good selectivity against parental BaF3 cells (GI<sub>50</sub> = 2.16 Î¼M). The analogous compound with the <i>m</i>-CF<sub>3</sub> substituent (<b>14</b>) also achieved good potency against c-KIT wt and c-KIT T670I (GI<sub>50</sub> = 0.020 and 0.001 Î¼M, respectively). However, changing the substituent of R<sup>1</sup> from <i>m</i>-CF<sub>3</sub> to <i>m</i>-F (<b>15</b>) or <i>m</i>-OMe (<b>16</b>) all resulted in significant activity loss. Addition of the <i>p</i>-F substituent to the R<sup>1</sup> moiety of <b>14</b> (<b>17</b>) lost about 13-fold activity against c-KIT T670I in comparison with <b>14</b>, although it still displayed a similar potency toward c-KIT wt. Interestingly, changing the F atom to a larger Cl atom (<b>18</b>) not only remarkably increased the potency against c-KIT wt (GI<sub>50</sub> = 0.001 Î¼M) and c-KIT T670I (GI<sub>50</sub> = 0.004 Î¼M) but also improved the selectivity window toward the parental BaF3 cells (GI<sub>50</sub> = 5.97 Î¼M). However, further increasing the size of the substituent with a methyl group (<b>19</b>) slightly decreased the activity toward c-KIT wt and c-KIT T670I, even though it still kept good selectivity against the parental BaF3 cells. Replacement of the CF<sub>3</sub> group in <b>19</b> with a methyl group (<b>20</b>) displayed similar trends to <b>19</b>. Further investigating the effects of other substituents at the meta- and para-positions of the benzene ring, such as 3,4-dimethoxy (<b>21</b>), 3,4-difluoro (<b>22</b>), and 3,4-dichloro (<b>23</b>) all resulted in significant activity loss against c-KIT wt. Installing a F or CF<sub>3</sub> group at the ortho-position of the benzene ring (<b>24â26</b>) also led to activity loss. Relatively larger groups at R<sup>1</sup>, for example, benzodioxole (<b>27</b>) and naphthyl (<b>28</b>), both resulted in activity loss. Additionally, aliphatic rings such as cyclohexyl (<b>29</b>) and <i>N</i>-methyl piperazine (<b>30</b>) at R<sup>1</sup> both significantly decreased the potency. Furthermore, reversed amide counterpart of L2 in <b>13</b> (<b>31</b>) and <b>14</b> (<b>32</b>) lost the activity to both c-KIT wt and c-KIT T670I as well.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative inhibitors that bear c-KIT kinase activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Exploration Focused on the L2/R<sup>1</sup> Moieties<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0015.gif" alt="" id="GRAPHIC-d7e802-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0016.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div><div class="NLM_p">Because <b>18</b> exhibited potent antiproliferative efficacy in the BaF3-tel-c-KIT and BaF3-tel-c-KIT-T670I cells, we then fixed the L2 moiety as acetamide and R<sup>1</sup> moiety as 4-chloro-3-(trifluoromethyl)phenyl and further explored the âlinker 1â (L1) moiety (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Replacement of the oxygen atom linkage in <b>18</b> with âNH (<b>33</b>), âNMe (<b>34</b>), or S atom (<b>35</b>) all resulted in significant activity loss against c-KIT wt and c-KIT T670I. Therefore, we kept the phenoxy group and explored a series of substituents of the benzene ring in the L1 moiety. Addition of one F atom at the ortho-position of the acetamide (<b>36</b>) increased the activity against c-KIT wt (GI<sub>50</sub> = 0.049 Î¼M) and c-KIT T670I (GI<sub>50</sub> = 0.018 Î¼M). Changing the F atom to Cl atom (<b>37</b>) or the methyl group (<b>38</b>) retained similar activities compared with <b>36</b>. Switching the F atom from the ortho- to meta-position (<b>39</b>) led to decrease of the activity against c-KIT wt (GI<sub>50</sub> = 0.116 Î¼M). Variation of different substituents at this position such as Cl (<b>40</b>), methyl (<b>41</b>), methoxyl (<b>42</b>), trifluoromethyl (<b>43</b>), and nitrile (<b>44</b>) groups all resulted in activity loss in comparison with <b>18</b>.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of discovery of compound <b>18</b> (CHMFL-KIT-64) from <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR Exploration Focused on the Substitution (L1) Moiety<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0017.gif" alt="" id="GRAPHIC-d7e902-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0018.gif" alt="" id="gr16" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div><div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Selectivity Profiling of Compound <b>18</b></h3><div class="NLM_p">Because <b>18</b> displayed the best potency against both c-KIT wt and T670I and meanwhile exhibited the best selectivity window to parental BaF3 cells, we then further screened it in a panel of broad-spectrum mutants with BaF3 cell lines expressing a variety of clinically relevant secondary mutants of c-KIT kinase, including those in the juxtamembrane domain (V559D/A/G, V560D, and L576P), ATP binding pocket (V654A, V654A/V559D, T670E/I, T670I/V559D, and S709F) and the activation loop (D816E/H/V, D820G/Y, N822K, Y823D, and A829P) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The results showed that <b>18</b> displayed the best potency against c-KIT wt and selectivity window to parental BaF3 cells compared with <b>1</b> and <b>2</b>. In addition, <b>18</b> exhibited similar or better activities compared with <b>1</b> and <b>2</b> against all of the primary gain-of-function mutations of c-KIT in exon 11 including V559A/D/G, V560D, and L576P. Furthermore, <b>18</b> showed better potencies than <b>2</b> against the compound <b>1</b>-resistant c-KIT gatekeeper residue T670I/E mutation. <b>18</b> and <b>2</b> could also overcome compound <b>1</b>-resistant secondary mixed mutation T670I/V559D and display better potencies against S709F mutation which is located in exon 14 but outside the ATP binding pocket. Only <b>2</b> but not <b>1</b> or <b>18</b> was resistant to the V654A mutant which is located in exon 13 and inside the ATP binding pocket. Interestingly, <b>18</b> exhibited much better activities than <b>1</b> and <b>2</b> against activation loop mutants including D816E/H, D820E/G/Y, D822K, Y823D, and A829P except D816V which was resistant to all of these three compounds.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antiproliferative Effects of Compounds <b>1</b>, <b>2</b>, and <b>18</b> against a Panel of c-KIT wt/Mutant-Transformed BaF3 Cells</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cells</th><th class="colsep0 rowsep0" align="center">c-KIT status</th><th class="colsep0 rowsep0" align="center">compd. <b>1</b> (GI<sub>50</sub>:Â Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">compd. <b>2</b> (GI<sub>50</sub>:Â Î¼M)</th><th class="colsep0 rowsep0" align="center">compd. <b>18</b> (GI<sub>50</sub>:Â Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3</td><td class="colsep0 rowsep0" align="left">parental</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">1.01</td><td class="colsep0 rowsep0" align="left">5.97</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT</td><td class="colsep0 rowsep0" align="left">WT</td><td class="colsep0 rowsep0" align="left">0.35</td><td class="colsep0 rowsep0" align="char" char=".">0.003</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V559A</td><td class="colsep0 rowsep0" align="left">exonÂ 11/juxtamembrane domain</td><td class="colsep0 rowsep0" align="left">0.905</td><td class="colsep0 rowsep0" align="char" char=".">0.02</td><td class="colsep0 rowsep0" align="left">0.021</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V559D</td><td class="colsep0 rowsep0" align="left">exonÂ 11/juxtamembrane domain</td><td class="colsep0 rowsep0" align="left">0.01</td><td class="colsep0 rowsep0" align="char" char=".">0.001</td><td class="colsep0 rowsep0" align="left">0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V559G</td><td class="colsep0 rowsep0" align="left">exonÂ 11/juxtamembrane domain</td><td class="colsep0 rowsep0" align="left">0.008</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="left"><0.0003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V560D</td><td class="colsep0 rowsep0" align="left">exonÂ 11/juxtamembrane domain</td><td class="colsep0 rowsep0" align="left">0.003</td><td class="colsep0 rowsep0" align="char" char=".">0.035</td><td class="colsep0 rowsep0" align="left">0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-L576P</td><td class="colsep0 rowsep0" align="left">exonÂ 11/juxtamembrane domain</td><td class="colsep0 rowsep0" align="left">0.085</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V654A/V559D</td><td class="colsep0 rowsep0" align="left">exonÂ 13/11/ATP binding pocket</td><td class="colsep0 rowsep0" align="left">0.608</td><td class="colsep0 rowsep0" align="char" char=".">0.019</td><td class="colsep0 rowsep0" align="left">0.042</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-V654A</td><td class="colsep0 rowsep0" align="left">exonÂ 13/ATP binding pocket</td><td class="colsep0 rowsep0" align="left">1.41</td><td class="colsep0 rowsep0" align="char" char=".">0.005</td><td class="colsep0 rowsep0" align="left">0.32</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-T670E</td><td class="colsep0 rowsep0" align="left">exonÂ 14/ATP binding pocket</td><td class="colsep0 rowsep0" align="left">4.08</td><td class="colsep0 rowsep0" align="char" char=".">0.089</td><td class="colsep0 rowsep0" align="left">0.071</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-T670I</td><td class="colsep0 rowsep0" align="left">exonÂ 14/ATP binding pocket</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td><td class="colsep0 rowsep0" align="left">0.004</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-T670I/V559D</td><td class="colsep0 rowsep0" align="left">exonÂ 14/11/ATP binding pocket</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.012</td><td class="colsep0 rowsep0" align="left">0.045</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-S709F</td><td class="colsep0 rowsep0" align="left">exonÂ 14/outsideÂ the ATP binding pocket</td><td class="colsep0 rowsep0" align="left">0.115</td><td class="colsep0 rowsep0" align="char" char=".">0.028</td><td class="colsep0 rowsep0" align="left">0.017</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D816E</td><td class="colsep0 rowsep0" align="left">exonÂ 17/activation loop</td><td class="colsep0 rowsep0" align="left">0.174</td><td class="colsep0 rowsep0" align="char" char=".">0.059</td><td class="colsep0 rowsep0" align="left">0.016</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D816H</td><td class="colsep0 rowsep0" align="left">exonÂ 17/activation loop</td><td class="colsep0 rowsep0" align="left">0.651</td><td class="colsep0 rowsep0" align="char" char=".">0.315</td><td class="colsep0 rowsep0" align="left">0.097</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D816V</td><td class="colsep0 rowsep0" align="left">exonÂ 17/activation loop</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">1.72</td><td class="colsep0 rowsep0" align="left">1.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D820E</td><td class="colsep0 rowsep0" align="left">exonÂ 17/activation loop</td><td class="colsep0 rowsep0" align="left">0.035</td><td class="colsep0 rowsep0" align="char" char=".">0.093</td><td class="colsep0 rowsep0" align="left">0.001</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D820G</td><td class="colsep0 rowsep0" align="left">exonÂ 17/activation loop</td><td class="colsep0 rowsep0" align="left">0.337</td><td class="colsep0 rowsep0" align="char" char=".">0.389</td><td class="colsep0 rowsep0" align="left">0.009</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-D820Y</td><td class="colsep0 rowsep0" align="left">exonÂ 17/activation loop</td><td class="colsep0 rowsep0" align="left">0.435</td><td class="colsep0 rowsep0" align="char" char=".">0.172</td><td class="colsep0 rowsep0" align="left">0.003</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-N822K</td><td class="colsep0 rowsep0" align="left">exonÂ 17/activation loop</td><td class="colsep0 rowsep0" align="left">1.47</td><td class="colsep0 rowsep0" align="char" char=".">0.384</td><td class="colsep0 rowsep0" align="left">0.026</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-Y823D</td><td class="colsep0 rowsep0" align="left">exonÂ 17/activation loop</td><td class="colsep0 rowsep0" align="left">5.87</td><td class="colsep0 rowsep0" align="char" char=".">0.704</td><td class="colsep0 rowsep0" align="left">0.035</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BaF3-tel-c-KIT-A829P</td><td class="colsep0 rowsep0" align="left">exonÂ 18/activation loop</td><td class="colsep0 rowsep0" align="left">0.58</td><td class="colsep0 rowsep0" align="char" char=".">0.018</td><td class="colsep0 rowsep0" align="left">0.022</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div></div><div class="NLM_p">We then moved forward to investigate the selectivity profile of <b>18</b> against other protein kinases with DiscoverXâs KINOMEscan assay.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> The data demonstrated that <b>18</b> bears a good selectivity (<i>S</i> score (1) = 0.02) in a panel of 468 kinases and mutants at 1 Î¼M concentration (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf" class="ext-link">Table S1</a>). Besides high binding affinity to c-KIT and c-KIT mutant kinases, <b>18</b> also displayed strong binding to CSF1R, DDR1, FLT4, PDGFRÎ±, PDGFRÎ², LOK, and RET kinases (percent activity remaining less than 1% at 1 Î¼M of <b>18</b>). Given the fact that KINOMEscan is binding assay and sometimes it cannot really reflect the inhibitory activity of a compound, we then used Invitrogenâs Zâ-Lyte and Promegaâs ADP-Glo-based biochemical activity assays with the purified kinase proteins to confirm the inhibition activity of <b>18</b> against those kinase targets (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). The results showed that <b>18</b> could potently inhibit the activity of c-KIT wt (IC<sub>50</sub>: 4 nM), c-KIT T670I (IC<sub>50</sub>: 8 nM), CSF1R (IC<sub>50</sub>: 18 nM), PDGFRÎ± (IC<sub>50</sub>: 25 nM), and RET (IC<sub>50</sub>: 34 nM), and it relatively less potently inhibited DDR1 (IC<sub>50</sub>: 135 nM), FLT4 (IC<sub>50</sub>: 121 nM), and PDGFRÎ² (IC<sub>50</sub>: 97 nM). We also tested the antiproliferative effects of <b>18</b> against CSF1R, DDR1, FLT4, PDGFRÎ±, PDGFRÎ², and RET kinases in the transformed BaF3 cells. The results showed that <b>18</b> exhibited strong inhibition to CSF1R, PDGFRÎ±, and PDGFRÎ² kinases. This is not surprising because c-KIT, CSF1R, PDGFRÎ±, and PDGFRÎ² kinases all belong to the type III receptor tyrosine kinase family and the ATP binding pockets of these kinases are highly conserved. These data indicated that c-KIT, PDGFRÎ±, PDGFRÎ², and CSF1R kinases are the main targets of <b>18</b>.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Biochemical examination of compound <b>18</b>. (A) Treespot demonstration of selectivity profiling of <b>18</b> with DiscoverX KINOMEscan technology. Measurements were performed at a concentration of 1 Î¼M of the inhibitor. The affinity was defined with respect to a dimethyl sulfoxide (DMSO) control. (B) Biochemical tests of <b>18</b> with Invitrogen SelectScreen platform or Promegaâs ADP-Glo assay (IC<sub>50</sub>) and the antiproliferative effects of <b>18</b> on a panel of transformed BaF3 cells (GI<sub>50</sub>) against the kinase targets that demonstrated strong binding to <b>18</b> with a percent control number less than 1% in the KINOMEscan profiling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In order to better understand the sensitivity of <b>18</b> among different c-KIT mutants and the SAR, we then compared the binding modes of <b>18</b> with <b>1</b> and <b>2</b>. As shown in the X-ray crystal structure of <b>1</b> with c-KIT wt, <b>1</b> fitted well with c-KIT wt via four hydrogen bonds, including the N atom of the pyridine ring with Cys673 in the hinge-binding area, the NH of aminopyrimidine with Thr670, and two canonical type II inhibitor hydrogen bonds between the amide and Glu640/Asp810 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A). Compound <b>1</b> was resistant to c-KIT V654A because the conformational change affected the binding of <b>1</b> to c-KIT<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>B). The hydrogen bond of the NH of aminopyrimidine with Thr670 was lost when Thr670 mutated to Ile670, which resulted in the resistance to <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>C). As shown in the X-ray crystal structure of <b>2</b> with c-KIT wt, <b>2</b> bounds to inactivated c-KIT wt through two hydrogen bonds with Cys673 and Glu671 in the hinge-binding area with the N and O atom of hydroxy indole (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>D). The mutants of Val654 and Thr670 did not affect the binding of <b>2</b>; therefore, they were still sensitive to <b>2</b> (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>E,F). Docking of <b>18</b> into c-KIT wt (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK">6GQK</a>) showed that <b>18</b> adopted a canonical type II binding mode (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>G). As expected, the quinoline nitrogen formed a hydrogen bond with Cys673 in the hinge-binding area. The amide in the linker formed two hydrogen bonds with Asp810 in the DFG motif and Glu640 in the c-Helix. The âtailâ part occupied the hydrophobic pocket generated by the DFG-out shifting. In the homology model of the c-KIT T670I mutant, <b>18</b> adopted a similar type II binding mode (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>H). The V654A mutant might weaken the van der Waals interactions of <b>18</b> or the conformational change resulted in a similar effect to <b>1</b> which made it insensitive to <b>18</b>. The O-bridged phenyl moiety in <b>18</b> oriented to an angle that provided enough space for the bulky isoleucine residue, which could explain its potency against the T670I mutant (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>I). The D816V mutant was also resistant to <b>18</b>, but it was located outside of the ATP binding pocket and hence very hard to model.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Molecular modeling analysis of the binding modes of c-KIT wt/V654A/T670I with compounds <b>1</b>, <b>2</b>, and <b>18</b>. (A) X-ray of <b>1</b> with c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>); (B) binding mode of <b>1</b> with the c-KIT V654A homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>); (C) binding mode of <b>1</b> with c-KIT T670I homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>); (D) X-ray of <b>2</b> with c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G0E">3G0E</a>); (E) binding mode of <b>2</b> with the c-KIT V654A homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G0E">3G0E</a>); (F) binding mode of <b>2</b> with the c-KIT T670I homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G0E">3G0E</a>); (G) binding mode of <b>18</b> with c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK">6GQK</a>); (H) binding mode of <b>18</b> with the c-KIT V654A homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK">6GQK</a>); (I) binding mode of <b>18</b> with the c-KIT T670I homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK">6GQK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The modeling study also helps to understand the SAR observed in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. The residues of Val643, Leu644, His790, and Cys809 formed the hydrophobic pocket generated by DFG-out shifting. The trifluoromethyl in the âtailâ (R<sup>1</sup>) pointed to Val643 and Leu644, which helped to gain better potency due to the hydrophobic interaction. In addition, the substituent <i>p</i>-Cl of phenyl in the âtailâ moiety could achieve higher binding affinity due to the halogen bond interaction with His790.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Loss of hydrophobicity (<b>29</b>, <b>30</b>) or the halogen bond resulted in the activity loss. The amide moiety (L2) which could form two typical hydrogen bonds with Glu640 and Asp810 were critical for the binding. Elongation of L2 (<b>31</b>, <b>32</b>) would result in the loss of these bonds. In addition, ÏâÏ stack between the phenyl in the L1 moiety and Phe811 might help to stabilize the binding conformation. Smaller substituents in the L1 moiety (<b>36â40</b>) would not affect the rotation of phenyl. However, larger substituents in the L1 moiety (<b>43â44</b>) might distort the conformation and lead to decreased activity to c-KIT wt and the T670I mutant.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Cellular Evaluation of Compound <b>18</b></h3><div class="NLM_p">Next, we examined the antiproliferative effects of <b>18</b> against a panel of established GISTs cancer cell lines. Not surprisingly, it did potently inhibit the growth of c-KIT-dependent GIST cancer cells such as GIST-T1 (GI<sub>50</sub>: 0.006 Î¼M) and GIST-882 (GI<sub>50</sub>: 0.013 Î¼M) which are also sensitive to <b>1</b> and <b>2</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). In the compound <b>1</b>-resistant cell line GIST-T1-T670I (generated by CRISPR knock-in method) and GIST-5R (generated by continuous treatment of <b>1</b>) cell lines, both <b>18</b> and <b>2</b> exhibited strong growth inhibition effects. In addition, <b>18</b> also displayed a good selectivity window over GIST-48B (GI<sub>50</sub>: 1.37 Î¼M), whose growth is c-KIT independent. This further confirmed that <b>18</b> exerted its antiproliferative effect against GIST cancer cells through the on-target inhibition of c-KIT but not general toxicity.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Antiproliferation Effects of Compounds <b>1</b>, <b>2</b>, and <b>18</b> against a Variety of GIST Cancer Cell Lines<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cell line</th><th class="colsep0 rowsep0" align="center">c-KIT status</th><th class="colsep0 rowsep0" align="center">compd. <b>1</b> (GI<sub>50</sub>:Â Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">compd. <b>2</b> (GI<sub>50</sub>:Â Î¼M)</th><th class="colsep0 rowsep0" align="center" char=".">compd. <b>18</b> (GI<sub>50</sub>:Â Î¼M)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-T1</td><td class="colsep0 rowsep0" align="left">Î560-578</td><td class="colsep0 rowsep0" align="left">0.015</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td><td class="colsep0 rowsep0" align="char" char=".">0.006</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-882</td><td class="colsep0 rowsep0" align="left">K642E</td><td class="colsep0 rowsep0" align="left">0.048</td><td class="colsep0 rowsep0" align="char" char=".">0.014</td><td class="colsep0 rowsep0" align="char" char=".">0.013</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-T1-T670I</td><td class="colsep0 rowsep0" align="left">Î560-578/T670I</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.004</td><td class="colsep0 rowsep0" align="char" char=".">0.011</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-5R</td><td class="colsep0 rowsep0" align="left">Î560-578/T670I</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.035</td><td class="colsep0 rowsep0" align="char" char=".">0.073</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GIST-48B</td><td class="colsep0 rowsep0" align="left">KIT negative</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">0.74</td><td class="colsep0 rowsep0" align="char" char=".">1.37</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">All GI<sub>50</sub> values were obtained by triplet testing.</p></div></div></div><div class="NLM_p">We also investigated the effects of <b>18</b> on the c-KIT-mediated signaling pathways in the c-KIT wt and c-KIT T670I-driven GISTs cell lines GIST-T1, GIST-T1-T670I, and GIST-5R, respectively (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A). <b>18</b> blocked the autophosphorylation of c-KIT pY703, pY719, and pY823 in GIST-T1, GIST-T1-T670I, and GIST-5R, respectively, cells at a concentration of 30 nM and also remarkably inhibited the downstream signaling mediators pAKT (T308/S473), pS6 (S235/236), and pERK (T202/204) (EC<sub>50</sub> less than 100 nM). <b>1</b> and <b>2</b> displayed similar effects on the signaling pathways. In compound <b>1</b>-resistant cell lines GIST-T1-T670I and GIST-5R (c-KIT T670I), <b>18</b> also significantly affected the phosphorylation of c-KIT pY703, pY719, and pY823 and downstream mediators (EC<sub>50</sub> less than 100 nM). Similar effects were observed from <b>2</b> but not <b>1</b>. It is worth noting that both <b>18</b> and <b>2</b> strongly inhibited the phosphorylation of STAT3 in GIST-T1-T670I and GIST-5R cells but moderately in GIST-T1 cells. Furthermore, <b>18</b> and <b>2</b> affected the autophosphorylation of AKT308 in GIST-T1 and GIST-5R cells but not GIST-T1-T670I cells. These discrepancies reflected the different genetic backgrounds of these cells. In addition, <b>18</b> could induce dose-dependent cell apoptotic death (by examining the cleaved PARP and cleaved caspase 3) and arrest the cell cycle into the G0/G1 phase in all of these three cell lines (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B,C).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cellular effects of compound <b>18</b> in GIST cell lines GIST-T1, GIST-T1-T670I, and GIST-5R. (A) Effects of <b>18</b> on c-KIT mediated signaling pathways. (B) Effects of <b>18</b> on apoptosis. (C) Effects of <b>18</b> on cell cycle progression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In order to exclude the off-target effects (such as PDGFRs and CSF1R) on the signaling pathway, we also detected the expression and phosphorylation of PDGFRÎ±/Î² and CSF1R kinases in GIST-T1 cells (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf" class="ext-link">Figure S1</a>). The results showed that only PDGFRÎ± expressed and phosphorylated in GIST-T1 cells, and <b>18</b> could inhibit its autophosphorylation at the Y849 site. CSF1R did not express in GIST-T1 cells, and phosphorylated PDGFRÎ² was not detected either. In order to further exclude the effects of downstream mediators caused by the inhibition of PDGFRÎ±, we also used highly selective PDGFRÎ± inhibitor CHMFL-PDGFR-159<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> to test the PDGFR signaling pathway and the antiproliferative effect in GIST-T1 cells (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf" class="ext-link">Figure S2</a>). The data demonstrated that although <i>p</i>-PDGFR was potently inhibited, the downstream mediators such as AKT, STAT3, and ERK were less potently inhibited. Furthermore, the antiproliferative effect of the selective PDGFRÎ± inhibitor was much less than <b>1</b>, which further proved that the PDGFRÎ± inhibition did not play essential roles in the inhibition of <b>18</b> to the c-KIT mediated signaling pathway. All these data suggested that <b>18</b> exerted its inhibitory effect to the GIST cancer cells through the on-target inhibition of c-KIT.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Inhibition of the Proliferation of Primary GIST Patient Cells</h3><div class="NLM_p">We then investigated the effects of <b>18</b> in a more pathologically relevant setting of ex vivo culture of primary cells derived from GIST patients (PDC) (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). In cells from patient A which harbor the c-KIT V559D gain-of-function mutation, <b>18</b> displayed a better growth inhibitory effect than <b>1</b> although both of them exhibited dose-dependent antiproliferative effects. Interestingly, <b>18</b> also exhibited potent and dose-dependent inhibitory effects against cells from patient B, harboring c-KIT wt which are known to be compound <b>1</b>-resistant.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(22â24)</a> These data suggested that <b>18</b> might be more potent and effective than <b>1</b> in the genetically more complicated GIST cells and therefore indicated potential clinical benefits.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antiproliferative effects of compounds <b>18</b> and <b>1</b> against primary cells derived from GIST patients upon 6 days of drug treatment with the CellTiter-Glo assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> In Vivo PK/PD and Efficacy Evaluation of Compound <b>18</b></h3><div class="NLM_p">The in vivo PK properties of <b>18</b> were evaluated in different species including mice, Sprague Dawley rats, and beagle dogs following intravenous (iv) injection and oral administration (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf" class="ext-link">Figure S3</a>). <b>18</b> exhibited good drug exposure (AUC<sub>0â<i>t</i></sub>) in all of these three species, that is, 25â054 ng/mL<sup>.</sup>h at 10 mg/kg in rats, 12â608 ng/mL<sup>.</sup>h at 10 mg/kg in mice, and 19â065 ng/mL<sup>.</sup>h at 5 mg/kg in dogs. This compound displayed different half-lives (<i>T</i><sub>1/2</sub>) in these three different species after oral administration, that is, 4.5 h in mice and relative longer time in rats (6.4 h) and in dogs (19.4 h). These results indicated that <b>18</b> was metabolized very slowly in dogs than in mice and rats. <b>18</b> possessed acceptable bioavailability in mice (<i>F</i> = 43%), rats (<i>F</i> = 50%), and dogs (<i>F</i> = 81%). These PK properties indicated that <b>18</b> would be suitable for oral administration.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. PK Study of Compound <b>18</b> in Mice, Sprague Dawley Rats, and Beagle Dogs<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="Â±" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="Â±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" align="center"><b>18</b></th><th class="rowsep1 colsep0" colspan="2" align="center" char="Â±">rats</th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">mice</th><th class="rowsep1 colsep0" colspan="2" align="center" char="Â±">beagle dogs</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">parameter</th><th class="colsep0 rowsep0" align="center" char="Â±">iv (1Â mg/kg)</th><th class="colsep0 rowsep0" align="center">p.o. (10Â mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">iv (1Â mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">p.o. (10Â mg/kg)</th><th class="colsep0 rowsep0" align="center" char="Â±">iv (1Â mg/kg)</th><th class="colsep0 rowsep0" align="center">p.o. (5Â mg/kg)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AUC<sub>(0â<i>t</i>)</sub> (ng/mLÂ·h)</td><td class="colsep0 rowsep0" align="char" char="Â±">2553Â Â±Â 155.1</td><td class="colsep0 rowsep0" align="left">25054Â Â±Â 7060</td><td class="colsep0 rowsep0" align="char" char=".">2989</td><td class="colsep0 rowsep0" align="char" char=".">12â608</td><td class="colsep0 rowsep0" align="char" char="Â±">5323Â Â±Â 569</td><td class="colsep0 rowsep0" align="left">19065Â Â±Â 5696</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>max</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="Â±">0Â Â±Â 0</td><td class="colsep0 rowsep0" align="left">9Â Â±Â 0</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="char" char="Â±">0.033Â Â±Â 0</td><td class="colsep0 rowsep0" align="left">5.33Â Â±Â 1.15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="char" char="Â±">15.85Â Â±Â 3.72</td><td class="colsep0 rowsep0" align="left">6.41Â Â±Â 0.34</td><td class="colsep0 rowsep0" align="char" char=".">5.4</td><td class="colsep0 rowsep0" align="char" char=".">4.5</td><td class="colsep0 rowsep0" align="char" char="Â±">20.61Â Â±Â 4.82</td><td class="colsep0 rowsep0" align="left">19.4Â Â±Â 4.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>C</i><sub>max</sub> (ng/mL)</td><td class="colsep0 rowsep0" align="char" char="Â±">660Â Â±Â 17</td><td class="colsep0 rowsep0" align="left">1643Â Â±Â 462</td><td class="colsep0 rowsep0" align="char" char=".">520</td><td class="colsep0 rowsep0" align="char" char=".">1390</td><td class="colsep0 rowsep0" align="char" char="Â±">1107Â Â±Â 117</td><td class="colsep0 rowsep0" align="left">1163Â Â±Â 288</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i>Â (%)</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="char" char=".">Â </td><td class="colsep0 rowsep0" align="char" char=".">43</td><td class="colsep0 rowsep0" align="char" char="Â±">Â </td><td class="colsep0 rowsep0" align="left">81</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">All testing data were obtained from three independent mice (Â±SD).</p></div></div></div><div class="NLM_p">We also evaluated the pharmacodynamic (PD) profile of <b>18</b> in the GIST-T1-T670I mouse model at the 80 mg/kg/day dosage (p.o.) for the impact on phosphorylation levels of c-KIT and downstream signaling mediators such as ERK and AKT and so forth (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf" class="ext-link">S4</a>). Meanwhile, we also monitored the drug concentration in the blood plasma. Following a single-dose treatment, in 4, 8, and 12 h time courses, the phosphorylation levels of c-KIT/ERK/AKT were decreased time dependently and then started to get back at 24 h. The drug concentration in the plasma reached the highest level in 4 h and then gradually decreased; even up to 24 h, it did not reduce to the basal level. These data indicated that the drug concentration in the plasma was well correlated to the phosphorylation levels of the signaling mediators. In addition, it is worth noting that the plasma protein binding rate of <b>18</b> was over 90%.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PD effect of <b>18</b> on tumor p-c-KIT, p-ERK, and p-AKT in the GIST-T1-T670I mouse xenograft model with a single dose of 80 mg/kg/day (p.o.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We finally evaluated the in vivo antitumor efficacy of <b>18</b> in three transformed BaF3 cells, that is, BaF3-tel-c-KIT-T670I (<b>1</b> resistant, <b>2</b> and <b>18</b> sensitive), BaF3-tel-c-KIT-D820G (<b>18</b> sensitive, <b>1</b> and <b>2</b> resistant), and BaF3-tel-c-KIT-Y823D (<b>18</b> sensitive, <b>1</b> and <b>2</b> resistant) and three GISTs intact cells, that is, GIST-T1 (<b>1</b>, <b>2</b> and <b>18</b> sensitive)-, GIST-T1-T670I (<b>1</b> resistant, <b>2</b> and <b>18</b> sensitive)-, and GIST-5R (<b>1</b> resistant, <b>2</b> and <b>18</b> sensitive)-inoculated xenograft mouse models by oral administration (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> and <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). All dosages of <b>18</b> (20, 40, 80, and 100 mg/kg/day) did not affect the animal weights which indicated that there was no general cytotoxicity at those dosages (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figures <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>AâC and <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>AâC left lane). During 11 days of continuous treatment, <b>18</b> dose dependently inhibited the BaF3-tel-c-KIT-T670I tumor progression and exhibited almost 100% TGI (tumor growth inhibition) at a dosage of 100 mg/kg/day (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>A). After 9 days of continuous treatment, <b>18</b> dose dependently inhibited the BaF3-tel-c-KIT-D820G and BaF3-tel-c-KIT-Y823D tumor progression and exhibited 92.9 and 90.2% TGI, respectively, at a dosage of 80 mg/kg/day (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>B,C). Comparably, <b>2</b> did not show apparent efficacy in the BaF3-tel-c-KIT-D820G or BaF3-tel-c-KIT-Y823D xenograft mouse model. In the GIST-T1 cell-inoculated xenograft mouse models, <b>18</b> dose dependently inhibited the tumor progression, and a dosage of 20 mg/kg/day exhibited 95.6% TGI (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A) which was much better than the efficacy of <b>1</b> at 100 mg/kg/day. In addition, for the <b>1</b>-resistant cell lines GIST-T1-T670I and GIST-5R, <b>18</b> dose dependently inhibited the tumor progression and a dosage of 40 mg/kg/day exhibited 76.4% and 96.9% TGI, respectively (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B,C). It is worth noting that the mice treated with <b>2</b> started to die at the third day in the GIST-T1-T670I xenograft models, and there was only one mouse alive at the 28th day. However, the mice treated with <b>18</b> were in good condition. All these in vivo data suggested that <b>18</b> bore suitable anti-GISTs efficacy in different c-KIT mutant spectra from <b>1</b> and <b>2</b> and it might have a potential usage in the clinic.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Antitumor efficacy of <b>18</b> in the BaF3-tel-c-KIT-T670I xenograft mouse model. Female BALB/C-nu mice bearing established BaF3-tel-c-KIT-T670I tumor xenografts were treated with <b>18</b> at 40 and 100 mg/kg/day dosage or vehicle. (B) Antitumor efficacy of <b>18</b> in the BaF3-tel-c-KIT-D820G xenograft mouse model. Female BALB/C-nu mice bearing established BaF3-tel-c-KIT-D820G tumor xenografts were treated with <b>18</b> at 40 and 80 mg/kg/day dosage or vehicle. Daily oral administration was initiated when BaF3-tel-c-KIT-D820G tumors had reached a size of 200â400 mm<sup>3</sup>. (C) Antitumor efficacy of <b>18</b> in the BaF3-tel-c-KIT-Y823D xenograft mouse model. Female BALB/C-nu mice bearing established BaF3-tel-c-KIT-Y823D tumor xenografts were treated with <b>18</b> at 40 and 80 mg/kg/day dosage or vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Antitumor efficacy of <b>18</b> in the GIST-T1 xenograft mouse model. Female BALB/C-nu mice bearing established GIST-T1 tumor xenografts were treated with <b>18</b> at 20 and 40 mg/kg/day dosage or vehicle. (B) Antitumor efficacy of <b>18</b> in the GIST-T1-T670I xenograft mouse model. Female BALB/C-nu mice bearing established GIST-T1-T670I tumor xenografts were treated with <b>18</b> at 20 and 40 mg/kg/day dosage or vehicle. (C) Antitumor efficacy of <b>18</b> in the GIST-5R xenograft mouse model. Female BALB/C-nu mice bearing established GIST-5R tumor xenografts were treated with <b>18</b> at 20 and 40 mg/kg/day dosage or vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_34204" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_34204" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p"><a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> depicts the synthetic route for the preparation of target compounds <b>10â30</b>, <b>36â37</b>, and <b>39</b>. 4-Chloro-6,7-dimethoxyquinoline was reacted with aminophenols using NaH as the base in DMSO at 110 Â°C to give the quinoline intermediates <b>46a-b</b>. <b>46c-d</b> were prepared with 4-chloro-6,7-dimethoxyquinoline and nitrophenols in Ph<sub>2</sub>O at 140 Â°C followed by reduction with Fe powder in EtOH under reflux. The desired quinoline derivatives were obtained from direct amide coupling of <b>46aâd</b> and various substituted phenylacetic acids or acyl chloride.</div><figure id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>10â30</b>, <b>36â37</b>, and <b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-aminophenol or 4-amino-3-chlorophenol, NaH, DMSO, 110 Â°C, overnight; (b) R<sup>1</sup>CH<sub>2</sub>COOH or 1-phenyl-1-cyclopropanecarboxylic acid, HATU, DIPEA, DMF, rt, overnight; (c) cyclohexylacetyl chloride, DIPEA, DCM, 0 Â°C, 30 min; (d) 2-fluoro-4-nitrophenol or 3-fluoro-4-nitrophenol, Ph<sub>2</sub>O, 140 Â°C, overnight; (e) Fe, NH<sub>4</sub>Cl, EtOH, reflux, 5 h; (f) 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid, HATU, DIPEA, DMF, rt, overnight.</p></p></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, intermediate <b>47</b> was prepared by nucleophilic substitution of 4-chloro-6,7-dimethoxyquinoline with methyl 4-hydroxybenzoate at 145 Â°C. Then, hydrolysis of the ester under basic conditions resulted in carboxylic acid <b>48</b>, which underwent an amidation reaction with substituted phenethyl amine to provide the final products <b>31</b> and <b>32</b>.</div><figure id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>31â32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl 4-hydroxybenzoate, 145 Â°C, overnight; (b) LiOH, CH<sub>3</sub>OH/THF, rt, overnight; (c) R<sup>1</sup>CH<sub>2</sub>NH<sub>2</sub>, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt, overnight.</p></p></figure><div class="NLM_p">Quinoline analogues <b>33â34</b> were prepared as illustrated in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>. 4-Chloro-6,7-dimethoxyquinoline was reacted with 4-nitroaniline in NMP at 120 Â°C followed by treating with TsOH to give phenylamine derivative <b>50</b>, and then intermediate <b>52</b> was obtained by further methylation. Reduction of the nitro group in <b>50</b> and <b>52</b> with Pd/C under a hydrogen atmosphere provided amines <b>51</b> and <b>53</b>, which were then coupled with 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid to furnish the title compounds.</div><figure id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>33â34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-nitroaniline, TsOH, NMP, 120 Â°C, overnight; (b) Pd/C, MeOH, rt, overnight; (c) 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid, HATU, DIPEA, DMF, rt, overnight; (d) MeI, NaH, anhydrous THF, 0 Â°C-rt, 1 h.</p></p></figure><div class="NLM_p"><b>35</b> was obtained from an amidation reaction of 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid and amine <b>54</b>, which was synthesized by nucleophilic substitution of 4-chloro-6,7-dimethoxyquinoline and 4-aminobenzenethiol (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-aminobenzenethiol, rt, overnight; (b) 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid, HATU, DIPEA, DMF, rt, overnight.</p></p></figure><div class="NLM_p">As outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>, intermediates <b>45câh</b> were synthesized by nucleophilic substitution of 6,7-dimethoxyquinolin-4-ol with a variety of substituted 4-fluoronitrobenzene <b>49aâf</b> using <i>t</i>BuOK or Cs<sub>2</sub>CO<sub>3</sub> as the base in DMSO at 100 Â°C. The nitro group was then reduced with Fe powder in EtOH under reflux to afford aniline intermediates <b>46eâj</b>. Final quinoline products <b>38</b> and <b>40â44</b> were obtained from amidation reaction of <b>46eâj</b> and 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid.</div><figure id="sch5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>38</b> and <b>40â44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>t</i>BuOK or Cs<sub>2</sub>CO<sub>3</sub>, anhydrous DMSO, rt-100 Â°C, 3 h; (b) Fe, NH<sub>4</sub>Cl, EtOH, reflux, 5 h; (c) 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid, HATU, DIPEA, DMF, rt, overnight.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68164" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68164" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Starting from the previously developed type II c-KIT kinase inhibitor <b>9</b>, which has good c-KIT potency but poor PK and in-vivo efficacy properties, through the type II kinase inhibitor binding element hybrid drug design approach, we have discovered novel potent c-KIT kinase inhibitor <b>18</b>. It not only exhibited better potency than <b>1</b> against the c-KIT wt kinase but also potently inhibited a broad spectrum of mutants including the primary gain-of-function mutations and secondary drug-acquired mutations in the ATP binding pocket and activation loops, some of which are resistant to <b>1</b> (first-line treatment in clinic) or <b>2</b> (second-line treatment in clinic). For example, <b>18</b> was potent to <b>2</b>-insensitive c-KIT A-loop mutants such as D816H, D820G, Y823G, N822K, and so forth, which are important mutants observed in the clinic. In addition, from the results of KINOMEscan, in-vitro biochemical assay and antiproliferative assay of transformed BaF3 cell lines, <b>18</b> exhibited a good selectivity profile in the kinome and only showed inhibitory activities to the type III kinase family including CSF1R and PDGFRÎ±/Î² kinases but not other protein kinases. Importantly, <b>18</b> also displayed a potent growth inhibitory effect against the patientsâ primary cells harboring c-KIT wt which is known to be compound <b>1</b>-resistant. This might benefit from the different target profiles of <b>18</b> from <b>1</b>. Combining the in vivo PK/PD and efficacy properties, the current data suggest that <b>18</b> might be a potential first-line/second-line drug candidate as a supplementation for the current anti-GIST therapies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23642" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23642" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Chemistry</h3><div class="NLM_p last">All reagents and solvents were purchased from commercial sources and used without further purification. All the reference compounds were purchased from MedChemExpress (China). <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker 400 (<sup>1</sup>H: 400 MHz, <sup>13</sup>C: 100 MHz) or Bruker 500 (<sup>1</sup>H: 500 MHz, <sup>13</sup>C: 125 MHz) spectrometer and referenced to deuterium DMSO (DMSO-<i>d</i><sub>6</sub>). Chemical shifts are expressed in ppm. In the NMR tabulation, s indicates singlet; d, doublet; t, triplet; q, quartet; m, multiplet; and br, broad peak. LC/MS was performed on Agilent 6224 TOF using an ESI source coupled to an Agilent 1260 Infinity high-performance liquid chromatography system operating in the reverse mode with an Agilent Eclipse Plus C18 1.8 Î¼m, 3.0 mm Ã 50 mm column. Flash column chromatography was conducted using silica gel (SiliCycle 40â64 Î¼m). All of the compounds were determined to be >95% pure.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-phenylacetamide (<b>10</b>)</h3><div class="NLM_p">To a solution of <b>45a</b> (50 mg, 0.16 mmol) in anhydrous <i>N</i>,<i>N</i>-dimethylformamide (DMF) (1 mL) were added 2-phenylacetic acid (34 mg, 0.25 mmol), hexafluorophosphate azabenzotriazole tetramethyl uronium (HATU) (95 mg, 0.25 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA) (62 mg, 0.48 mmol), and the mixture was stirred at room temperature overnight. Water was added to the reaction solution, and the mixture was extracted with EtOAc (3 Ã 10 mL). The EtOAc layer was washed with a saturated aqueous NaCl solution and was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed by distillation under reduced pressure, and the crude product was purified by silica gel flash chromatography [eluting with MeOH in dimethyl chloride (DCM) 5%] to give title compound <b>10</b> as a white solid (53 mg, yield 80%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.34 (s, 1H), 8.47 (s, 1H), 7.75 (s, 2H), 7.52 (s, 1H), 7.36â7.23 (m, 8H), 6.44 (s, 1H), 3.94 (s, 6H), 3.67 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 415.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>11â28</b>, <b>30</b>, and <b>33â44</b> were prepared following the synthetic procedure of <b>10</b>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(pyridin-4-yl)acetamide (<b>11</b>)</h3><div class="NLM_p last">It was obtained with a yield of 65%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.42 (s, 1H), 8.54â8.52 (m, 2H), 8.47 (d, <i>J</i> = 5.3 Hz, 1H), 7.75â7.72 (m, 2H), 7.51 (s, 1H), 7.39 (s, 1H), 7.38â7.37 (m, 2H), 7.25â7.22 (m, 2H), 6.45 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.74 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 416.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-1-phenylcyclopropane-1-carboxamide (<b>12</b>)</h3><div class="NLM_p last">It was obtained with a yield of 77%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.29 (s, 1H), 8.45 (s, 1H), 7.71 (s, 2H), 7.50 (s, 1H), 7.44â7.39 (m, 5H), 7.32 (s, 1H), 7.20â7.18 (m, 2H), 6.42 (s, 1H), 3.94 (s, 6H), 1.47 (s, 2H), 1.15 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 441.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(4-(trifluoromethyl)phenyl)acetamide (<b>13</b>)</h3><div class="NLM_p last">It was obtained with a yield of 78%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.40 (s, 1H), 8.47 (d, <i>J</i> = 5.3 Hz, 1H), 7.75â7.71 (m, 4H), 7.58 (d, <i>J</i> = 8.0 Hz, 2H), 7.51 (s, 1H), 7.39 (s, 1H), 7.25â7.22 (m, 2H), 6.44 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.80 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 168.86, 160.52, 153.07, 149.81, 149.71, 149.23, 146.79, 141.20, 137.11, 130.54, 127.84 (q, <i>J</i> = 32.0 Hz), 125.61 (q, <i>J</i> = 4.0 Hz), 124.86 (q, <i>J</i> = 272.0 Hz), 121.93, 121.33, 115.61, 108.21, 103.50, 99.57, 56.18, 56.15, 43.35. LC/MS (ESI, <i>m</i>/<i>z</i>): 483.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(3-(trifluoromethyl)phenyl)acetamide (<b>14</b>)</h3><div class="NLM_p last">It was obtained with a yield of 80%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.40 (s, 1H), 8.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.75â7.72 (m, 3H), 7.67â7.63 (m, 2H), 7.61â7.58 (m, 1H), 7.51 (s, 1H), 7.40 (s, 1H), 7.25â7.23 (m, 2H), 6.45 (d, <i>J</i> = 5.3 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.82 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 483.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(3-fluorophenyl)acetamide (<b>15</b>)</h3><div class="NLM_p last">It was obtained with a yield of 83%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.34 (s, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.75â7.72 (m, 2H), 7.50 (s, 1H), 7.41â7.37 (m, 2H), 7.24â7.18 (m, 4H), 7.12â7.08 (m, 1H), 6.43 (d, <i>J</i> = 5.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.71 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 433.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(3-methoxyphenyl)acetamide (<b>16</b>)</h3><div class="NLM_p last">It was obtained with a yield of 81%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.33 (s, 1H), 8.53 (d, <i>J</i> = 5.6 Hz, 1H), 7.76 (d, <i>J</i> = 9.0 Hz, 2H), 7.56 (s, 1H), 7.42 (s, 1H), 7.27â7.24 (m, 3H), 6.94â6.92 (m, 2H), 6.85â6.83 (m, 1H), 6.53 (d, <i>J</i> = 5.5 Hz, 1H), 3.97 (s, 3H), 3.95 (s, 3H), 3.76 (s, 3H), 3.63 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 445.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(4-fluoro-3-(trifluoromethyl)phenyl)acetamide (<b>17</b>)</h3><div class="NLM_p last">It was obtained with a yield of 68%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.38 (s, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.77 (dd, <i>J</i> = 7.1, 2.2 Hz, 1H), 7.74â7.70 (m, 3H), 7.51â7.48 (m, 2H), 7.39 (s, 1H), 7.23 (d, <i>J</i> = 9.0 Hz, 2H), 6.43 (d, <i>J</i> = 5.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.81 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 501.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>18</b>)</h3><div class="NLM_p last">It was obtained with a yield of 72%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.40 (s, 1H), 8.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.86 (s, 1H), 7.75â7.66 (m, 4H), 7.51 (s, 1H), 7.40 (s, 1H), 7.24 (d, <i>J</i> = 8.8 Hz, 2H), 6.44 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.83 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 168.71, 160.45, 153.05, 149.80, 149.75, 149.24, 146.85, 137.03, 136.44, 135.59, 131.95, 129.42, 129.20 (q, <i>J</i> = 5.1 Hz), 126.80 (q, <i>J</i> = 30.6 Hz), 123.40 (q, <i>J</i> = 273.0 Hz), 121.93, 121.35, 115.60, 108.26, 103.51, 99.56, 56.18, 56.15, 42.31. LC/MS (ESI, <i>m</i>/<i>z</i>): 517.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(4-methyl-3-(trifluoromethyl)phenyl)acetamide (<b>19</b>)</h3><div class="NLM_p last">It was obtained with a yield of 74%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 1.37 (s, 1H), 8.47 (s, 1H), 7.75â7.67 (m, 3H), 7.54â7.51 (m, 2H), 7.44â7.40 (m, 2H), 7.24â7.22 (m, 2H), 6.43 (s, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.76 (s, 2H), 2.44 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 169.18, 160.46, 153.03, 149.79, 149.69, 149.26, 146.86, 137.12, 134.71, 134.61, 133.63, 132.67, 127.69 (q, <i>J</i> = 29.2 Hz), 126.81 (q, <i>J</i> = 5.5 Hz), 125.09 (q, <i>J</i> = 273.8 Hz), 121.93, 121.32, 115.60, 108.28, 103.50, 99.56, 56.18, 56.16, 42.75, 18.86. LC/MS (ESI, <i>m</i>/<i>z</i>): 497.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(3,4-dimethylphenyl)acetamide (<b>20</b>)</h3><div class="NLM_p last">It was obtained with a yield of 72%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.25 (s, 1H), 8.45 (d, <i>J</i> = 5.2 Hz, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 2H), 7.50 (s, 1H), 7.39 (s, 1H), 7.21 (d, <i>J</i> = 9.0 Hz, 2H), 7.13â7.04 (m, 3H), 6.42 (d, <i>J</i> = 5.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.57 (s, 2H), 2.21 (s, 3H), 2.19 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 443.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> 2-(3,4-Dimethoxyphenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>21</b>)</h3><div class="NLM_p last">It was obtained with a yield of 77%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.24 (s, 1H), 8.45 (d, <i>J</i> = 5.2 Hz, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 2H), 7.50 (s, 1H), 7.39 (s, 1H), 7.22 (d, <i>J</i> = 9.0 Hz, 2H), 6.97 (d, <i>J</i> = 2.1 Hz, 1H), 6.93â6.84 (m, 2H), 6.43 (d, <i>J</i> = 5.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.76 (s, 3H), 3.73 (s, 3H), 3.58 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 169.89, 160.52, 153.04, 149.79, 149.57, 149.22, 149.04, 148.14, 146.81, 137.33, 128.76, 121.89, 121.56, 121.29, 115.61, 113.53, 112.32, 108.22, 103.46, 99.57, 56.15, 56.13, 56.00, 55.93, 43.40. LC/MS (ESI, <i>m</i>/<i>z</i>): 475.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> 2-(3,4-Difluorophenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>22</b>)</h3><div class="NLM_p last">It was obtained with a yield of 85%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.33 (s, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 2H), 7.50 (s, 1H), 7.44â7.37 (m, 3H), 7.23 (d, <i>J</i> = 9.0 Hz, 2H), 7.20â7.17 (m, 1H), 6.43 (d, <i>J</i> = 5.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.70 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 451.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> 2-(3,4-Dichlorophenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>23</b>)</h3><div class="NLM_p last">It was obtained with a yield of 84%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.35 (s, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 2H), 7.63 (d, <i>J</i> = 2.0 Hz, 1H), 7.61 (d, <i>J</i> = 8.2 Hz, 1H), 7.50 (s, 1H), 7.39 (s, 1H), 7.35 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.23 (d, <i>J</i> = 9.0 Hz, 2H), 6.43 (d, <i>J</i> = 5.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.72 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 168.74, 160.44, 153.02, 149.79, 149.74, 149.25, 146.89, 137.41, 137.05, 131.77, 131.23, 130.84, 130.17, 129.82, 121.92, 121.35, 115.61, 108.28, 103.49, 99.56, 56.16, 56.13, 42.39. LC/MS (ESI, <i>m</i>/<i>z</i>): 483.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (<b>24</b>)</h3><div class="NLM_p last">It was obtained with a yield of 66%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.37 (s, 1H), 8.48 (d, <i>J</i> = 5.3 Hz, 1H), 7.74â7.71 (m, 3H), 7.67 (t, <i>J</i> = 7.5 Hz, 1H), 7.55 (d, <i>J</i> = 7.7 Hz, 1H), 7.52 (s, 1H), 7.50 (d, <i>J</i> = 7.7 Hz, 1H), 7.40 (s, 1H), 7.24 (d, <i>J</i> = 9.0 Hz, 2H), 6.47 (d, <i>J</i> = 5.3 Hz, 1H), 3.96â3.95 (m, 5H), 3.94 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 483.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 2-(2,6-Difluorophenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>25</b>)</h3><div class="NLM_p last">It was obtained with a yield of 67%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.45 (s, 1H), 8.50 (d, <i>J</i> = 5.4 Hz, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 2H), 7.53 (s, 1H), 7.44â7.37 (m, 2H), 7.25 (d, <i>J</i> = 9.0 Hz, 2H), 7.12 (t, <i>J</i> = 7.8 Hz, 2H), 6.49 (d, <i>J</i> = 5.4 Hz, 1H), 3.96 (s, 3H), 3.94 (s, 3H), 3.81 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 451.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 2-(2,4-Difluorophenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>26</b>)</h3><div class="NLM_p last">It was obtained with a yield of 77%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.36 (s, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 2H), 7.51 (s, 1H), 7.49â7.44 (m, 1H), 7.39 (s, 1H), 7.26â7.20 (m, 3H), 7.08 (tt, <i>J</i> = 8.6, 1.7 Hz, 1H), 6.44 (d, <i>J</i> = 5.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.75 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 451.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 2-(Benzo[<i>d</i>][1,3]dioxol-5-yl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>27</b>)</h3><div class="NLM_p last">It was obtained with a yield of 75%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.25 (s, 1H), 8.45 (d, <i>J</i> = 5.2 Hz, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 2H), 7.50 (s, 1H), 7.39 (s, 1H), 7.22 (d, <i>J</i> = 9.0 Hz, 2H), 6.92 (d, <i>J</i> = 1.8 Hz, 1H), 6.87 (d, <i>J</i> = 7.9 Hz, 1H), 6.81 (dd, <i>J</i> = 7.9, 1.7 Hz, 1H), 6.43 (d, <i>J</i> = 5.2 Hz, 1H), 5.99 (s, 2H), 3.94 (s, 3H), 3.93 (s, 3H), 3.57 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 459.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(naphthalen-2-yl)acetamide (<b>28</b>)</h3><div class="NLM_p last">It was obtained with a yield of 84%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.40 (s, 1H), 8.47 (d, <i>J</i> = 5.3 Hz, 1H), 7.91â7.89 (m, 3H), 7.86 (s, 1H), 7.76 (d, <i>J</i> = 9.0 Hz, 2H), 7.54â7.47 (m, 4H), 7.39 (s, 1H), 7.23 (d, <i>J</i> = 9.0 Hz, 2H), 6.45 (d, <i>J</i> = 5.3 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.85 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 465.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 2-Cyclohexyl-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>29</b>)</h3><div class="NLM_p last">To a solution of <b>45a</b> (50 mg, 0.16 mmol) in anhydrous DCM (1 mL) was added DIPEA (62 mg, 0.48 mmol). Next, commercially available 2-cyclohexylacetyl chloride (38 mg, 0.24 mmol) was added thereto, and the mixture was stirred at 0 Â°C for 30 min. The mixture was removed by distillation under reduced pressure, and the crude product was purified by silica gel flash chromatography (eluting with MeOH in DCM 5%) to give title compound <b>29</b> as a white solid (53 mg, yield 79%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.00 (s, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.73 (d, <i>J</i> = 9.0 Hz, 2H), 7.51 (s, 1H), 7.39 (s, 1H), 7.21 (d, <i>J</i> = 8.9 Hz, 2H), 6.43 (d, <i>J</i> = 5.2 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 2.21 (d, <i>J</i> = 7.1 Hz, 2H), 1.81â1.61 (m, 6H), 1.28â1.13 (m, 3H), 1.06â0.95 (m, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 421.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>N</i>-(4-((6,7-Dimethoxyquinolin-4-yl)oxy)phenyl)-2-(4-methylpiperazin-1-yl)acetamide (<b>30</b>)</h3><div class="NLM_p last">It was obtained with a yield of 82%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.84 (s, 1H), 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.78 (d, <i>J</i> = 9.0 Hz, 2H), 7.51 (s, 1H), 7.39 (s, 1H), 7.23 (d, <i>J</i> = 8.9 Hz, 2H), 6.44 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.14 (s, 2H), 2.53 (s, 4H), 2.40 (s, 4H), 2.19 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 168.78, 160.46, 153.02, 149.78, 149.77, 149.29, 146.90, 136.64, 121.85, 121.64, 115.60, 108.30, 103.49, 99.55, 62.25, 56.18, 56.15, 54.96, 53.11, 46.15. LC/MS (ESI, <i>m</i>/<i>z</i>): 437.2 [M + H]<sup>+</sup>.</div></div><div id="sec5_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-<i>N</i>-(4-(trifluoromethyl)benzyl)benzamide (<b>31</b>)</h3><div class="NLM_p">To a solution of <b>48</b> (20 mg, 0.06 mmol) in anhydrous DMF (1 mL) were added (4-(trifluoromethyl)phenyl)methanamine (12.6 mg, 0.072 mmol), EDCI (17.2 mg, 0.09 mmol), HOBt (12.1 mg, 0.09 mmol), and Et<sub>3</sub>N (12.1 mg, 0.12 mmol) and the mixture was stirred at room temperature overnight. Water was added to the reaction solution, and the mixture was extracted with EtOAc (3 Ã 5 mL). The EtOAc layer was washed with a saturated aqueous NaCl solution and was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed by distillation under reduced pressure, and the crude product was purified by silica gel flash chromatography (eluting with EtOAc in PE 50%) to give title compound <b>31</b> as a white solid (14 mg, yield 48%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.22 (t, <i>J</i> = 6.0 Hz, 1H), 8.53 (d, <i>J</i> = 5.2 Hz, 1H), 8.05 (d, <i>J</i> = 8.7 Hz, 2H), 7.71 (d, <i>J</i> = 8.0 Hz, 2H), 7.56 (d, <i>J</i> = 7.9 Hz, 2H), 7.47 (s, 1H), 7.43 (s, 1H), 7.36 (d, <i>J</i> = 8.7 Hz, 2H), 6.61 (d, <i>J</i> = 5.2 Hz, 1H), 4.58 (d, <i>J</i> = 5.8 Hz, 2H), 3.96 (s, 3H), 3.92 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 483.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compound <b>32</b> was prepared following the synthetic procedure of <b>31</b>.</div></div><div id="sec5_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-<i>N</i>-(3-(trifluoromethyl)benzyl)benzamide (<b>32</b>)</h3><div class="NLM_p last">It was obtained with a yield of 40%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.21 (t, <i>J</i> = 6.0 Hz, 1H), 8.53 (d, <i>J</i> = 5.2 Hz, 1H), 8.04 (d, <i>J</i> = 8.8 Hz, 2H), 7.69 7.58 (m, 4H), 7.46 (s, 1H), 7.42 (s, 1H), 7.36 (d, <i>J</i> = 8.7 Hz, 2H), 6.62 (d, <i>J</i> = 5.2 Hz, 1H), 4.58 (d, <i>J</i> = 5.9 Hz, 2H), 3.95 (s, 3H), 3.91 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 165.95, 159.43, 157.37, 153.25, 150.05, 149.17, 146.90, 141.65, 131.95, 131.38, 130.23, 129.89, 129.50 (q, <i>J</i> = 31.3 Hz), 124.76 (q, <i>J</i> = 272.2 Hz), 124.27 (q, <i>J</i> = 3.8 Hz), 124.04 (q, <i>J</i> = 4.1 Hz), 120.74, 116.00, 108.17, 105.05, 99.50, 56.26, 56.19, 42.81. LC/MS (ESI, <i>m</i>/<i>z</i>): 483.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)amino)phenyl)acetamide (<b>33</b>)</h3><div class="NLM_p last">It was obtained with a yield of 66%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.29 (s, 1H), 8.76 (s, 1H), 8.24 (d, <i>J</i> = 5.4 Hz, 1H), 7.86 (d, <i>J</i> = 2.0 Hz, 1H), 7.72â7.64 (m, 5H), 7.28 (d, <i>J</i> = 8.8 Hz, 2H), 7.24 (s, 1H), 6.68 (d, <i>J</i> = 5.5 Hz, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.81 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 167.43, 151.14, 147.59, 147.12, 146.68, 144.56, 135.55, 135.22, 134.60, 134.51, 130.89, 128.33, 128.11 (q, <i>J</i> = 5.3 Hz), 125.74 (q, <i>J</i> = 31.1 Hz), 122.96, 122.36 (d, <i>J</i> = 273.0 Hz), 119.63, 112.93, 107.13, 100.47, 99.57, 55.35, 54.91, 41.28. LC/MS (ESI, <i>m</i>/<i>z</i>): 516.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)(methyl)amino)phenyl)acetamide (<b>34</b>)</h3><div class="NLM_p last">It was obtained with a yield of 62%. <sup>1</sup>HNMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.17 (s, 1H), 8.59 (d, <i>J</i> = 5.3 Hz, 1H), 7.81 (d, <i>J</i> = 2.0 Hz, 1H), 7.69 (d, <i>J</i> = 8.2 Hz, 1H), 7.62 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.49 (d, <i>J</i> = 8.8 Hz, 2H), 7.30 (s, 1H), 7.10 (d, <i>J</i> = 5.3 Hz, 1H), 6.93 (d, <i>J</i> = 8.7 Hz, 2H), 6.77 (s, 1H), 3.89 (s, 3H), 3.76 (s, 2H), 3.43 (s, 3H), 3.41 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 167.34, 151.54, 151.18, 147.34, 146.58, 144.53, 144.10, 135.49, 134.49, 133.60, 130.86, 128.29, 128.06 (q, <i>J</i> = 5.3 Hz), 125.71 (q, <i>J</i> = 30.7 Hz), 122.33 (q, <i>J</i> = 273.1 Hz), 121.19, 119.90, 116.42, 109.71, 106.26, 102.77, 55.07, 54.32, 41.66, 41.16. LC/MS (ESI, <i>m</i>/<i>z</i>): 530.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)thio)phenyl)acetamide (<b>35</b>)</h3><div class="NLM_p last">It was obtained with a yield of 63%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.52 (s, 1H), 8.41 (d, <i>J</i> = 4.9 Hz, 1H), 7.85 (d, <i>J</i> = 2.0 Hz, 1H), 7.77 (d, <i>J</i> = 8.7 Hz, 2H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.66 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.57 (d, <i>J</i> = 8.6 Hz, 2H), 7.39 (s, 1H), 7.31 (s, 1H), 6.63 (d, <i>J</i> = 4.8 Hz, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.85 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 169.18, 152.73, 150.07, 147.73, 145.48, 144.75, 141.01, 136.38, 136.24, 135.64, 131.96, 129.46, 129.26 (q, <i>J</i> = 5.2 Hz), 126.81 (q, <i>J</i> = 30.9 Hz), 123.39 (q, <i>J</i> = 273.0 Hz), 122.77, 121.01, 120.76, 116.56, 108.84, 101.52, 56.22, 56.14, 42.36. LC/MS (ESI, <i>m</i>/<i>z</i>): 533.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-fluorophenyl)acetamide (<b>36</b>)</h3><div class="NLM_p last">It was obtained with a yield of 73%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.14 (s, 1H), 8.50 (d, <i>J</i> = 5.2 Hz, 1H), 7.96 (t, <i>J</i> = 8.9 Hz, 1H), 7.87 (d, <i>J</i> = 2.0 Hz, 1H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.66 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.47 (s, 1H), 7.41 (s, 1H), 7.35 (dd, <i>J</i> = 11.4, 2.7 Hz, 1H), 7.10â7.08 (m, 1H), 6.57 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.89 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 535.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(2-chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>37</b>)</h3><div class="NLM_p last">It was obtained with a yield of 70%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.93 (s, 1H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 7.89 (d, <i>J</i> = 1.9 Hz, 1H), 7.77 (d, <i>J</i> = 8.9 Hz, 1H), 7.72 (d, <i>J</i> = 8.3 Hz, 1H), 7.68 (d, <i>J</i> = 8.8 Hz, 1H), 7.52 (d, <i>J</i> = 2.7 Hz, 1H), 7.47 (s, 1H), 7.41 (s, 1H), 7.25 (dd, <i>J</i> = 8.9, 2.7 Hz, 1H), 6.58 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 3H), 3.92 (s, 3H), 3.90 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 551.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-2-methylphenyl)acetamide (<b>38</b>)</h3><div class="NLM_p last">It was obtained with a yield of 60%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.67 (s, 1H), 8.48 (d, <i>J</i> = 5.3 Hz, 1H), 7.88 (d, <i>J</i> = 2.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.3 Hz, 1H), 7.68 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.51 (d, <i>J</i> = 8.6 Hz, 1H), 7.49 (s, 1H), 7.40 (s, 1H), 7.16 (d, <i>J</i> = 2.8 Hz, 1H), 7.07 (dd, <i>J</i> = 8.7, 2.8 Hz, 1H), 6.48 (d, <i>J</i> = 5.3 Hz, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.85 (s, 2H), 2.22 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 168.89, 160.24, 153.09, 151.51, 149.84, 149.22, 146.82, 136.79, 135.48, 134.86, 133.93, 131.99, 129.35, 129.04 (q, <i>J</i> = 5.3 Hz), 127.31, 126.82 (q, <i>J</i> = 30.9 Hz), 123.41 (q, <i>J</i> = 273.0 Hz), 122.94, 118.81, 115.71, 108.21, 103.88, 99.53, 56.20, 56.15, 41.83, 18.26.LC/MS (ESI, <i>m</i>/<i>z</i>): 531.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-fluorophenyl)acetamide (<b>39</b>)</h3><div class="NLM_p last">It was obtained with a yield of 68%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.58 (s, 1H), 8.47 (d, <i>J</i> = 5.2 Hz, 1H), 7.87â7.84 (m, 2H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.66 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 7.52 (s, 1H), 7.44â7.42 (m, 2H), 7.41 (s, 1H), 6.44 (dd, <i>J</i> = 5.2, 1.0 Hz, 1H), 3.95 (s, 3H), 3.95 (s, 3H), 3.85 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 535.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(3-chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>40</b>)</h3><div class="NLM_p last">It was obtained with a yield of 66%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.57 (s, 1H), 8.48 (d, <i>J</i> = 5.3 Hz, 1H), 8.04 (d, <i>J</i> = 2.5 Hz, 1H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.66 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.60 (dd, <i>J</i> = 8.9, 2.5 Hz, 1H), 7.54 (s, 1H), 7.43 (d, <i>J</i> = 8.8 Hz, 1H), 7.41 (s, 1H), 6.36 (d, <i>J</i> = 5.3 Hz, 1H), 3.96 (s, 3H), 3.95 (s, 3H), 3.85 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 551.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-methylphenyl)acetamide (<b>41</b>)</h3><div class="NLM_p last">It was obtained with a yield of 62%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.32 (s, 1H), 8.43 (d, <i>J</i> = 5.2 Hz, 1H), 7.85 (d, <i>J</i> = 2.0 Hz, 1H), 7.71 (d, <i>J</i> = 8.2 Hz, 1H), 7.66 (dd, <i>J</i> = 7.4, 2.2 Hz, 2H), 7.56 (s, 1H), 7.54 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 7.39 (s, 1H), 7.15 (d, <i>J</i> = 8.7 Hz, 1H), 6.26 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 6H), 3.81 (s, 2H), 2.08 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 531.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-methoxyphenyl)acetamide (<b>42</b>)</h3><div class="NLM_p last">It was obtained with a yield of 82%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.41 (s, 1H), 8.42 (d, <i>J</i> = 5.3 Hz, 1H), 7.86 (d, <i>J</i> = 2.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.67 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.63 (d, <i>J</i> = 2.2 Hz, 1H), 7.52 (s, 1H), 7.38 (s, 1H), 7.24â7.20 (m, 2H), 6.28 (d, <i>J</i> = 5.3 Hz, 1H), 3.94 (s, 3H), 3.94 (s, 3H), 3.83 (s, 2H), 3.68 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 547.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(4-((6,7-dimethoxyquinolin-4-yl)oxy)-3-(trifluoromethyl)phenyl)acetamide (<b>43</b>)</h3><div class="NLM_p last">It was obtained with a yield of 72%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.67 (s, 1H), 8.51 (d, <i>J</i> = 5.2 Hz, 1H), 8.24 (d, <i>J</i> = 2.6 Hz, 1H), 7.89 (dd, <i>J</i> = 9.0, 2.6 Hz, 1H), 7.86 (d, <i>J</i> = 2.1 Hz, 1H), 7.72 (d, <i>J</i> = 8.2 Hz, 1H), 7.67 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.45â7.43 (m, 2H), 7.42 (s, 1H), 6.55 (d, <i>J</i> = 5.2 Hz, 1H), 3.96 (s, 3H), 3.91 (s, 3H), 3.86 (s, 2H). LC/MS (ESI, <i>m</i>/<i>z</i>): 585.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> 2-(4-Chloro-3-(trifluoromethyl)phenyl)-<i>N</i>-(3-cyano-4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (<b>44</b>)</h3><div class="NLM_p last">It was obtained with a yield of 77%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 10.72 (s, 1H), 8.55 (d, <i>J</i> = 5.3 Hz, 1H), 8.24 (d, <i>J</i> = 2.6 Hz, 1H), 7.90 (dd, <i>J</i> = 9.1, 2.6 Hz, 1H), 7.86 (d, <i>J</i> = 2.0 Hz, 1H), 7.72 (d, <i>J</i> = 8.3 Hz, 1H), 7.66 (dd, <i>J</i> = 8.3, 2.1 Hz, 1H), 7.51 (s, 1H), 7.47â7.45 (m, 2H), 6.61 (d, <i>J</i> = 5.3 Hz, 1H), 3.97 (s, 3H), 3.94 (s, 3H), 3.87 (s, 2H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 169.37, 159.51, 153.51, 151.22, 150.31, 148.96, 146.52, 137.46, 136.01, 135.70, 131.97, 129.53, 129.32 (q, <i>J</i> = 5.3 Hz), 126.82 (q, <i>J</i> = 30.5 Hz), 126.49, 123.93, 123.38 (q, <i>J</i> = 273.0 Hz), 123.23, 115.58, 115.50, 107.91, 105.91, 104.28, 99.33, 56.34, 56.31, 42.17. LC/MS (ESI, <i>m</i>/<i>z</i>): 542.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 4-(3-Fluoro-4-nitrophenoxy)-6,7-dimethoxyquinoline (<b>45a</b>)</h3><div class="NLM_p">A mixture of 4-chloro-6,7-dimethoxyquinoline (0.71 g, 3.18 mmol) and 3-fluoro-4-nitrophenol (1.0 g, 6.37 mmol) in Ph<sub>2</sub>O (12 mL) was heated at 140 Â°C for overnight. The reaction mixture was allowed to cool to room temperature; then, the solid was collected by filtration and washed with Et<sub>2</sub>O to give title compound <b>45a</b> as a yellow solid (700 mg, yield 63%), <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.92 (d, <i>J</i> = 6.4 Hz, 1H), 8.42 (t, <i>J</i> = 8.8 Hz, 1H), 7.89â7.85 (m, 2H), 7.68 (s, 1H), 7.54 (dd, <i>J</i> = 9.1, 2.5 Hz, 1H), 7.23 (d, <i>J</i> = 6.5 Hz, 1H), 4.04 (s, 3H), 4.02 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 345.0 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compound <b>45b</b> was prepared following the synthetic procedure of <b>45a</b>.</div></div><div id="sec5_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 4-(2-Fluoro-4-nitrophenoxy)-6,7-dimethoxyquinoline (<b>45b</b>)</h3><div class="NLM_p last">Yield 55%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.90 (d, <i>J</i> = 6.3 Hz, 1H), 8.57 (dd, <i>J</i> = 10.2, 2.7 Hz, 1H), 8.33â8.31 (m, 1H), 7.89 (d, <i>J</i> = 8.5 Hz, 1H), 7.74 (s, 1H), 7.73 (s, 1H), 7.17 (d, <i>J</i> = 6.4 Hz, 1H), 4.05 (s, 3H), 4.03 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 345.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 6,7-Dimethoxy-4-(3-methyl-4-nitrophenoxy)quinoline (<b>45c</b>)</h3><div class="NLM_p">To a solution of 6,7-dimethoxyquinolin-4-ol (3.0 g, 14.6 mmol) in anhydrous DMSO (30 mL) was added <i>t</i>BuOK (1.63 g, 14.6 mmol) in batches, and the mixture was stirred at room temperature for 20 min. Next, commercially available 4-fluoro-2-methyl-1-nitrobenzene <b>49a</b> (2.71 g, 17.5 mmol) was added thereto, and the mixture was stirred at 100 Â°C for 3 h. Water was added to the reaction solution, and the mixture was extracted with EtOAc (3 Ã 300 mL). The EtOAc layer was washed with water and a saturated aqueous NaCl solution and was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. EtOAc was concentrated to give the crude product which was then purified by silica gel flash chromatography (eluting with EtOAc in petroleum ether 50%) to give product <b>45c</b> as a yellow solid (1.2 g, yield 24%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.59 (d, <i>J</i> = 5.1 Hz, 1H), 8.15 (d, <i>J</i> = 9.0 Hz, 1H), 7.45 (s, 1H), 7.40 (d, <i>J</i> = 2.5 Hz, 2H), 7.26 (dd, <i>J</i> = 9.0, 2.7 Hz, 1H), 6.80 (d, <i>J</i> = 5.1 Hz, 1H), 3.96 (s, 3H), 3.90 (s, 3H), 2.56 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 157.69, 157.13, 152.20, 149.15, 148.32, 146.27, 144.53, 135.98, 126.84, 122.70, 117.49, 115.14, 107.39, 105.34, 98.21, 55.21, 55.14, 19.37. LC/MS (ESI, <i>m</i>/<i>z</i>): 341.1 [M + H]<sup>+</sup></div><div class="NLM_p last">Compounds <b>45dâg</b> were prepared following the synthetic procedure of <b>45c</b>. Compound <b>45h</b> was prepared following the same procedure; only the base <i>t</i>BuOK was replaced with Cs<sub>2</sub>CO<sub>3.</sub></div></div><div id="sec5_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 4-(2-Chloro-4-nitrophenoxy)-6,7-dimethoxyquinoline (<b>45d</b>)</h3><div class="NLM_p last">It was obtained with a yield of 64%, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.59â8.58 (m, 2H), 8.29 (dd, <i>J</i> = 9.0, 2.8 Hz, 1H), 7.54 (d, <i>J</i> = 9.0 Hz, 1H), 7.46 (s, 1H), 7.42 (s, 1H), 6.73 (d, <i>J</i> = 5.1 Hz, 1H), 3.97 (s, 3H), 3.91 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 157.73, 155.99, 153.37, 150.37, 149.33, 147.33, 145.10, 126.95, 126.44, 125.23, 122.78, 115.59, 108.49, 105.64, 99.11, 56.32, 56.26. LC/MS (ESI, <i>m</i>/<i>z</i>): 361.0 [M + H]<sup>+</sup></div></div><div id="sec5_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 6,7-Dimethoxy-4-(2-methyl-4-nitrophenoxy)quinoline (<b>45e</b>)</h3><div class="NLM_p last">It was obtained with a yield of 65%, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.55 (d, <i>J</i> = 5.1 Hz, 1H), 8.36 (d, <i>J</i> = 2.4 Hz, 1H), 8.16 (dd, <i>J</i> = 8.9, 2.9 Hz, 1H), 7.46 (s, 1H), 7.45 (s, 1H), 7.31 (d, <i>J</i> = 8.9 Hz, 1H), 6.61 (d, <i>J</i> = 5.1 Hz, 1H), 3.97 (s, 3H), 3.92 (s, 3H), 2.35 (s, 3H); <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 158.47, 158.19, 153.27, 150.20, 149.37, 147.24, 144.62, 132.00, 127.44, 124.02, 121.17, 115.75, 108.46, 105.15, 99.34, 56.23, 16.09. LC/MS (ESI, <i>m</i>/<i>z</i>): 341.1 [M + H]<sup>+</sup></div></div><div id="sec5_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 6,7-Dimethoxy-4-(2-methoxy-4-nitrophenoxy)quinoline (<b>45f</b>)</h3><div class="NLM_p last">It was obtained with a yield of 37%, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.48 (d, <i>J</i> = 5.2 Hz, 1H), 8.04 (d, <i>J</i> = 2.6 Hz, 1H), 7.97 (dd, <i>J</i> = 8.8, 2.6 Hz, 1H), 7.50 (d, <i>J</i> = 8.7 Hz, 1H), 7.47 (s, 1H), 7.42 (s, 1H), 6.49 (d, <i>J</i> = 5.2 Hz, 1H), 3.96 (s, 3H), 3.93 (s, 3H), 3.89 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 357.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> 6,7-Dimethoxy-4-(4-nitro-2-(trifluoromethyl)phenoxy)quinoline (<b>45g</b>)</h3><div class="NLM_p last">It was obtained with a yield of 64%, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.68 (d, <i>J</i> = 5.1 Hz, 1H), 8.62â8.61 (m, 1H), 8.53â8.50 (m, 1H), 7.49 (d, <i>J</i> = 1.4 Hz, 1H), 7.44 (d, <i>J</i> = 9.1 Hz, 1H), 7.25 (s, 1H), 7.06 (dd, <i>J</i> = 5.0, 1.0 Hz, 1H), 3.97 (s, 3H), 3.85 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 395.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> 2-((6,7-Dimethoxyquinolin-4-yl)oxy)-5-nitrobenzonitrile (<b>45h</b>)</h3><div class="NLM_p last">It was obtained with a yield of 44%, <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.98 (d, <i>J</i> = 2.8 Hz, 1H), 8.70 (d, <i>J</i> = 5.1 Hz, 1H), 8.48 (dd, <i>J</i> = 9.3, 2.8 Hz, 1H), 7.50 (s, 1H), 7.34â7.32 (m, 2H), 7.12 (d, <i>J</i> = 5.1 Hz, 1H), 3.97 (s, 3H), 3.89 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 162.31, 156.62, 153.57, 150.75, 149.47, 147.66, 143.77, 131.22, 130.91, 119.67, 116.30, 114.47, 108.62, 108.48, 105.14, 98.97, 56.39, 56.35. LC/MS (ESI, <i>m</i>/<i>z</i>): 352.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> 4-((6,7-Dimethoxy-4-quinolyl)oxy)aniline (<b>46a</b>)</h3><div class="NLM_p">To a solution of 4-aminophenol (10 g, 91.7 mmol) in anhydrous DMSO (60 mL) was added NaH (60 wt %, 4.0 g, 100.9 mol) in batches, and the mixture was stirred at room temperature for 20 min. Next, commercially available 4-chloro-6,7-dimethoxyquinoline (20 g, 91.7 mmol) was added thereto, and the mixture was stirred at 110 Â°C for overnight. Water was added to the reaction solution, and the mixture was extracted with EtOAc (3 Ã 50 mL). The EtOAc layer was washed with a saturated aqueous NaHCO<sub>3</sub> solution and was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed by distillation under reduced pressure. Methanol was added to the residue, and the precipitated crystal was collected by suction filtration to give <b>46a</b> (21.6 g, yield 80%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.44 (d, <i>J</i> = 5.3 Hz, 1H), 7.52 (s, 1H), 7.38 (s, 1H), 6.95 (d, <i>J</i> = 8.7 Hz, 2H), 6.70 (d, <i>J</i> = 8.7 Hz, 2H), 6.39 (d, <i>J</i> = 5.2 Hz, 1H), 5.18 (s, 2H), 3.95 (s, 3H), 3.94 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 160.37, 151.82, 148.52, 148.26, 146.08, 145.70, 142.88, 121.20, 114.44, 114.31, 107.22, 101.71, 98.62, 55.08, 55.05. LC/MS (ESI, <i>m</i>/<i>z</i>): 297.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compound <b>46b</b> was prepared following the synthetic procedure of <b>46a</b>.</div></div><div id="sec5_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 2-Chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline (<b>46b</b>)</h3><div class="NLM_p last">It was obtained with a yield of 85%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.45 (d, <i>J</i> = 5.2 Hz, 1H), 7.50 (s, 1H), 7.38 (s, 1H), 7.21 (d, <i>J</i> = 2.7 Hz, 1H), 7.00 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.92 (d, <i>J</i> = 8.7 Hz, 1H), 6.43 (d, <i>J</i> = 5.2 Hz, 1H), 5.44 (s, 2H), 3.95 (s, 3H), 3.94 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 159.92, 151.89, 148.61, 148.27, 145.74, 142.84, 142.27, 121.39, 120.50, 116.51, 115.43, 114.34, 107.22, 101.90, 98.55, 55.09, 55.07. LC/MS (ESI, <i>m</i>/<i>z</i>): 331.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2-fluoroaniline (<b>46c</b>)</h3><div class="NLM_p">A mixture of <b>45a</b> (1.0 g, 2.9 mmol), Fe (0.81 g, 14.5 mmol), and NH<sub>4</sub>Cl (5 mL) in EtOH (15 mL) was stirred reflux for 5 h. The reaction mixture was removed by distillation under reduced pressure, and the crude product was purified by silica gel flash chromatography (eluting with EtOAc in PE 50%) to give product <b>46c</b> as a yellow solid (0.8 g, yield 88%), <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.45 (d, <i>J</i> = 5.3 Hz, 1H), 7.49 (s, 1H), 7.38 (s, 1H), 7.06 (dd, <i>J</i> = 11.8, 2.5 Hz, 1H), 6.92â6.82 (m, 2H), 6.43 (d, <i>J</i> = 5.3 Hz, 1H), 5.21 (s, 2H), 3.94 (s, 3H), 3.94 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 160.99, 152.93, 150.66 (d, <i>J</i> = 239.9 Hz), 149.66, 149.33, 146.79, 143.33 (d, <i>J</i> = 9.2 Hz), 134.92 (d, <i>J</i> = 12.8 Hz), 117.95 (d, <i>J</i> = 3.4 Hz), 116.91 (d, <i>J</i> = 5.6 Hz), 115.39, 109.62 (d, <i>J</i> = 21.0 Hz), 108.28, 102.96, 99.58, 56.15, 56.14. LC/MS (ESI, <i>m</i>/<i>z</i>): 315.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compounds <b>46dâj</b> were prepared following the synthetic procedure of <b>46c</b>.</div></div><div id="sec5_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-3-fluoroaniline (<b>46d</b>)</h3><div class="NLM_p last">It was obtained with a yield of 85%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.46 (d, <i>J</i> = 5.3 Hz, 1H), 7.52 (s, 1H), 7.39 (s, 1H), 7.08 (t, <i>J</i> = 9.0 Hz, 1H), 6.57 (dd, <i>J</i> = 13.1, 2.6 Hz, 1H), 6.48 (dd, <i>J</i> = 8.7, 2.5 Hz, 1H), 6.41 (dd, <i>J</i> = 5.2, 1.1 Hz, 1H), 5.50 (s, 2H), 3.95 (s, 6H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 159.58, 153.79 (d, <i>J</i> = 243.5 Hz), 151.91, 148.67, 148.29, 147.96 (d, <i>J</i> = 10.2 Hz), 145.67, 128.71 (d, <i>J</i> = 12.8 Hz), 123.55, 113.94, 109.55, 107.21, 100.98, 100.87 (d, <i>J</i> = 21.1 Hz), 98.47, 55.11. LC/MS (ESI, <i>m</i>/<i>z</i>): 315.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-2-methylaniline (<b>46e</b>)</h3><div class="NLM_p last">It was obtained with a yield of 88%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.42 (d, <i>J</i> = 5.2 Hz, 1H), 7.51 (s, 1H), 7.37 (s, 1H), 6.86 (d, <i>J</i> = 2.7 Hz, 1H), 6.82 (dd, <i>J</i> = 8.5, 2.8 Hz, 1H), 6.72 (d, <i>J</i> = 8.5 Hz, 1H), 6.38 (d, <i>J</i> = 5.3 Hz, 1H), 4.93 (s, 2H), 3.94 (s, 3H), 3.93 (s, 3H), 2.09 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 160.40, 151.80, 148.50, 148.25, 145.65, 143.94, 142.97, 122.27, 121.94, 118.52, 114.42, 114.13, 107.19, 101.77, 98.58, 55.07, 55.03, 16.85. LC/MS (ESI, <i>m</i>/<i>z</i>): 311.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 3-Chloro-4-((6,7-dimethoxyquinolin-4-yl)oxy)aniline (<b>46f</b>)</h3><div class="NLM_p last">It was obtained with a yield of 83%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.46 (d, <i>J</i> = 5.2 Hz, 1H), 7.53 (s, 1H), 7.40 (s, 1H), 7.10 (d, <i>J</i> = 8.7 Hz, 1H), 6.80 (d, <i>J</i> = 2.6 Hz, 1H), 6.65 (dd, <i>J</i> = 8.7, 2.6 Hz, 1H), 6.31 (d, <i>J</i> = 5.2 Hz, 1H), 5.49 (s, 2H), 3.95 (s, 6H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 160.33, 152.97, 149.71, 149.31, 148.61, 146.76, 138.79, 126.40, 124.59, 115.09, 114.83, 114.26, 108.29, 102.35, 99.55, 56.18. LC/MS (ESI, <i>m</i>/<i>z</i>): 331.0 [M + H]<sup>+</sup>.</div></div><div id="sec5_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-3-methylaniline (<b>46g</b>)</h3><div class="NLM_p last">It was obtained with a yield of 77%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.42 (d, <i>J</i> = 5.2 Hz, 1H), 7.56 (s, 1H), 7.38 (s, 1H), 6.86 (d, <i>J</i> = 8.4 Hz, 1H), 6.56 (d, <i>J</i> = 2.6 Hz, 1H), 6.51 (dd, <i>J</i> = 8.5, 2.7 Hz, 1H), 6.26 (d, <i>J</i> = 5.2 Hz, 1H), 5.09 (s, 2H), 3.95â3.94 (m, 6H), 1.96 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 160.80, 152.89, 149.58, 149.39, 147.17, 146.72, 142.15, 130.52, 122.56, 116.72, 115.24, 113.19, 108.31, 102.16, 99.67, 56.15, 16.10. LC/MS (ESI, <i>m</i>/<i>z</i>): 311.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-3-methoxyaniline (<b>46h</b>)</h3><div class="NLM_p last">It was obtained with a yield of 78%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.40 (d, <i>J</i> = 5.3 Hz, 1H), 7.50 (s, 1H), 7.35 (s, 1H), 6.88 (d, <i>J</i> = 8.5 Hz, 1H), 6.43 (d, <i>J</i> = 2.4 Hz, 1H), 6.27 (d, <i>J</i> = 5.2 Hz, 1H), 6.21 (dd, <i>J</i> = 8.5, 2.4 Hz, 1H), 5.20 (s, 2H), 3.93 (s, 6H), 3.62 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 160.05, 151.68, 151.05, 148.36, 148.23, 147.45, 145.55, 130.81, 122.36, 114.11, 107.15, 105.14, 101.01, 98.68, 98.49, 55.05, 54.58. LC/MS (ESI, <i>m</i>/<i>z</i>): 327.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)-3-(trifluoromethyl)aniline (<b>46i</b>)</h3><div class="NLM_p last">It was obtained with a yield of 82%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.48 (d, <i>J</i> = 5.3 Hz, 1H), 7.48 (s, 1H), 7.40 (s, 1H), 7.15 (d, <i>J</i> = 8.7 Hz, 1H), 7.02 (d, <i>J</i> = 2.7 Hz, 1H), 6.92 (dd, <i>J</i> = 8.7, 2.7 Hz, 1H), 6.43 (d, <i>J</i> = 5.3 Hz, 1H), 5.66 (s, 2H), 3.96 (s, 3H), 3.92 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 160.76, 153.02, 149.79, 149.31, 147.53, 146.78, 140.19, 124.94, 123.81 (q, <i>J</i> = 272.9 Hz), 122.46 (q, <i>J</i> = 30.4 Hz), 118.83, 115.35, 111.31 (q, <i>J</i> = 4.8 Hz), 108.29, 102.81, 99.32, 56.20, 56.07. LC/MS (ESI, <i>m</i>/<i>z</i>): 365.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> 5-Amino-2-((6,7-dimethoxyquinolin-4-yl)oxy)benzonitrile (<b>46j</b>)</h3><div class="NLM_p last">It was obtained with a yield of 88%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.50 (d, <i>J</i> = 5.2 Hz, 1H), 7.53 (s, 1H), 7.43 (s, 1H), 7.19 (d, <i>J</i> = 8.5 Hz, 1H), 7.00â6.97 (m, 2H), 6.42 (d, <i>J</i> = 5.2 Hz, 1H), 5.70 (s, 2H), 3.96 (s, 3H), 3.95 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 159.30, 152.09, 148.88, 148.28, 146.76, 145.76, 143.81, 123.03, 119.53, 115.91, 115.19, 114.17, 107.23, 105.19, 101.83, 98.36, 55.17. LC/MS (ESI, <i>m</i>/<i>z</i>): 322.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 4-((6,7-Dimethoxyquinolin-4-yl)oxy)benzoic Acid (<b>48</b>)</h3><div class="NLM_p last">A mixture of 4-chloro-6,7-dimethoxyquinoline (1.0 g, 4.48 mmol) and 4-hydroxybenzoate (817 mg, 5.38 mmol) was heated at 145 Â°C for overnight. The reaction mixture was cooled and treated with saturated NaHCO<sub>3</sub>. The solution was extracted with EtOAc (20 mL Ã 3). The organic layer was washed with brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The mixture was purified by silica gel flash chromatography (eluting with MeOH in DCM 5%) to give <b>47</b> as a white solid (700 mg, yield 46%), LC/MS (ESI, <i>m</i>/<i>z</i>): 340.1 [M + H]<sup>+</sup>. To a solution of <b>47</b> (600 mg, 1.77 mmol) in MeOH/THF (6 mL/6 mL) was added LiOH (212 mg, 8.85 mmol). The mixture was stirred at room temperature overnight. The mixture was removed by distillation under reduced pressure, and the crude product was acidized with conc. HCl until pH = 5â6. The white solid was filtered and was washed with water and diethyl ether. Then, the solid was dried to give title compound <b>48</b> as a white solid (310 mg, yield 54%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.82 (d, <i>J</i> = 6.7 Hz, 1H), 8.16 (d, <i>J</i> = 8.4 Hz, 2H), 7.81 (s, 1H), 7.71 (s, 1H), 7.58 (d, <i>J</i> = 8.3 Hz, 2H), 6.94 (d, <i>J</i> = 6.6 Hz, 1H), 4.04 (s, 3H), 4.04 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 166.83, 164.81, 156.44, 156.39, 151.58, 143.02, 137.72, 132.61, 129.87, 121.90, 116.05, 104.30, 100.63, 100.20, 57.04, 56.91. LC/MS (ESI, <i>m</i>/<i>z</i>): 326.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 6,7-Dimethoxy-<i>N</i>-(4-nitrophenyl)quinolin-4-amine (<b>50</b>)</h3><div class="NLM_p last">A mixture of 4-chloro-6,7-dimethoxyquinoline (1.0 g, 4.48 mmol), 4-nitroaniline (742 mg, 5.38 mmol), and TsOH (925 mg, 5.38 mmol) in NMP (10 mL) was heated at 120 Â°C for overnight. The reaction mixture was allowed to cool to room temperature; then, the solid was collected by filtration and washed with saturated NaHCO<sub>3</sub> to give title compound <b>50</b> as a yellow solid (1.1 g, yield 75%), <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 9.70 (s, 1H), 8.52 (d, <i>J</i> = 5.2 Hz, 1H), 8.21 (d, <i>J</i> = 9.2 Hz, 2H), 7.62 (s, 1H), 7.44 (d, <i>J</i> = 9.2 Hz, 2H), 7.36 (s, 1H), 7.26 (d, <i>J</i> = 5.2 Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 151.68, 148.48, 148.34, 147.09, 145.16, 142.96, 139.56, 125.11, 116.82, 115.42, 107.15, 106.09, 100.62, 55.31, 55.08. LC/MS (ESI, <i>m</i>/<i>z</i>): 326.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> <i>N</i><sup>1</sup>-(6,7-Dimethoxyquinolin-4-yl)benzene-1,4-diamine (<b>51</b>)</h3><div class="NLM_p last">A mixture of <b>50</b> (1.0 g, 4.48 mmol) and Pd/C (250 mg) in MeOH (30 mL) was stirred at room temperature for 5 h under H<sub>2</sub> atmosphere. The reaction mixture was filtered, and the filtrate was removed by distillation under reduced pressure to afford title compound <b>51</b> as a yellow solid (1.2 g, yield 91%), <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.60 (s, 1H), 8.15 (d, <i>J</i> = 5.5 Hz, 1H), 7.74 (s, 1H), 7.21 (s, 1H), 7.00 (d, <i>J</i> = 8.5 Hz, 2H), 6.66 (d, <i>J</i> = 8.5 Hz, 2H), 6.38 (d, <i>J</i> = 5.5 Hz, 1H), 5.07 (br, 2H), 3.92 (s, 3H), 3.89 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 152.00, 149.58, 148.34, 148.00, 146.83, 145.22, 128.61, 126.70, 115.02, 113.34, 107.99, 101.71, 99.53, 56.44, 55.90. LC/MS (ESI, <i>m</i>/<i>z</i>): 296.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 6,7-Dimethoxy-<i>N</i>-methyl-<i>N</i>-(4-nitrophenyl)quinolin-4-amine (<b>52</b>)</h3><div class="NLM_p">To a solution of <b>50</b> (1.0 g, 3.07 mmol) in anhydrous THF (20 mL) was added NaH (60 wt %, 147 mg, 3.69 mmol) in batches, and the mixture was stirred at 0 Â°C for 20 min. Next, CH<sub>3</sub>I (0.23 mL, 3.69 mmol) was added thereto, and the mixture was stirred at 0 Â°C for 1 h. The solvent was removed by distillation under reduced pressure, and the crude product was purified by silica gel flash chromatography (eluting with EtOAc) to give product <b>52</b> as a yellow solid (0.8 g, yield 80%). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.78 (d, <i>J</i> = 4.8 Hz, 1H), 8.07 (d, <i>J</i> = 9.3 Hz, 2H), 7.50 (s, 1H), 7.36 (d, <i>J</i> = 4.8 Hz, 1H), 6.89 (s, 1H), 6.71 (d, <i>J</i> = 9.0 Hz, 2H), 3.96 (s, 3H), 3.71 (s, 3H), 3.52 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 152.76, 152.00, 149.57, 148.68, 148.16, 146.51, 137.20, 125.06, 119.33, 117.11, 112.51, 108.03, 99.93, 55.26, 55.06. LC/MS (ESI, <i>m</i>/<i>z</i>): 340.1 [M + H]<sup>+</sup>.</div><div class="NLM_p last">Compound <b>53</b> was prepared following the synthetic procedure of <b>51</b>.</div></div><div id="sec5_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> <i>N</i><sup>1</sup>-(6,7-Dimethoxyquinolin-4-yl)-<i>N</i><sup>1</sup>-methylbenzene-1,4-diamine (<b>53</b>)</h3><div class="NLM_p last">It was obtained with a yield of 85%. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.49 (s, 1H), 7.29 (s, 1H), 6.96 (d, <i>J</i> = 5.7 Hz, 1H), 6.87 (d, <i>J</i> = 8.2 Hz, 2H), 6.76 (s, 1H), 6.58 (d, <i>J</i> = 8.2 Hz, 2H), 3.87 (s, 3H), 3.40 (s, 3H), 3.37 (s, 3H). <sup>13</sup>C NMR (125 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 152.96, 151.32, 146.33, 146.24, 143.39, 140.76, 137.43, 125.19, 114.02, 113.95, 104.99, 104.33, 103.52, 55.11, 54.12, 43.37. LC/MS (ESI, <i>m</i>/<i>z</i>): 310.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 4-((6,7-Dimethoxyquinolin-4-yl)thio)aniline (<b>54</b>)</h3><div class="NLM_p last">A mixture of 4-chloro-6,7-dimethoxyquinoline (1.0 g, 4.48 mmol) and 4-aminobenzenethiol (672 mg, 5.38 mmol) was stirred at room temperature overnight. The solid was collected by filtration and washed with Et<sub>2</sub>O to give title compound <b>54</b> as a yellow solid (0.8 g, yield 57%).<sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>): Î´ 8.59 (d, <i>J</i> = 6.2 Hz, 1H), 7.71 (s, 1H), 7.42 (s, 1H), 7.36â7.29 (m, 2H), 6.83â6.80 (m, 3H), 4.05 (s, 3H), 4.01 (s, 3H). LC/MS (ESI, <i>m</i>/<i>z</i>): 313.1 [M + H]<sup>+</sup>.</div></div><div id="sec5_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Cell Lines, Cell Culture Antibodies, and Chemicals</h3><div class="NLM_p">The human GIST-T1 cell line was purchased from Cosmo Bio Co., Ltd. Tokyo, Japan. GIST-T1-T670I cell line was constructed using CRISPR-Cas 9 by our group. GIST-882 and GIST-48B cell lines were kindly provided by the group of Professor Jonathan A. Fletcher, Brigham, and Womenâs Hospital in Boston. The GIST-5R cell line was provided by Prof. Brian Rubin, Department of Molecular Genetics, Lerner Research Institute, and Department of Anatomic Pathology and Taussing Cancer Center, Clevel and Clinic, Cleveland, OH 44195. All cells were grown in a humidified incubator (Thermo, USA) at 37 Â°C under 5% CO<sub>2</sub>. GIST-T1 and GIST-T1-T670I cells were maintained in Dulbeccoâs modified Eagleâs medium (DMEM) (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. GIST-882 and GIST-48B were grown in Iscoveâs modified Dulbeccoâs media (Gibco, USA) supplemented with 10% FBS and 1% penicillin/streptomycin. All other cell lines and all isogenic BaF3 cells were grown in RPMI 1640 (Gibco, USA) medium supported with 10% FBS and 1% penicillin/streptomycin. Adherent cells were grown in tissue culture flasks until they were 85â95% confluent prior to use. For suspension cells, cells were collected by spinning down at 800 rpm for 4 min before use.</div><div class="NLM_p">The following antibodies were purchased from Cell Signaling Technology (Danvers, MA): AKT (pan) (C67E7) rabbit mAb (no. 4691), Phospho-AKT (Thr308) (244F9) rabbit mAb (no. 4056), Phospho-AKT (Ser473) (D9E) XP rabbit mAb (no. 4060), PARP (46D11) rabbit mAb (no. 9532), caspase-3 (8G10) rabbit mAb (no. 9665), Phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204) (197G2) rabbit mAb (no. 4377), p44/42 MAPK (ERK1/2) (137F5) rabbit mAb (no. 4695), c-Kit (Ab81) mouse mAb (no. 3308), Phospho-c-Kit (Tyr703) (D12E12) rabbit mAb (no. 3073), Phospho-c-Kit (Tyr719) rabbit mAb (no. 3391), Phospho-anti-c-Kit (pY823) rabbit mAb (no. 77522), Phospho-STAT3 (Tyr705) (D3A7) XP rabbit mAb (Biotinylated) (no. 4093), STAT3 (D3Z2G) rabbit mAb no. 12640, phospho-S6 ribosomal protein (Ser235/236) rabbit mAb (no. 2211), and S6 ribosomal protein (5G10) rabbit mAb no. 2217. Î±-Tubulin (TU-02) mouse mAb (no. sc-8035) was purchased from Santa Cruz Biotechnology.</div><div class="NLM_p last">Imatinib and sunitinib were purchased from MedChemExpress (Shanghai, China).</div></div><div id="sec5_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> Generation of the GIST-T1-T670I Cell Line Using the CRISPR/Cas9 System</h3><div class="NLM_p last">SgRNA targeting the genomic region surrounding the T670 site of the KIT gene was designed and synthesized; annealed sgRNAoligos were inserted into pSpCas9(BB)-2A-Puro (PX459) V2.0 vector (Addgene, Cambridge, MA, USA) and transfected into GIST-T1 cells together with a 90 nt oligo containing T670I mutation as the HDR template by Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). Antibiotic selection with puromycin was performed two days after transfection and then cells were diluted and cultured in 96-well plates with only one cell per well for 3 weeks. Correctly edited T670I knock-in cell clones were then confirmed by Sanger sequencing at the targeted genomic region.</div></div><div id="sec5_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> General Procedure for Antiproliferation Assays</h3><div class="NLM_p last">For the nonadherent BaF3 cells, a density of 1.5 Ã 10<sup>4</sup> cells/mL cells was mixed with various concentrations of compounds; then, 100 Î¼L suspension was added to each well and then incubated at 37 Â°C with 5% CO<sub>2</sub> for 72 h. For the adherent GIST cells, a density of 2â5 Ã 10<sup>4</sup> cells/mL was added to the 96-well plate, incubated at 37 Â°C with 5% CO<sub>2</sub> overnight. The next day, the supernatant was changed with fresh medium containing different various concentrations of compounds and then incubated for 72 h. Cell viability was determined using CCK-8 assay (MedChemExpress, China) according to the instruction manual. The absorbance was measured in a microplate reader (iMARK, Bio-Rad, USA) at 450 nm. Data were normalized to the control group (DMSO). GI<sub>50</sub> values were calculated using Prism 7.0 (GraphPad Software, San Diego, CA).</div></div><div id="sec5_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Culture of Primary Human GIST Cells</h3><div class="NLM_p last">Human GIST samples were obtained with informed consent from the patients of the Peopleâs Liberation Army Joint Service Support Force no. 901 Hospital. All procedures were performed according to the hospital guidelines of the Research Ethics Committees and the World Medical Association Declaration of Helsinki. Fresh tumor tissue fragments were dissociated using collagenase/hyaluronidase and dispase (StemCell Technologies, Canada) at 37 Â°C for 2 h with shaking. Primary cells were placed in flasks coated with collagen I (Corning, USA) in the culture medium. The culture medium included DMEM/F12 medium freshly supplemented with 5% FBS (Gibco, USA), GlutaMAX-I (Gibco, USA), primocin (Invivogen, USA), 25 Î¼g/mL hydrocortisone (Sigma, USA), 5 Î¼g/mL insulin (Gibco, USA), 125 ng/mL EGF (Sigma, USA), and 10 Î¼M Rho kinase inhibitor Y27632 (MedChemExpress). Cells were grown in humidified 37 Â°C incubators in an atmosphere of 5% CO<sub>2</sub> and 2% O<sub>2</sub>. Medium was replaced every 3â4 days, and the primary cells were cultured for a period of 3â4 weeks.</div></div><div id="sec5_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Signaling Pathway Study</h3><div class="NLM_p last">GIST-T1, GIST-T1-T670I, and GIST-5R cells were cultured in 10% FBS-containing DMEM medium. Serially diluted compound <b>18</b>, 1 Î¼M imatinib, and 0.1 Î¼M sunitinib were added to cells for 2 h. The cells were collected and lysed. The cell lysates were analyzed by western blotting. Western blotting was performed by standard methods, as previously described.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div></div><div id="sec5_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> Apoptosis Effect Examination</h3><div class="NLM_p last">GIST-T1, GIST-T1-T670I, and GIST-5R cells were cultured in 10% FBS-containing DMEM medium. Serially diluted compound <b>18</b>, 1 Î¼M imatinib, and 0.1 Î¼M sunitinib were added to cells for 24 h. Then, apoptosis of GIST-T1, GIST-T1-T670I, and GIST-5R cells was detected by the western blot using PARP, caspase 3, and Î±-tubulin antibodies (Cell Signaling Technology).</div></div><div id="sec5_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> Cell Cycle Analysis</h3><div class="NLM_p last">GIST-T1, GIST-T1-T670I, and GIST-5R cells were treated with DMSO, serially diluted compound <b>18</b>, 1 Î¼M imatinib, and 0.1 Î¼M sunitinib for indicated periods. The cells were fixed in 70% cold ethanol and incubated at â20 Â°C overnight and then stained with PI/RNase staining buffer (BD Pharmingen). Flow cytometry was performed using a FACS Calibur (BD), and the results were analyzed by ModFit software.</div></div><div id="sec5_68" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> PK Study</h3><div class="NLM_p last">This study protocol was approved by the Animal Ethics Committee of Hefei Institutes of Physical Science, Chinese Academy of Sciences (Hefei, China). The male SpragueâDawley rats (190â210 g) were provided by Laboratory Animal Center of Anhui Medical University (Hefei, China). The animals were housed in an air-conditioned animal room at a temperature of 23 Â± 2 Â°C and a relative humidity of 50 Â± 10% and allowed free access to tap water and lab. The mice, rats, and dogs were acclimatized to the facilities for one week and then fasted for 12 h with free access to water prior to the experiment. The six mice, rats, or dogs were randomly and equally divided into two groups for one compoundâs PK study. One group was injected with iv formulation at a dose of 1 mg/kg compound <b>18</b>, and the other group was treated by oral administration of p.o. formulation at doses of 10 mg/kg compound <b>18</b>. The p.o. formulation (2 or 3 mg/mL) consisted of 10 mg compound dissolved in 0.5 mL of DMSO and 4.5 mL of 5% glucose water. The iv formulation is made with 0.5 mL of the p.o. formulation and 4.5 mL of 5% glucose water. About 300 Î¼L of blood samples were collected into heparinized tubes at 2, 5, 15, 30, 60, 120, 240, 360, 540, and 720 min after iv injection and at 5, 15, 30, 60, 90, 120, 240, 360, 540, and 720 min after oral administration. Plasma (100 Î¼L) was harvested by centrifuging the blood sample at 4 Â°C and 5000 rpm for 3 min and then stored at â80 Â°C until analysis. An aliquot of 100 Î¼L of each plasma sample was mixed with 20 Î¼L of internal standard working solution (200 ng/mL of caffeine). Methanol (400 Î¼L) was then added for precipitation. After vortexing for 5 min and centrifuging at 14â000 rpm for 10 min, 5 Î¼L of the supernatant was injected for LCâMS/MS analysis. The PK parameters were analyzed through the noncompartment model using WinNonlin 6.1 software (Pharsight Corporation, Mountain View, USA), including half-life (<i>T</i><sub>1/2</sub>), plasma concentration at 0 min (<i>C</i><sub>0</sub>), the peak of the plasma concentration (<i>C</i><sub>max</sub>), the time to peak of the plasma concentration (<i>T</i><sub>max</sub>), the area under the plasma concentrationâtime curve during the period of observation (AUC<sub>0â<i>t</i></sub>), the area under the plasma concentrationâtime curve from zero to infinity (AUC<sub>0ââ</sub>), clearance (<i>C</i><sub>L</sub>), apparent volume of distribution (<i>V</i><sub>d</sub>), and the mean residence time. The oral bioavailability (<i>F</i>) is calculated according to the following equation: <i>F</i> = AUC<sub>0ââ</sub> (oral)/AUC<sub>0ââ</sub> (iv) Ã dose (iv)/dose (oral) Ã 100%.</div></div><div id="sec5_69" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> Xenograft Tumor Model</h3><div class="NLM_p last">Five-week old female BALB/C-nu mice were purchased from the Shanghai Experimental Center, Chinese Academy of Sciences (Shanghai, China). All animals were housed in a specific pathogen-free facility and used according to the animal care regulations of Hefei Institutes of Physical Science, Chinese Academy of Sciences (Hefei, China). Prior to implantation, cells were harvested during exponential growth. One to five million BaF3-tel-c-KIT-T670I, BaF3-tel-c-KIT-D820G, BaF3-tel-c-KIT-Y823D, GIST-T1, GIST-T1-T670I, and GIST-5R cells in phosphate-buffered saline were formulated as a 1:1 mixture with Matrigel (BD Biosciences) and injected into the subcutaneous space on the right flank of nu/nu mice. Daily oral administration was initiated when tumors had reached a size of 200â400 mm<sup>3</sup>. Animals were then randomized into treatment groups of 5 mice each for efficacy studies. Compound <b>18</b> was delivered daily in a HKI solution (0.5% methocellulose/0.4% Tween80 in <i>dd</i>H<sub>2</sub>O) by oral gavage. A range of doses of compound <b>18</b> or its vehicle as the control were administered. Body weight was measured daily, and tumor growth was measured every day after compound <b>18</b> treatment. Tumor volume was calculated as follows: tumor volume (mm<sup>3</sup>) = [(<i>W</i><sup>2</sup> Ã <i>L</i>)/2] in which width (<i>W</i>) is defined as the smaller of the two measurements, and length (<i>L</i>) is defined as the larger of the two measurements.</div></div><div id="sec5_70" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> Molecular Modeling</h3><div class="NLM_p last">All calculations were performed using the SchrÃ¶dinger Suite. The DFG-out c-KIT complex (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK">6GQK</a>) was used for docking studies. The crystal structure was prepared using the Protein Preparation Wizard, and the T670I mutant was modeled in situ within Maestro. The ligand structures were built in Maestro and prepared for docking using LigPrep (LigPrep 3.4, SchrÃ¶dinger, LLC, New York, NY) and further docked into the receptor by the IFD protocol (Induced Fit Docking protocol, SchrÃ¶dinger, LLC, New York, NY).</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i92"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00280" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37313" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37313" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00280" class="ext-link">10.1021/acs.jmedchem.9b00280</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">DiscoverXâs KINOMEScan selectivity profiling data of <b>18</b>, expression and autophosphorylation inhibition of PDGFRÎ±, PDGFRÎ², and CSF1R in GIST-T1 cells, effects of selective PDGFRÎ± inhibitor CHMFL-PDGFR-159 on PDGFR-mediated signaling pathways in GIST-T1 cells and antiproliferation against GIST-T1 cells, PK profiles of <b>18</b> in mice, rats, and beagle dogs, and PD effect of <b>18</b> on tumor p-c-KIT, p-ERK, and p-AKT in the GIST-T1-T670I mouse xenograft model from a single dose of 80 mg/kg/day (p.o.) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Docking poses for <b>1</b>, <b>2</b>, and <b>18</b> with c-KIT wt, c-KIT V654A, and c-KIT T670I (PDB) (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_003.zip" class="ext-link">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf">jm9b00280_si_001.pdf (733.28 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_002.csv">jm9b00280_si_002.csv (5.56 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_003.zip">jm9b00280_si_003.zip (0.98 MB)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00280" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71802" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71802" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingsong Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Institutes
of Physical Science and Information Technology, Anhui University, Hefei, Anhui 230601, P. R. China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-7829-2547" title="Orcid link">http://orcid.org/0000-0002-7829-2547</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#fc8d8f909589c5cbbc94919a90d29d9fd29f92"><span class="__cf_email__" data-cfemail="7706041b1e024e40371f1a111b591614591419">[emailÂ protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jing Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-9513-3591" title="Orcid link">http://orcid.org/0000-0001-9513-3591</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#690300070e05001c2901040f0547080a470a07"><span class="__cf_email__" data-cfemail="177d7e79707b7e62577f7a717b397674397479">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yun Wu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beilei Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Junjie Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuang Qi</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengming Zou</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ziping Qi</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Feiyang Liu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qingwang Liu</span> - <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Chen</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chen Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhenquan Hu</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Aoli Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Li Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">University
of Science and Technology of China, Hefei, Anhui 230026, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenchao Wang</span> - <span class="hlFld-Affiliation affiliation">High
Magnetic Field Laboratory, Key Laboratory of High Magnetic Field and
Ion Beam Physical Biology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, Anhui 230031, China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Ren</span> - <span class="hlFld-Affiliation affiliation">Precision
Medicine Research Laboratory of Anhui Province, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precision
Targeted Therapy Discovery Center, Institute of Technology Innovation,
Hefei Institutes of Physical Science, Chinese
Academy of Sciences, Hefei, Anhui 230088, P. R. China</span>;Â 
    <span class="hlFld-Affiliation affiliation">Precedo
Pharmaceuticals Inc, Hefei, Anhui 230088, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yujiao Cai</span> - <span class="hlFld-Affiliation affiliation">Department
of General Surgery, Second Hospital Affiliated
to Army Medical University, Xinqiao Road, Chongqing 400037, P. R. China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingfeng Bai</span> - <span class="hlFld-Affiliation affiliation">Molecular
Imaging Laboratory, Department of Radiology, University of Pittsburgh
Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania 15219, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>The manuscript was written through contributions of all the authors. All the authors have given approval to the final version of the manuscript. Y.W., B.W., J.W., and S.Q. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i94">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78302" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78302" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by the National Natural Science Foundation of China (grants 81872748, 81603123, 81673469, 81773777, 81803366, 81703007, and 81370054), the âPersonalized Medicines-Molecular Signature-Based Drug Discovery and Developmentâ, Strategic Priority Research Program of the Chinese Academy of Sciences (grant XDA12020224), the Natural Science Foundation of Anhui Province (grants 1808085MH268, 1808085QH263), the Major Science and Technology Program of Anhui Province (grant 18030801116), the Key Research and Development Program of Anhui Province (grant 1704a0802140), the Key Technology Research and Development Program of Hefei (grant ZR201711290017), the Key Program of 13th five-year plan of CASHIPS (grant KP-2017-26), the Presidential Foundation of CASHIPS (grant YZJJ2018QN17), and the Frontier Science Key Research Program of CAS (grant QYZDB-SSW-SLH037). We are also grateful for the National Program for Support of Top-Notch Young Professionals for J.L. and the support of Hefei leading talent in 2017 for F.Z.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">GISTs</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumors</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">CSF1R</td><td class="NLM_def"><p class="first last">colony stimulating factor 1 receptor</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dimethyl chloride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyl uronium</p></td></tr><tr><td class="NLM_term">HOBT</td><td class="NLM_def"><p class="first last">hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3-dimethylaminopropyl)carbodiimide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72870" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72870" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 24 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumour</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">1731</span>â <span class="NLM_lpage">1741</span>, <span class="refDoi">Â DOI: 10.1016/s0140-6736(07)60780-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1016%2Fs0140-6736%2807%2960780-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=17512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFertrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2007&pages=1731-1741&author=B.+P.+Rubinauthor=M.+C.+Heinrichauthor=C.+L.+Corless&title=Gastrointestinal+stromal+tumour&doi=10.1016%2Fs0140-6736%2807%2960780-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Rubin, Brian P.; Heinrich, Michael C.; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">9574</span>),
    <span class="NLM_cas:pages">1731-1741</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy.  Such tumors usually have activating mutations in either KIT (75-80%) or PDGFRA (5-10%), two closely related receptor tyrosine kinases.  These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA.  Targeting these activated proteins with imatinib mesylate, a small-mol. kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumors and is now being tested as an adjuvant or neoadjuvant.  However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available.  The important interplay between the mol. genetics of gastrointestinal stromal tumor and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNtDxolv4iBrVg90H21EOLACvtfcHk0lgJmG9XmZ-pdw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFertrk%253D&md5=9a9d1fc97239da0bb0cfa8edb925524b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fs0140-6736%2807%2960780-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0140-6736%252807%252960780-6%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DGastrointestinal%2520stromal%2520tumour%26jtitle%3DLancet%26date%3D2007%26volume%3D369%26spage%3D1731%26epage%3D1741%26doi%3D10.1016%2Fs0140-6736%2807%2960780-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steigen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, T. J.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors (GISTs): a review</span>. <i>APMIS</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">73</span>â <span class="NLM_lpage">86</span>, <span class="refDoi">Â DOI: 10.1111/j.1600-0463.2008.00020.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1111%2Fj.1600-0463.2008.00020.x" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2010&pages=73-86&author=S.+E.+Steigenauthor=T.+J.+Eide&title=Gastrointestinal+stromal+tumors+%28GISTs%29%3A+a+review&doi=10.1111%2Fj.1600-0463.2008.00020.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0463.2008.00020.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0463.2008.00020.x%26sid%3Dliteratum%253Aachs%26aulast%3DSteigen%26aufirst%3DS.%2BE.%26aulast%3DEide%26aufirst%3DT.%2BJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors%2520%2528GISTs%2529%253A%2520a%2520review%26jtitle%3DAPMIS%26date%3D2010%26volume%3D117%26spage%3D73%26epage%3D86%26doi%3D10.1111%2Fj.1600-0463.2008.00020.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lennartsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ¶nnstrand, L.</span></span> <span> </span><span class="NLM_article-title">Stem cell factor receptor/c-Kit: from basic science to clinical implications</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1619</span>â <span class="NLM_lpage">1649</span>, <span class="refDoi">Â DOI: 10.1152/physrev.00046.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1152%2Fphysrev.00046.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=23073628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=1619-1649&author=J.+Lennartssonauthor=L.+R%C3%B6nnstrand&title=Stem+cell+factor+receptor%2Fc-Kit%3A+from+basic+science+to+clinical+implications&doi=10.1152%2Fphysrev.00046.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Stel cell factor receptor/c-Kit: from basic science to clinical implications</span></div><div class="casAuthors">Lennartsson, Johan; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1619-1649</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Stem cell factor (SCF) is a dimeric mol. that exerts its biol. functions by binding to and activating the receptor tyrosine kinase c-Kit.  Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction.  Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit.  Activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type.  Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system.  Deregulated c-Kit kinase activity has been found in a no. of pathol. conditions, including cancer and allergy.  The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clin. used inhibitor imatinib mesylate.  Also other clin. used multiselective kinase inhibitors, for instance, sorafenib and sunitinib, have c-Kit included in their range of targets.  Furthermore, loss-of-function mutations in c-Kit have been obsd. and shown to give rise to a condition called piebaldism.  This review provides a summary of our current knowledge regarding structural and functional aspects of c-Kit signaling both under normal and pathol. conditions, as well as advances in the development of low-mol.-wt. mols. inhibiting c-Kit function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiAi_V1Wivd7Vg90H21EOLACvtfcHk0lg2EGEgRSXZRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK&md5=b874bfb881938c505b6718732950be51</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00046.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00046.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLennartsson%26aufirst%3DJ.%26aulast%3DR%25C3%25B6nnstrand%26aufirst%3DL.%26atitle%3DStem%2520cell%2520factor%2520receptor%252Fc-Kit%253A%2520from%2520basic%2520science%2520to%2520clinical%2520implications%26jtitle%3DPhysiol.%2520Rev.%26date%3D2012%26volume%3D92%26spage%3D1619%26epage%3D1649%26doi%3D10.1152%2Fphysrev.00046.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad
Tunio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, Y.</span></span> <span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">580</span>, <span class="refDoi">Â DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad%0ATunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0lg2EGEgRSXZRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehren, M. v.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreevey, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbeele, A. D. V. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4342</span>â <span class="NLM_lpage">4349</span>, <span class="refDoi">Â DOI: 10.1200/jco.2003.04.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1200%2Fjco.2003.04.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=14645423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4342-4349&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=G.+D.+Demetriauthor=C.+D.+Blankeauthor=M.+v.+Mehrenauthor=H.+Joensuuauthor=L.+S.+McGreeveyauthor=C.-J.+Chenauthor=A.+D.+V.+d.+Abbeeleauthor=B.+J.+Drukerauthor=B.+Kieseauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=S.+Singerauthor=C.+D.+M.+Fletcherauthor=S.+Silbermanauthor=S.+Dimitrijevicauthor=J.+A.+Fletcher&title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor&doi=10.1200%2Fjco.2003.04.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Demetri, George D.; Blanke, Charles D.; von Mehren, Margaret; Joensuu, Heikki; McGreevey, Laura S.; Chen, Chang-Jie; Van den Abbeele, Annick D.; Druker, Brian J.; Kiese, Beate; Eisenberg, Burton; Roberts, Peter J.; Singer, Samuel; Fletcher, Christopher D. M.; Silberman, Sandra; Dimitrijevic, Sasa; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4342-4349</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.  The relationship between mutations in these kinases and clin. response to imatinib was examd. in a group of patients with advanced GIST.  Patients and Methods: GISTs from 127 patients enrolled onto a phase II clin. study of imatinib were examd. for mutations of KIT or PDGFRA.  Mutation types were correlated with clin. outcome.  Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, resp.  Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85).  All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro.  In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors contg. an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), resp.  Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.  Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clin. response to imatinib.  PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHal4hZZoc7Vg90H21EOLACvtfcHk0lg2EGEgRSXZRg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D&md5=cbfd753460bdf0005c3bd93f12df98dc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2Fjco.2003.04.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2003.04.190%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DMehren%26aufirst%3DM.%2Bv.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DMcGreevey%26aufirst%3DL.%2BS.%26aulast%3DChen%26aufirst%3DC.-J.%26aulast%3DAbbeele%26aufirst%3DA.%2BD.%2BV.%2Bd.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKinase%2520mutations%2520and%2520imatinib%2520response%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4342%26epage%3D4349%26doi%3D10.1200%2Fjco.2003.04.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zalcberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cesne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlemmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Glabbeke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, I. R.</span></span> <span> </span><span class="NLM_article-title">Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1751</span>â <span class="NLM_lpage">1757</span>, <span class="refDoi">Â DOI: 10.1016/j.ejca.2005.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1016%2Fj.ejca.2005.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=16098458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Wit7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=1751-1757&author=J.+R.+Zalcbergauthor=J.+Verweijauthor=P.+G.+Casaliauthor=A.+Le+Cesneauthor=P.+Reichardtauthor=J.-Y.+Blayauthor=M.+Schlemmerauthor=M.+Van+Glabbekeauthor=M.+Brownauthor=I.+R.+Judson&title=Outcome+of+patients+with+advanced+gastro-intestinal+stromal+tumours+crossing+over+to+a+daily+imatinib+dose+of+800mg+after+progression+on+400mg&doi=10.1016%2Fj.ejca.2005.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg</span></div><div class="casAuthors">Zalcberg, John R.; Verweij, Jaap; Casali, Paolo G.; Le Cesne, Axel; Reichardt, Peter; Blay, Jean-Yves; Schlemmer, Marcus; Van Glabbeke, Martine; Brown, Michelle; Judson, Ian R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1751-1757</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the EORTC-ISG-AGITG trial 946 patients with advanced gastro-intestinal stromal tumors (GIST) were randomized to receive 400 or 800 mg of imatinib daily.  An increase in progression free survival (PFS) was demonstrated for patients randomized to the high-dose arm.  Patients randomized to low-dose could cross-over to high-dose upon progression.  We evaluated the feasibility, safety and efficacy of this policy.  Of the 241 patients available for follow-up, 133 patients (55%) crossed over to high-dose imatinib according to the protocol.  Of these patients, 92% had not had a prior dose redn.  The cumulative incidence of subsequent dose redns. after cross-over was 17% after six months with 51% discontinuing therapy without requiring a dose redn.  The extent of anemia and fatigue increased significantly after cross-over, while neutropenia was less severe than during low-dose treatment.  Objective responses after cross-over included three patients (2%) with a partial response and 36 (27%) with stable disease.  The median PFS after cross-over was 81 days, although 18.1% of patients were still alive and progression free one year after cross-over.  We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVMCGcB-afobVg90H21EOLACvtfcHk0lj8LhQh2gN7Ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Wit7g%253D&md5=5d3478838ab344cfaf07ddbbfcc73f03</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DZalcberg%26aufirst%3DJ.%2BR.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DSchlemmer%26aufirst%3DM.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26atitle%3DOutcome%2520of%2520patients%2520with%2520advanced%2520gastro-intestinal%2520stromal%2520tumours%2520crossing%2520over%2520to%2520a%2520daily%2520imatinib%2520dose%2520of%2520800mg%2520after%2520progression%2520on%2520400mg%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D1751%26epage%3D1757%26doi%3D10.1016%2Fj.ejca.2005.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quenzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1542</span>â <span class="NLM_lpage">1547</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.-A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.-M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0lj8LhQh2gN7Ig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.-A.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.-M.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mckinley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5352</span>â <span class="NLM_lpage">5359</span>, <span class="refDoi">Â DOI: 10.1200/jco.2007.15.7461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1200%2Fjco.2007.15.7461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=18955458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCmtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5352-5359&author=M.+C.+Heinrichauthor=R.+G.+Makiauthor=C.+L.+Corlessauthor=C.+R.+Antonescuauthor=A.+Harlowauthor=D.+Griffithauthor=A.+Townauthor=A.+Mckinleyauthor=W.-B.+Ouauthor=J.+A.+Fletcherauthor=C.+D.+M.+Fletcherauthor=X.+Huangauthor=D.+P.+Cohenauthor=C.+M.+Baumauthor=G.+D.+Demetri&title=Primary+and+secondary+kinase+genotypes+correlate+with+the+biological+and+clinical+activity+of+sunitinib+in+imatinib-resistant+gastrointestinal+stromal+tumor&doi=10.1200%2Fjco.2007.15.7461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Maki, Robert G.; Corless, Christopher L.; Antonescu, Cristina R.; Harlow, Amy; Griffith, Diana; Town, Ajia; McKinley, Arin; Ou, Wen-Bin; Fletcher, Jonathan A.; Fletcher, Christopher D. M.; Huang, Xin; Cohen, Darrel P.; Baum, Charles M.; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5352-5359</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor Î± (PDGFRA) kinases, which are imatinib targets.  Sunitinib, which targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with GIST after they experience imatinib failure.  We evaluated the impact of primary and secondary kinase genotype on sunitinib activity.  Tumor responses were assessed radiol. in a phase I/II trial of sunitinib in 97 patients with metastatic, imatinib-resistant/intolerant GIST.  KIT/PDGFRA mutational status was detd. for 78 patients by using tumor specimens obtained before and after prior imatinib therapy.  Kinase mutants were biochem. profiled for sunitinib and imatinib sensitivity.  Clin. benefit (partial response or stable disease for â¥ 6 mo) with sunitinib was obsd. for the three most common primary GIST genotypes: KIT exon 9 (58%), KIT exon 11 (34%), and wild-type KIT/PDGFRA (56%).  Progression-free survival (PFS) was significantly longer for patients with primary KIT exon 9 mutations (P = .0005) or with a wild-type genotype (P = .0356) than for those with KIT exon 11 mutations.  The same pattern was obsd. for overall survival (OS).  PFS and OS were longer for patients with secondary KIT exon 13 or 14 mutations (which involve the KIT-ATP binding pocket) than for those with exon 17 or 18 mutations (which involve the KIT activation loop).  Biochem. profiling studies confirmed the clin. results.  The clin. activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases, which has implications for optimization of the treatment of patients with GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-Yvw1bbDYrVg90H21EOLACvtfcHk0lhNktIgaBc9ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCmtQ%253D%253D&md5=b84e19da0589f0ba6b12d8ed6b0da2c6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2Fjco.2007.15.7461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2007.15.7461%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DHarlow%26aufirst%3DA.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DMckinley%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DW.-B.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCohen%26aufirst%3DD.%2BP.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DPrimary%2520and%2520secondary%2520kinase%2520genotypes%2520correlate%2520with%2520the%2520biological%2520and%2520clinical%2520activity%2520of%2520sunitinib%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5352%26epage%3D5359%26doi%3D10.1200%2Fjco.2007.15.7461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butrynski, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Abbeele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manola, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2401</span>â <span class="NLM_lpage">2407</span>, <span class="refDoi">Â DOI: 10.1200/jco.2011.39.9394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1200%2Fjco.2011.39.9394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=22614970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aisbbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2401-2407&author=S.+Georgeauthor=Q.+Wangauthor=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=M.+Zhuauthor=J.+E.+Butrynskiauthor=J.+A.+Morganauthor=A.+J.+Wagnerauthor=E.+Choyauthor=W.+D.+Tapauthor=J.+T.+Yapauthor=A.+D.+Van+den+Abbeeleauthor=J.+B.+Manolaauthor=S.+M.+Solomonauthor=J.+A.+Fletcherauthor=M.+von+Mehrenauthor=G.+D.+Demetri&title=Efficacy+and+safety+of+regorafenib+in+patients+with+metastatic+and%2For+unresectable+GI+stromal+tumor+after+failure+of+imatinib+and+sunitinib%3A+A+multicenter+phase+II+trial&doi=10.1200%2Fjco.2011.39.9394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial</span></div><div class="casAuthors">George, Suzanne; Wang, Qian; Heinrich, Michael C.; Corless, Christopher L.; Zhu, Meijun; Butrynski, James E.; Morgan, Jeffrey A.; Wagner, Andrew J.; Choy, Edwin; Tap, William D.; Yap, Jeffrey T.; Van den Abbeele, Annick D.; Manola, Judith B.; Solomon, Sarah M.; Fletcher, Jonathan A.; von Mehren, Margaret; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2401-2407</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of imatinib and sunitinib.  Regorafenib is a structurally unique inhibitor of multiple cancer-assocd. kinases, including KIT and platelet-derived growth factor receptor (PDGFR), with broad-spectrum anticancer activity in preclin. and early-phase trials.  Because KIT and PDGFR-Î± remain drivers of GIST after resistance to imatinib and sunitinib, we performed a multicenter single-stage phase II trial of regorafenib in patients with advanced GIST after failure of at least imatinib and sunitinib.  Patients and Methods: Patients received regorafenib orally, 160 mg daily, on days 1 to 21 of a 28-day cycle.  Disease assessment was performed every two cycles per RECIST 1.1.  Primary end point was clin. benefit rate (CBR), defined as objective responses (ie, complete or partial response [PR] as well as stable disease [SD] â¥ 16 wk).  Serial tumor biopsies were obtained from consenting patients whenever possible.  Results From Feb. to Dec. 2010, 34 patients were enrolled at four US centers.  As of July 28, 2011, 33 patients had received at least two cycles of regorafenib (range, two to 17 cycles).  CBR was 79% (95% CI, 61% to 91%).  Four patients achieved PR, and 22 exhibited SD â¥ 16 wk.  Median progression-free survival was 10.0 mo.  The most common grade 3 toxicities were hypertension and hand-foot-skin reaction.  Conclusion: Regorafenib has significant activity in patients with advanced GIST after failure of both imatinib and sunitinib.  A phase III trial of regorafenib vs. placebo is ongoing to define more fully the safety and efficacy of regorafenib in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RtWuSuSFcbVg90H21EOLACvtfcHk0lhNktIgaBc9ZQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aisbbM&md5=54875f152708a1020a429f24cf398b30</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.39.9394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.39.9394%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DYap%26aufirst%3DJ.%2BT.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DManola%26aufirst%3DJ.%2BB.%26aulast%3DSolomon%26aufirst%3DS.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520regorafenib%2520in%2520patients%2520with%2520metastatic%2520and%252For%2520unresectable%2520GI%2520stromal%2520tumor%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%253A%2520A%2520multicenter%2520phase%2520II%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D2401%26epage%3D2407%26doi%3D10.1200%2Fjco.2011.39.9394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valverde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivares, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-Valverde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SuÃ¡rez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Barrera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carles, J.</span></span> <span> </span><span class="NLM_article-title">Novel insights into the treatment of imatinib-resistant gastrointestinal stromal tumors</span>. <i>Targeted Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">288</span>, <span class="refDoi">Â DOI: 10.1007/s11523-017-0490-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1007%2Fs11523-017-0490-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=28478525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A280%3ADC%252BC1crkslWgtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=277-288&author=C.+Serranoauthor=S.+Georgeauthor=C.+Valverdeauthor=D.+Olivaresauthor=A.+Garc%C3%ADa-Valverdeauthor=C.+Su%C3%A1rezauthor=R.+Morales-Barreraauthor=J.+Carles&title=Novel+insights+into+the+treatment+of+imatinib-resistant+gastrointestinal+stromal+tumors&doi=10.1007%2Fs11523-017-0490-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Serrano Cesar; Valverde Claudia; Suarez Cristina; Morales-Barrera Rafael; Carles Joan; Serrano Cesar; Olivares David; Garcia-Valverde Alfonso; George Suzanne; George Suzanne; Carles Joan</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-288</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) have emerged as a compelling clinical and biological model for the rational development of therapeutic strategies targeting critical oncogenic events over the past two decades.  Oncogenic activation of KIT or PDGFRA receptor tyrosine kinases is the crucial driver for GIST tumor initiation, transformation, and cancer cell proliferation.  Three tyrosine kinase inhibitors (TKIs) with KIT inhibitory activity - imatinib, sunitinib, and regorafenib - are approved to treat advanced GIST and have successfully exploited this addiction to KIT oncogenic signaling, demonstrating remarkable activity in a disease that historically had no successful systemic therapy options.  However, GIST refractory to approved TKIs remain an unmet clinical need, as virtually all patients with metastatic GIST eventually progress on any given therapy.  The main and best-established mechanism of resistance is the polyclonal expansion of multiple subpopulations harboring different secondary KIT mutations.  The present review aims at summarizing current and forthcoming treatment directions in advanced imatinib-resistant GIST supported by a strong biological rationale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOQAvzbjNN2pdYoSR9eyvsfW6udTcc2eYr5NYCbor1z7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crkslWgtQ%253D%253D&md5=071c98b43a1d806ee1fe9393957e6ab2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs11523-017-0490-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-017-0490-9%26sid%3Dliteratum%253Aachs%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DValverde%26aufirst%3DC.%26aulast%3DOlivares%26aufirst%3DD.%26aulast%3DGarc%25C3%25ADa-Valverde%26aufirst%3DA.%26aulast%3DSu%25C3%25A1rez%26aufirst%3DC.%26aulast%3DMorales-Barrera%26aufirst%3DR.%26aulast%3DCarles%26aufirst%3DJ.%26atitle%3DNovel%2520insights%2520into%2520the%2520treatment%2520of%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DTargeted%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3D277%26epage%3D288%26doi%3D10.1007%2Fs11523-017-0490-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vodala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5745</span>â <span class="NLM_lpage">5755</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-14-1397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1078-0432.ccr-14-1397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=25239608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5745-5755&author=A.+P.+Garnerauthor=J.+M.+Gozgitauthor=R.+Anjumauthor=S.+Vodalaauthor=A.+Schrockauthor=T.+Zhouauthor=C.+Serranoauthor=G.+Eilersauthor=M.+Zhuauthor=J.+Ketzerauthor=S.+Wardwellauthor=Y.+Ningauthor=Y.+Songauthor=A.+Kohlmannauthor=F.+Wangauthor=T.+Clacksonauthor=M.+C.+Heinrichauthor=J.+A.+Fletcherauthor=S.+Bauerauthor=V.+M.+Rivera&title=Ponatinib+inhibits+polyclonal+drug-resistant+KIT+oncoproteins+and+shows+therapeutic+potential+in+heavily+pretreated+gastrointestinal+stromal+tumor+%28GIST%29+patients&doi=10.1158%2F1078-0432.ccr-14-1397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients</span></div><div class="casAuthors">Garner, Andrew P.; Gozgit, Joseph M.; Anjum, Rana; Vodala, Sadanand; Schrock, Alexa; Zhou, Tianjun; Serrano, Cesar; Eilers, Grant; Zhu, Meijun; Ketzer, Julia; Wardwell, Scott; Ning, Yaoyu; Song, Youngchul; Kohlmann, Anna; Wang, Frank; Clackson, Tim; Heinrich, Michael C.; Fletcher, Jonathan A.; Bauer, Sebastian; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5745-5755</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST).  Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic.  Here, we explore the KIT-inhibitory activity of ponatinib in preclin. models and describe initial characterization of its activity in patients with GIST.  Exptl. Design: The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines.  The ponatinib-KIT costructure was also detd.  The clin. activity of ponatinib was examd. in three patients with GIST previously treated with all three FDA-approved agents.  Results: In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop.  Ponatinib also induced regression in engineered and GIST-derived tumor models contg. these secondary mutations.  In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L.  This inhibitory profile could be rationalized on the basis of structural analyses.  Ponatinib (30 mg daily) displayed encouraging clin. activity in two of three patients with GIST.  Conclusion:Ponatinib possesses potent activity against most major clin. relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST.  These data strongly support further evaluation of ponatinib in patients with GIST.  Clin Cancer Res; 20(22); 5745-55. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGG18CSl3XLVg90H21EOLACvtfcHk0liKVXJs0xNZNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E&md5=7537e45f37546f9e0cb799bdf05ed847</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-14-1397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-14-1397%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DVodala%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520inhibits%2520polyclonal%2520drug-resistant%2520KIT%2520oncoproteins%2520and%2520shows%2520therapeutic%2520potential%2520in%2520heavily%2520pretreated%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5745%26epage%3D5755%26doi%3D10.1158%2F1078-0432.ccr-14-1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebreyohannes, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¶ffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Looy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vreys, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornillie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanleeuw, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debiec-Rychter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib is active against human gastrointestinal stromal tumor xenografts carrying different KIT mutations</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2845</span>â <span class="NLM_lpage">2852</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-16-0224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1535-7163.mct-16-0224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=27777285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFynt7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2845-2852&author=Y.+K.+Gebreyohannesauthor=P.+Sch%C3%B6ffskiauthor=T.+Van+Looyauthor=J.+Wellensauthor=L.+Vreysauthor=J.+Cornillieauthor=U.+Vanleeuwauthor=D.+T.+Aftabauthor=M.+Debiec-Rychterauthor=R.+Sciotauthor=A.+Wozniak&title=Cabozantinib+is+active+against+human+gastrointestinal+stromal+tumor+xenografts+carrying+different+KIT+mutations&doi=10.1158%2F1535-7163.mct-16-0224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations</span></div><div class="casAuthors">Gebreyohannes, Yemarshet K.; Schoffski, Patrick; Van Looy, Thomas; Wellens, Jasmien; Vreys, Lise; Cornillie, Jasmien; Vanleeuw, Ulla; Aftab, Dana T.; Debiec-Rychter, Maria; Sciot, Raf; Wozniak, Agnieszka</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2845-2852</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In the majority of gastrointestinal stromal tumors (GIST), oncogenic signaling is driven by KIT mutations.  Advanced GIST is treated with tyrosine kinase inhibitors (TKI) such as imatinib.  Acquired resistance to TKI is mainly caused by secondary KIT mutations, but can also be attributed to a switch of KIT dependency to another receptor tyrosine kinase (RTK).  We tested the efficacy of cabozantinib, a novel TKI targeting KIT, MET, AXL, and vascular endothelial growth factor receptors (VEGFR), in patient-derived xenograft (PDX) models of GIST, carrying different KIT mutations.  NMRI nu/nu mice (n = 52) were bilaterally transplanted with human GIST: UZLX-GIST4 (KIT exon 11 mutation, imatinib sensitive), UZLX-GIST2 (KIT exon 9, imatinib dose-dependent resistance), or UZLX-GIST9 (KIT exon 11 and 17 mutations, imatinib resistant).  Mice were grouped as control (untreated), imatinib (50 mg/kg/bid), and cabozantinib (30 mg/kg/qd) and treated orally for 15 days.  Cabozantinib resulted in significant tumor regression in UZLX-GIST4 and -GIST2 and delayed tumor growth in -GIST9.  In all three models, cabozantinib inhibited the proliferative activity, which was completely absent in UZLX-GIST4 and significantly reduced in -GIST2 and -GIST9.  Increased apoptotic activity was obsd. only in UZLX-GIST4.  Cabozantinib inhibited the KIT signaling pathway in UZLX-GIST4 and -GIST2.  In addn., compared with both control and imatinib, cabozantinib significantly reduced microvessel d. in all models.  In conclusion, cabozantinib showed antitumor activity in GIST PDX models through inhibition of tumor growth, proliferation, and angiogenesis, in both imatinib-sensitive and imatinib-resistant models.  Mol Cancer Ther; 15(12); 2845-52. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGOXU3S6aJ0rVg90H21EOLACvtfcHk0liKVXJs0xNZNA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFynt7jM&md5=7c8970124406fefac29156d3eb4d0e63</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-16-0224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-16-0224%26sid%3Dliteratum%253Aachs%26aulast%3DGebreyohannes%26aufirst%3DY.%2BK.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DVan%2BLooy%26aufirst%3DT.%26aulast%3DWellens%26aufirst%3DJ.%26aulast%3DVreys%26aufirst%3DL.%26aulast%3DCornillie%26aufirst%3DJ.%26aulast%3DVanleeuw%26aufirst%3DU.%26aulast%3DAftab%26aufirst%3DD.%2BT.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DWozniak%26aufirst%3DA.%26atitle%3DCabozantinib%2520is%2520active%2520against%2520human%2520gastrointestinal%2520stromal%2520tumor%2520xenografts%2520carrying%2520different%2520KIT%2520mutations%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2845%26epage%3D2852%26doi%3D10.1158%2F1535-7163.mct-16-0224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebreyohannes, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornillie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanleeuw, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardino, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debiec-Rychter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¶ffski, P.</span></span> <span> </span><span class="NLM_article-title">Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">609</span>â <span class="NLM_lpage">618</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-18-1858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1078-0432.ccr-18-1858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=30274985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A280%3ADC%252BB3czkslClsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=609-618&author=Y.+K.+Gebreyohannesauthor=A.+Wozniakauthor=M.-E.+Zhaiauthor=J.+Wellensauthor=J.+Cornillieauthor=U.+Vanleeuwauthor=E.+Evansauthor=A.+K.+Gardinoauthor=C.+Lengauerauthor=M.+Debiec-Rychterauthor=R.+Sciotauthor=P.+Sch%C3%B6ffski&title=Robust+Activity+of+Avapritinib%2C+Potent+and+Highly+Selective+Inhibitor+of+Mutated+KIT%2C+in+Patient-derived+Xenograft+Models+of+Gastrointestinal+Stromal+Tumors&doi=10.1158%2F1078-0432.ccr-18-1858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Gebreyohannes Yemarshet K; Wozniak Agnieszka; Zhai Madalina-Elena; Wellens Jasmien; Cornillie Jasmien; Vanleeuw Ulla; Schoffski Patrick; Evans Erica; Gardino Alexandra K; Lengauer Christoph; Debiec-Rychter Maria; Sciot Raf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-618</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  Gastrointestinal stromal tumors (GIST) are commonly treated with tyrosine kinase inhibitors (TKI).  The majority of patients with advanced GIST ultimately become resistant to TKI due to acquisition of secondary KIT mutations, whereas primary resistance is mainly caused by PDGFRA p.D842V mutation.  We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations, with differential sensitivity to standard TKI.Experimental Design: NMRI nu/nu mice (n = 93) were transplanted with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9 (KIT 11+17) ), exon 11 (UZLX-GIST3 (KIT 11) ), or exon 9 (UZLX-GIST2B (KIT9) ) mutations, respectively.  We compared avapritinib (10 and 30 mg/kg/once daily) versus vehicle, imatinib (50 mg/kg/bid) or regorafenib (30 mg/kg/once daily; UZLX-GIST9 (KIT11+17) ); avapritinib (10, 30, 100 mg/kg/once daily) versus vehicle or imatinib [UZLX-GIST3 (KIT11) ]; and avapritinib (10, 30, 60 mg/kg/once daily) versus vehicle, imatinib (50, 100 mg/kg/twice daily), or sunitinib (40 mg/kg/once daily; UZLX-GIST2B (KIT9) ).  RESULTS:  In all models, avapritinib resulted in reduction of tumor volume, significant inhibition of proliferation, and reduced KIT signaling.  In two models, avapritinib led to remarkable histologic responses, increase in apoptosis, and inhibition of MAPK-phosphorylation.  Avapritinib showed superior (UZLX-GIST9 (KIT 11+17) and -GIST2B (KIT 9) ) or equal (UZLX-GIST3 (KIT 11) ) antitumor activity to the standard dose of imatinib.  In UZLX-GIST9 (KIT 11+17) , the antitumor effects of avapritinib were significantly better than with imatinib or regorafenib.  CONCLUSIONS:  Avapritinib has significant antitumor activity in GIST PDX models characterized by different KIT mutations and sensitivity to established TKI.  These data provide strong support for the ongoing clinical trials with avapritinib in patients with GIST (NCT02508532, NCT03465722).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQPWswagAFJBOb6AVA-44PTfW6udTcc2eZrk24dh2sQbbntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czkslClsg%253D%253D&md5=cb62624c4777c7be59e1fd08a39a584f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-18-1858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-18-1858%26sid%3Dliteratum%253Aachs%26aulast%3DGebreyohannes%26aufirst%3DY.%2BK.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DZhai%26aufirst%3DM.-E.%26aulast%3DWellens%26aufirst%3DJ.%26aulast%3DCornillie%26aufirst%3DJ.%26aulast%3DVanleeuw%26aufirst%3DU.%26aulast%3DEvans%26aufirst%3DE.%26aulast%3DGardino%26aufirst%3DA.%2BK.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26atitle%3DRobust%2520Activity%2520of%2520Avapritinib%252C%2520Potent%2520and%2520Highly%2520Selective%2520Inhibitor%2520of%2520Mutated%2520KIT%252C%2520in%2520Patient-derived%2520Xenograft%2520Models%2520of%2520Gastrointestinal%2520Stromal%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D609%26epage%3D618%26doi%3D10.1158%2F1078-0432.ccr-18-1858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhavsar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moleva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimpl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stead, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(4-{[5-fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8797</span>â <span class="NLM_lpage">8810</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00938</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00938" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12isrzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8797-8810&author=J.+G.+Kettleauthor=R.+Anjumauthor=E.+Barryauthor=D.+Bhavsarauthor=C.+Brownauthor=S.+Boydauthor=A.+Campbellauthor=K.+Goldbergauthor=M.+Grondineauthor=S.+Guichardauthor=C.+J.+Hardyauthor=T.+Huntauthor=R.+D.+O.+Jonesauthor=X.+Liauthor=O.+Molevaauthor=D.+Oggauthor=R.+C.+Overmanauthor=M.+J.+Packerauthor=S.+Pearsonauthor=M.+Schimplauthor=W.+Shaoauthor=A.+Smithauthor=J.+M.+Smithauthor=D.+Steadauthor=S.+Stokesauthor=M.+Tuckerauthor=Y.+Ye&title=Discovery+of+N-%284-%7B%5B5-fluoro-7-%282-methoxyethoxy%29quinazolin-4-yl%5Damino%7Dphenyl%29-2-%5B4-%28propan-2-yl%29-1H-1%2C2%2C3-triazol-1-yl%5Dacetamide+%28AZD3229%29%2C+a+potent+pan-KIT+mutant+inhibitor+for+the+treatment+of+gastrointestinal+stromal+tumors&doi=10.1021%2Facs.jmedchem.8b00938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Kettle, Jason G.; Anjum, Rana; Barry, Evan; Bhavsar, Deepa; Brown, Crystal; Boyd, Scott; Campbell, Andrew; Goldberg, Kristin; Grondine, Michael; Guichard, Sylvie; Hardy, Christopher J.; Hunt, Tom; Jones, Rhys D. O.; Li, Xiuwei; Moleva, Olga; Ogg, Derek; Overman, Ross C.; Packer, Martin J.; Pearson, Stuart; Schimpl, Marianne; Shao, Wenlin; Smith, Aaron; Smith, James M.; Stead, Darren; Stokes, Steve; Tucker, Michael; Ye, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8797-8810</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of inhibiting KIT-driven proliferation, diverse mutations to this kinase drive resistance to established therapies.  Here we describe the identification of potent pan-KIT mutant kinase inhibitors that can be dosed without being limited by the tolerability issues seen with multitargeted agents.  This effort focused on identification and optimization of an existing kinase scaffold through the use of structure-based design.  Starting from a series of previously reported phenoxyquinazoline and quinoline based inhibitors of the tyrosine kinase PDGFRÎ±, potency against a diverse panel of mutant KIT driven Ba/F3 cell lines was optimized, with a particular focus on reducing activity against a KDR driven cell model in order to limit the potential for hypertension commonly seen in second and third line GIST therapies.  AZD3229 demonstrates potent single digit nM growth inhibition across a broad cell panel, with good margin to KDR-driven effects.  Selectivity over KDR can be rationalized predominantly by the interaction of water mols. with the protein and ligand in the active site, and its kinome selectivity is similar to the best of the approved GIST agents.  This compd. demonstrates excellent cross-species pharmacokinetics, shows strong pharmacodynamic inhibition of target, and is active in several in vivo models of GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa2ACsIdMk2bVg90H21EOLACvtfcHk0lhVS-KqQUGjNQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12isrzI&md5=c258e7b529e8c029804278526a6b2ee1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00938%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DBarry%26aufirst%3DE.%26aulast%3DBhavsar%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DC.%26aulast%3DBoyd%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DK.%26aulast%3DGrondine%26aufirst%3DM.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DHardy%26aufirst%3DC.%2BJ.%26aulast%3DHunt%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DR.%2BD.%2BO.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMoleva%26aufirst%3DO.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DOverman%26aufirst%3DR.%2BC.%26aulast%3DPacker%26aufirst%3DM.%2BJ.%26aulast%3DPearson%26aufirst%3DS.%26aulast%3DSchimpl%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DJ.%2BM.%26aulast%3DStead%26aufirst%3DD.%26aulast%3DStokes%26aufirst%3DS.%26aulast%3DTucker%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520N-%25284-%257B%255B5-fluoro-7-%25282-methoxyethoxy%2529quinazolin-4-yl%255Damino%257Dphenyl%2529-2-%255B4-%2528propan-2-yl%2529-1H-1%252C2%252C3-triazol-1-yl%255Dacetamide%2520%2528AZD3229%2529%252C%2520a%2520potent%2520pan-KIT%2520mutant%2520inhibitor%2520for%2520the%2520treatment%2520of%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8797%26epage%3D8810%26doi%3D10.1021%2Facs.jmedchem.8b00938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneeweiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenwort, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiljkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jawhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanzl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndlhofer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadzijusufovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleixner, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettelheim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geissler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperr, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span> <span> </span><span class="NLM_article-title">The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">799</span>â <span class="NLM_lpage">809</span>, <span class="refDoi">Â DOI: 10.3324/haematol.2017.179895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.3324%2Fhaematol.2017.179895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=29439183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFCnu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=799-809&author=M.+Schneeweissauthor=B.+Peterauthor=S.+Bibiauthor=G.+Eisenwortauthor=D.+Smiljkovicauthor=K.+Blattauthor=M.+Jawharauthor=D.+Bergerauthor=G.+Stefanzlauthor=S.+Herndlhoferauthor=G.+Greinerauthor=G.+Hoermannauthor=E.+Hadzijusufovicauthor=K.+V.+Gleixnerauthor=P.+Bettelheimauthor=K.+Geisslerauthor=W.+R.+Sperrauthor=A.+Reiterauthor=M.+Arockauthor=P.+Valent&title=The+KIT+and+PDGFRA+switch-control+inhibitor+DCC-2618+blocks+growth+and+survival+of+multiple+neoplastic+cell+types+in+advanced+mastocytosis&doi=10.3324%2Fhaematol.2017.179895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis</span></div><div class="casAuthors">Schneeweiss, Mathias; Peter, Barbara; Bibi, Siham; Eisenwort, Gregor; Smiljkovic, Dubravka; Blatt, Katharina; Jawhar, Mohamad; Berger, Daniela; Stefanzl, Gabriele; Herndlhofer, Susanne; Greiner, Georg; Hoermann, Gregor; Hadzijusufovic, Emir; Gleixner, Karoline V.; Bettelheim, Peter; Geissler, Klaus; Sperr, Wolfgang R.; Reiter, Andreas; Arock, Michel; Valent, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">799-809</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs.  Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib.  Clin. problems in systemic mastocytosis arise from mediator-related symptoms and/or organ destruction caused by malignant expansion of neoplastic mast cells and/or other myeloid cells in various organ systems.  DCC-2618 is a spectrum-selective pan KIT and PDGFRA inhibitor which blocks KIT D816V and multiple other kinase targets relevant to systemic mastocytosis.  We found that DCC-2618 inhibits the proliferation and survival of various human mast cell lines (HMC-1, ROSA, MCPV-1) as well as primary neoplastic mast cells obtained from patients with advanced systemic mastocytosis (IC50 <1 Î¼M).  Moreover, DCC-2618 decreased growth and survival of primary neoplastic eosinophils obtained from patients with systemic mastocytosis or eosinophilic leukemia, leukemic monocytes obtained from patients with chronic myelomonocytic leukemia with or without concomitant systemic mastocytosis, and blast cells obtained from patients with acute myeloid leukemia.  Furthermore, DCC-2618 was found to suppress the proliferation of endothelial cells, suggesting addnl. drug effects on systemic mastocytosis-related angiogenesis.  Finally, DCC-2618 was found to downregulate IgE-mediated histamine release from basophils and tryptase release from mast cells.  Together, DCC-2618 inhibits growth, survival and activation of multiple cell types relevant to advanced systemic mastocytosis.  Whether DCC-2618 is effective in vivo in patients with advanced systemic mastocytosis is currently under investigation in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGYf2PuUqSe7Vg90H21EOLACvtfcHk0ljA77eiWL9Org"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFCnu78%253D&md5=7db381be140adfbbe321d97bd31f2069</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.179895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.179895%26sid%3Dliteratum%253Aachs%26aulast%3DSchneeweiss%26aufirst%3DM.%26aulast%3DPeter%26aufirst%3DB.%26aulast%3DBibi%26aufirst%3DS.%26aulast%3DEisenwort%26aufirst%3DG.%26aulast%3DSmiljkovic%26aufirst%3DD.%26aulast%3DBlatt%26aufirst%3DK.%26aulast%3DJawhar%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DD.%26aulast%3DStefanzl%26aufirst%3DG.%26aulast%3DHerndlhofer%26aufirst%3DS.%26aulast%3DGreiner%26aufirst%3DG.%26aulast%3DHoermann%26aufirst%3DG.%26aulast%3DHadzijusufovic%26aufirst%3DE.%26aulast%3DGleixner%26aufirst%3DK.%2BV.%26aulast%3DBettelheim%26aufirst%3DP.%26aulast%3DGeissler%26aufirst%3DK.%26aulast%3DSperr%26aufirst%3DW.%2BR.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DArock%26aufirst%3DM.%26aulast%3DValent%26aufirst%3DP.%26atitle%3DThe%2520KIT%2520and%2520PDGFRA%2520switch-control%2520inhibitor%2520DCC-2618%2520blocks%2520growth%2520and%2520survival%2520of%2520multiple%2520neoplastic%2520cell%2520types%2520in%2520advanced%2520mastocytosis%26jtitle%3DHaematologica%26date%3D2018%26volume%3D103%26spage%3D799%26epage%3D809%26doi%3D10.3324%2Fhaematol.2017.179895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I âGatekeeperâ Mutant of cKIT Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8456</span>â <span class="NLM_lpage">8472</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7vK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8456-8472&author=B.+Liauthor=A.+Wangauthor=J.+Liuauthor=Z.+Qiauthor=X.+Liuauthor=K.+Yuauthor=H.+Wuauthor=C.+Chenauthor=C.+Huauthor=W.+Wangauthor=J.+Wuauthor=Z.+Huauthor=L.+Yeauthor=F.+Zouauthor=F.+Liuauthor=B.+Wangauthor=L.+Wangauthor=T.+Renauthor=S.+Zhangauthor=M.+Baiauthor=S.+Zhangauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+N-%28%281-%284-%283-%283-%28%286%2C7-Dimethoxyquinolin-3-yl%29oxy%29phenyl%29ureido%29-2-%28trifluoromethyl%29phenyl%29piperidin-4-yl%29methyl%29propionamide+%28CHMFL-KIT-8140%29+as+a+Highly+Potent+Type+II+Inhibitor+Capable+of+Inhibiting+the+T670I+%E2%80%9CGatekeeper%E2%80%9D+Mutant+of+cKIT+Kinase&doi=10.1021%2Facs.jmedchem.6b00902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase</span></div><div class="casAuthors">Li, Binhua; Wang, Aoli; Liu, Juan; Qi, Ziping; Liu, Xiaochuan; Yu, Kailin; Wu, Hong; Chen, Cheng; Hu, Chen; Wang, Wenchao; Wu, Jiaxin; Hu, Zhenquan; Ye, Ling; Zou, Fengming; Liu, Feiyang; Wang, Beilei; Wang, Li; Ren, Tao; Zhang, Shaojuan; Bai, Mingfeng; Zhang, Shanchun; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8456-8472</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CKIT kinase inhibitors, e.g., imatinib could induce drug-acquired mutations such as cKIT T670I that rendered drug resistance after chronic treatment.  Through a type II kinase inhibitor design approach the authors discovered a highly potent type II cKIT kinase inhibitor compd. 35 (CHMFL-KIT-8140), which potently inhibited both cKIT wt (IC50: 33 nM) and cKIT gatekeeper T670I mutant (IC50: 99 nM).  Compd. 35 displayed strong anti-proliferative effect against GISTs cancer cell lines GIST-T1 (cKIT wt, GI50: 4 nM) and GIST-5R (cKIT T670I, GI50: 26 nM).  In the cellular context it strongly inhibited c-KIT mediated signaling pathways and induced apoptosis.  In the BaF3-TEL-cKIT-T670I isogenic cell inoculated xenograft mouse model, 35 exhibited dose dependent tumor growth suppression efficacy and 100 mg/kg dosage provided 47.7% tumor growth inhibition (TGI) without obvious toxicity.  The authors believe compd. 35 would be a good pharmacol. tool for exploration of the cKIT-T670I mutant mediated pathol. in GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj62D00P-jObVg90H21EOLACvtfcHk0ljA77eiWL9Org"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7vK&md5=8911a8de7d377ab485504d493a0dd846</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00902%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520N-%2528%25281-%25284-%25283-%25283-%2528%25286%252C7-Dimethoxyquinolin-3-yl%2529oxy%2529phenyl%2529ureido%2529-2-%2528trifluoromethyl%2529phenyl%2529piperidin-4-yl%2529methyl%2529propionamide%2520%2528CHMFL-KIT-8140%2529%2520as%2520a%2520Highly%2520Potent%2520Type%2520II%2520Inhibitor%2520Capable%2520of%2520Inhibiting%2520the%2520T670I%2520%25E2%2580%259CGatekeeper%25E2%2580%259D%2520Mutant%2520of%2520cKIT%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8456%26epage%3D8472%26doi%3D10.1021%2Facs.jmedchem.6b00902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>â <span class="NLM_lpage">1241</span>, <span class="refDoi">Â DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+A+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0ljbFoSM-ghIlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520A%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ©lias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">336</span>, <span class="refDoi">Â DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0ljbFoSM-ghIlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odell, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrnes, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baleato, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashman, L. K.</span></span> <span> </span><span class="NLM_article-title">Resistance to c-KIT kinase inhibitors conferred by V654A mutation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1159</span>â <span class="NLM_lpage">1166</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-06-0641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1535-7163.mct-06-0641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=17363509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1159-1166&author=K.+G.+Robertsauthor=A.+F.+Odellauthor=E.+M.+Byrnesauthor=R.+M.+Baleatoauthor=R.+Griffithauthor=A.+B.+Lyonsauthor=L.+K.+Ashman&title=Resistance+to+c-KIT+kinase+inhibitors+conferred+by+V654A+mutation&doi=10.1158%2F1535-7163.mct-06-0641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to c-KIT kinase inhibitors conferred by V654A mutation</span></div><div class="casAuthors">Roberts, Kathryn G.; Odell, Adam F.; Byrnes, Ellen M.; Baleato, Rosa M.; Griffith, Renate; Lyons, Alan Bruce; Ashman, Leonie K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1159-1166</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Certain mutations within c-KIT cause constitutive activation of the receptor and have been assocd. with several human malignancies.  These include gastrointestinal stromal tumors (GIST), mastocytosis, acute myelogenous leukemia, and germ cell tumors.  The kinase inhibitor imatinib potently inhibits c-KIT and is approved for treatment of GIST.  However, secondary point mutations can develop within the kinase domain to confer resistance to imatinib and cause drug-resistant relapse.  A common mutation, which results in a V654A substitution, has been documented in imatinib-resistant GIST patients.  We expressed c-KIT cDNA constructs encoding the V654A substitution alone and in combination with a typical activating exon 11 mutation characteristic of GIST, V560G, in factor-dependent FDC-P1 cells.  The V654A substitution alone resulted in enhanced proliferation in c-KIT ligand (stem cell factor) but not factor independence.  Cells expressing the double mutant were, like those expressing single V560G mutant c-KIT, factor independent.  Anal. of cellular proliferation in the presence of imatinib showed that the V654A substitution alone conferred resistance.  The difference in sensitivity was esp. pronounced for cells expressing single mutant V560G c-KIT compared with double mutant V560G/V654A c-KIT.  The findings were supported by studies of c-KIT phosphorylation.  Anal. of the crystal structure of imatinib in complex with the kinase domain of c-KIT predicts that the V654A substitution directly affects the binding of imatinib to the receptor.  Alternative c-KIT inhibitors, nilotinib (AMN107) and PKC412, were also less active on V560G/V654A c-KIT than on the V560G single mutant; however, nilotinib, like imatinib, potently inhibited the V560G mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCNgmeMfhnN7Vg90H21EOLACvtfcHk0ljbFoSM-ghIlA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntLg%253D&md5=fbfc887ea53992caf668f89baf70a380</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-06-0641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-06-0641%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DK.%2BG.%26aulast%3DOdell%26aufirst%3DA.%2BF.%26aulast%3DByrnes%26aufirst%3DE.%2BM.%26aulast%3DBaleato%26aufirst%3DR.%2BM.%26aulast%3DGriffith%26aufirst%3DR.%26aulast%3DLyons%26aufirst%3DA.%2BB.%26aulast%3DAshman%26aufirst%3DL.%2BK.%26atitle%3DResistance%2520to%2520c-KIT%2520kinase%2520inhibitors%2520conferred%2520by%2520V654A%2520mutation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1159%26epage%3D1166%26doi%3D10.1158%2F1535-7163.mct-06-0641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcken, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span> <span> </span><span class="NLM_article-title">Principles and applications of halogen bonding in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1363</span>â <span class="NLM_lpage">1388</span>, <span class="refDoi">Â DOI: 10.1021/jm3012068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+applications+of+halogen+bonding+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Fjm3012068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0lixtosz_G4MKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520applications%2520of%2520halogen%2520bonding%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388%26doi%3D10.1021%2Fjm3012068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRÎ± kinase inhibitor for PDGFRÎ± driving chronic eosinophilic leukemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">366</span>â <span class="NLM_lpage">384</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1016%2Fj.ejmech.2018.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=29544149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslajtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=366-384&author=Q.+Wangauthor=F.+Liuauthor=S.+Qiauthor=Z.+Qiauthor=X.-E.+Yanauthor=B.+Wangauthor=A.+Wangauthor=W.+Wangauthor=C.+Chenauthor=X.+Liuauthor=Z.+Jiangauthor=Z.+Huauthor=L.+Wangauthor=W.+Wangauthor=T.+Renauthor=S.+Zhangauthor=C.-H.+Yunauthor=Q.+Liuauthor=J.+Liu&title=Discovery+of+4-%28%28N-%282-%28dimethylamino%29ethyl%29acrylamido%29methyl%29-N-%284-methyl-3-%28%284-%28pyridin-3-yl%29pyrimidin-2-yl%29amino%29phenyl%29benzamide+%28CHMFL-PDGFR-159%29+as+a+highly+selective+type+II+PDGFR%CE%B1+kinase+inhibitor+for+PDGFR%CE%B1+driving+chronic+eosinophilic+leukemia&doi=10.1016%2Fj.ejmech.2018.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRÎ± kinase inhibitor for PDGFRÎ± driving chronic eosinophilic leukemia</span></div><div class="casAuthors">Wang, Qiang; Liu, Feiyang; Qi, Shuang; Qi, Ziping; Yan, Xiao-E.; Wang, Beilei; Wang, Aoli; Wang, Wei; Chen, Cheng; Liu, Xiaochuan; Jiang, Zongru; Hu, Zhenquan; Wang, Li; Wang, Wenchao; Ren, Tao; Zhang, Shanchun; Yun, Cai-Hong; Liu, Qingsong; Liu, Jing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">366-384</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Through exploration of the non-highly conserved allosteric hydrophobic pocket generated by DFG-out shifting in the inactive conformation, we discovered a highly selective type II PDGFRÎ± kinase inhibitor 15i (CHMFL-PDGFRÎ±-159), which exhibited strong potency against purified PDGFRÎ± (IC50: 132 nM) but not structurally similar PDGFRÎ², ABL, c-KIT and VEGFR2 kinases.  In addn., it displayed a high selectivity profile (S score (10) = 0.02) at the concn. of 1 Î¼M among 468 kinases/mutants in the KINOMEscan profiling.  X-ray crystal structure of 15i in complex with PDGFRÎ± revealed a distinct binding feature in the allosteric hydrophobic pocket which might help to expand the diversity of type II kinase inhibitors.  Compd. 15i potently inhibited the proliferation of PDGFRÎ± driving Chronic Eosinophilic Leukemia (CEL) cell line EOL-1 through strong blockage of PDGFRÎ± mediated signaling pathways, arresting cell cycle progression, and induction of apoptosis.  Furthermore, compd. 15i effectively suppressed the EOL-1 tumor progression in the xenograft model and increased the survival rate in the engraftment tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAbce2hA0OhLVg90H21EOLACvtfcHk0lixtosz_G4MKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslajtrc%253D&md5=f256eddd3292193495c2f236e885304a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DX.-E.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%25204-%2528%2528N-%25282-%2528dimethylamino%2529ethyl%2529acrylamido%2529methyl%2529-N-%25284-methyl-3-%2528%25284-%2528pyridin-3-yl%2529pyrimidin-2-yl%2529amino%2529phenyl%2529benzamide%2520%2528CHMFL-PDGFR-159%2529%2520as%2520a%2520highly%2520selective%2520type%2520II%2520PDGFR%25CE%25B1%2520kinase%2520inhibitor%2520for%2520PDGFR%25CE%25B1%2520driving%2520chronic%2520eosinophilic%2520leukemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D366%26epage%3D384%26doi%3D10.1016%2Fj.ejmech.2018.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ison-Dugenny, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galimi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoddusi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee-Hoeflich, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holash, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluwe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleyer, S. C.</span></span> <span> </span><span class="NLM_article-title">Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4297</span>â <span class="NLM_lpage">4308</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-17-3795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1078-0432.ccr-17-3795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=29764854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFSgurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4297-4308&author=T.+Abramsauthor=A.+Connorauthor=C.+Fantonauthor=S.+B.+Cohenauthor=T.+Huberauthor=E.+E.+Hongauthor=X.+Niuauthor=J.+Klineauthor=M.+Ison-Dugennyauthor=S.+Harrisauthor=D.+Walkerauthor=K.+Krauserauthor=F.+Galimiauthor=Z.+Wangauthor=M.+Ghoddusiauthor=K.+Mansfieldauthor=S.+T.+Lee-Hoeflichauthor=J.+Holashauthor=N.+Pryerauthor=W.+Kluweauthor=S.+A.+Ettenbergauthor=W.+R.+Sellersauthor=E.+Leesauthor=P.+Kwonauthor=J.+A.+Abrahamauthor=S.+C.+Schleyer&title=Preclinical+antitumor+activity+of+a+novel+anti-c-KIT+antibody-drug+conjugate+against+mutant+and+wild-type+c-KIT-positive+solid+tumors&doi=10.1158%2F1078-0432.ccr-17-3795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors</span></div><div class="casAuthors">Abrams, Tinya; Connor, Anu; Fanton, Christie; Cohen, Steven B.; Huber, Thomas; Miller, Kathy; Hong, E. Erica; Niu, Xiaohong; Kline, Janine; Ison-Dugenny, Marjorie; Harris, Sarah; Walker, Dana; Krauser, Klaus; Galimi, Francesco; Wang, Zhen; Ghoddusil, Majid; Mansfield, Keith; Lee-Hoeflich, Si Tuen; Holash, Jocelyn; Pryer, Nancy; Kluwe, William; Ettenberg, Seth A.; Sellers, William R.; Lees, Emma; Kwon, Paul; Abraham, Judith A.; Schleyer, Slew C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4297-4308</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: c-KIT overexpression is well recognized in cancers such as gastrointestinal stromal tumors (GIST), small cell lung cancer (SCLC), melanoma, non-small cell lung cancer (NSCLC), and acute myelogenous leukemia (AML).  Treatment with the small-mol. inhibitors imatinib, sunitinib, and regorafenib resulted in resistance (c-KIT mutant tumors) or limited activity (c-KIT wild-type tumors).  We selected an anti-c-K1T ADC approach to evaluate the anticancer activity in multiple disease models.  Exptl. Design: A humanized anti-c-KIT antibody LMJ729 was conjugated to the microtubule destabilizing maytansinoid, DM I, via a nondeavable linker (SMCC).  The activity of the resulting ADC, LOP628, was evaluated in vitro against GIST, SCLC, and AML models and in vivo against GIST and SCLC models.  Results: 10P628 exhibited potent antiproliferative activity on c-KIT-pos. cell lines, whereas LMJ729 dis- played little to no effect.  At exposures predicted to be clin. achievable, LOP628 demonstrated single admin- istration regressions or stasis in GIST and SCLC xenograft models in mice.  LOP628 also displayed superior efficacy in an imatinib-resistant GIST model.  Further, LOP628 was well tolerated in monkeys with an adequate therapeutic index several fold above efficacious exposures.  Safety findings were consistent with the pharmacodynamic effect of neutropenia due to c-KIT-directed targeting.  Addnl. toxicities were considered off-target and were consistent with DM1, such as effects in the liver and hematopoietic/ lymphatic system.  Conclusions: The predinical findings suggest that the c-KIT-directed ADC may be a promising therapeutic for the treatment of mutant and wild-type c-KIT-pos. cancers and supported the clin. evaluation of LOP628 in GIST, AML and SCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUgbz5hjaoObVg90H21EOLACvtfcHk0lixtosz_G4MKg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFSgurg%253D&md5=d421d5fcb4b9a18d6c53c5a90d480a66</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-17-3795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-17-3795%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DConnor%26aufirst%3DA.%26aulast%3DFanton%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DHuber%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DE.%2BE.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DKline%26aufirst%3DJ.%26aulast%3DIson-Dugenny%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DKrauser%26aufirst%3DK.%26aulast%3DGalimi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGhoddusi%26aufirst%3DM.%26aulast%3DMansfield%26aufirst%3DK.%26aulast%3DLee-Hoeflich%26aufirst%3DS.%2BT.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DPryer%26aufirst%3DN.%26aulast%3DKluwe%26aufirst%3DW.%26aulast%3DEttenberg%26aufirst%3DS.%2BA.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DKwon%26aufirst%3DP.%26aulast%3DAbraham%26aufirst%3DJ.%2BA.%26aulast%3DSchleyer%26aufirst%3DS.%2BC.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520a%2520novel%2520anti-c-KIT%2520antibody-drug%2520conjugate%2520against%2520mutant%2520and%2520wild-type%2520c-KIT-positive%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D4297%26epage%3D4308%26doi%3D10.1158%2F1078-0432.ccr-17-3795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janeway, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahia, P. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liegl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raygada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâSullivan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Krijger, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinjens, W. N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratakis, C. A.</span></span> <span> </span><span class="NLM_article-title">Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">314</span>â <span class="NLM_lpage">318</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1009199108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1073%2Fpnas.1009199108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=21173220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms1Khug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=314-318&author=K.+A.+Janewayauthor=S.+Y.+Kimauthor=M.+Lodishauthor=V.+Noseauthor=P.+Rustinauthor=J.+Gaalauthor=P.+L.+M.+Dahiaauthor=B.+Lieglauthor=E.+R.+Ballauthor=M.+Raygadaauthor=A.+H.+Laiauthor=L.+Kellyauthor=J.+L.+Hornickauthor=M.+O%E2%80%99Sullivanauthor=R.+R.+de+Krijgerauthor=W.+N.+M.+Dinjensauthor=G.+D.+Demetriauthor=C.+R.+Antonescuauthor=J.+A.+Fletcherauthor=L.+Helmanauthor=C.+A.+Stratakis&title=Defects+in+succinate+dehydrogenase+in+gastrointestinal+stromal+tumors+lacking+KIT+and+PDGFRA+mutations&doi=10.1073%2Fpnas.1009199108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations</span></div><div class="casAuthors">Janeway, Katherine A.; Kim, Su Young; Lodish, Maya; Nose, Vania; Rustin, Pierre; Gaal, Jose; Dahia, Patricia L. M.; Liegl, Bernadette; Ball, Evan R.; Rayga, Margarita; Lai, Angela H.; Kelly, Lorna; Hornick, Jason L.; O'Sullivan, Maureen; de Krijger, Ronald R.; Dinjens, Winand N. M.; Demetri, George D.; Antonescu, Cristina R.; Fletcher, Jonathan A.; Helman, Lee; Stratakis, Constantine A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">314-318, S314/1-S314/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Carney-Stratakis syndrome, an inherited condition predisposing affected individuals to gastrointestinal stromal tumor (GIST) and paraganglioma, is caused by germline mutations in succinate dehydrogenase (SDH) subunits B, C, or D, leading to dysfunction of complex II of the electron transport chain.  We evaluated the role of defective cellular respiration in sporadic GIST lacking mutations in KIT or PDGFRA (WT).  Thirty-four patients with WT GIST without a personal or family history of paraganglioma were tested for SDH germline mutations.  WT GISTs lacking demonstrable SDH genetic inactivation were evaluated for SDHB expression by immunohistochem. and Western blotting and for complex II activity.  For comparison, SDHB expression was also detd. in KIT mutant and neurofibromatosis-1-assocd. GIST, and complex II activity was also measured in SDH-deficient paraganglioma and KIT mutant GIST; 4 of 34 patients (12%) with WT GIST without a personal or family history of paraganglioma had germline mutations in SDHB or SDHC.  WT GISTs lacking somatic mutations or deletions in SDH subunits had either complete loss of or substantial redn. in SDHB protein expression, whereas most KIT mutant GISTs had strong SDHB expression.  Complex II activity was substantially decreased in WT GISTs.  WT GISTs, particularly those in younger patients, have defects in SDH mitochondrial complex II, and in a subset of these patients, GIST seems to arise from germline-inactivating SDH mutations.  Testing for germline mutations in SDH is recommended in patients with WT GIST.  These findings highlight a potential central role of SDH dysregulation in WT GIST oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnKFZ6J_MtWLVg90H21EOLACvtfcHk0liNqy-T5ON2FQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms1Khug%253D%253D&md5=596ca3d096cb80d88bb2a67cfbf080a7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1009199108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1009199108%26sid%3Dliteratum%253Aachs%26aulast%3DJaneway%26aufirst%3DK.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLodish%26aufirst%3DM.%26aulast%3DNose%26aufirst%3DV.%26aulast%3DRustin%26aufirst%3DP.%26aulast%3DGaal%26aufirst%3DJ.%26aulast%3DDahia%26aufirst%3DP.%2BL.%2BM.%26aulast%3DLiegl%26aufirst%3DB.%26aulast%3DBall%26aufirst%3DE.%2BR.%26aulast%3DRaygada%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%2BH.%26aulast%3DKelly%26aufirst%3DL.%26aulast%3DHornick%26aufirst%3DJ.%2BL.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DM.%26aulast%3Dde%2BKrijger%26aufirst%3DR.%2BR.%26aulast%3DDinjens%26aufirst%3DW.%2BN.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DHelman%26aufirst%3DL.%26aulast%3DStratakis%26aufirst%3DC.%2BA.%26atitle%3DDefects%2520in%2520succinate%2520dehydrogenase%2520in%2520gastrointestinal%2520stromal%2520tumors%2520lacking%2520KIT%2520and%2520PDGFRA%2520mutations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D314%26epage%3D318%26doi%3D10.1073%2Fpnas.1009199108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janeway, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A.</span></span> <span> </span><span class="NLM_article-title">Treatment guidelines for gastrointestinal stromal tumors in children and young adults</span>. <i>J. Pediatr. Hematol./Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">S69</span>â <span class="NLM_lpage">S72</span>, <span class="refDoi">Â DOI: 10.1097/mph.0b013e31824e3899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1097%2Fmph.0b013e31824e3899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=22525410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVShtL7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=S69-S72&author=K.+A.+Janewayauthor=A.+Pappo&title=Treatment+guidelines+for+gastrointestinal+stromal+tumors+in+children+and+young+adults&doi=10.1097%2Fmph.0b013e31824e3899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment guidelines for gastrointestinal stromal tumors in children and young adults</span></div><div class="casAuthors">Janeway, Katherine A.; Pappo, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pediatric Hematology/Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">S69-S72</span>CODEN:
                <span class="NLM_cas:coden">JPHOFG</span>;
        ISSN:<span class="NLM_cas:issn">1077-4114</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumor (GIST) occurring in the pediatric population has a unique biol. and natural history when compared to GIST occurring in adults.  As a result of these unique features, management of GIST in children may need to differ from management of GIST in adults.  GIST is a very rare disease in children.  Consequently prospective clin. trials have not been performed.  A review of the biol., clin. presentation and natural history of GIST in children is presented.  Guidelines for diagnostic evaluation and management of GIST in children are presented.  The presented guidelines are based on clin. experience and data from case reports and case series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNqM5QsNCKwrVg90H21EOLACvtfcHk0liNqy-T5ON2FQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVShtL7N&md5=7091fba633742ba310acf94095cb9bf5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2Fmph.0b013e31824e3899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fmph.0b013e31824e3899%26sid%3Dliteratum%253Aachs%26aulast%3DJaneway%26aufirst%3DK.%2BA.%26aulast%3DPappo%26aufirst%3DA.%26atitle%3DTreatment%2520guidelines%2520for%2520gastrointestinal%2520stromal%2520tumors%2520in%2520children%2520and%2520young%2520adults%26jtitle%3DJ.%2520Pediatr.%2520Hematol.%252FOncol.%26date%3D2012%26volume%3D34%26spage%3DS69%26epage%3DS72%26doi%3D10.1097%2Fmph.0b013e31824e3899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 7 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Flocâh, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhengjie  Wang</span>, <span class="hlFld-ContribAuthor ">Limin  Liu</span>, <span class="hlFld-ContribAuthor ">Honglin  Dai</span>, <span class="hlFld-ContribAuthor ">Xiaojie  Si</span>, <span class="hlFld-ContribAuthor ">Luye  Zhang</span>, <span class="hlFld-ContribAuthor ">Erdong  Li</span>, <span class="hlFld-ContribAuthor ">Zhang  Yang</span>, <span class="hlFld-ContribAuthor ">Gao  Chao</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Zheng</span>, <span class="hlFld-ContribAuthor ">Yu  Ke</span>, <span class="hlFld-ContribAuthor ">Shan  Lihong</span>, <span class="hlFld-ContribAuthor ">Qiurong  Zhang</span>, <span class="hlFld-ContribAuthor ">Hongmin  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 2,4-disubstituted quinazoline derivatives targeting H1975 cells via EGFR-PI3K signaling pathway. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>43 </em>, 116265. <a href="https://doi.org/10.1016/j.bmc.2021.116265" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116265</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116265%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B2%25252C4-disubstituted%252Bquinazoline%252Bderivatives%252Btargeting%252BH1975%252Bcells%252Bvia%252BEGFR-PI3K%252Bsignaling%252Bpathway%26aulast%3DWang%26aufirst%3DZhengjie%26date%3D2021%26volume%3D43%26spage%3D116265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuping  Zhao</span>, <span class="hlFld-ContribAuthor ">Muhammad  Bilal</span>, <span class="hlFld-ContribAuthor ">Ali  Raza</span>, <span class="hlFld-ContribAuthor ">Muhammad Imran  Khan</span>, <span class="hlFld-ContribAuthor ">Shahid  Mehmood</span>, <span class="hlFld-ContribAuthor ">Uzma  Hayat</span>, <span class="hlFld-ContribAuthor ">Sherif T.S.  Hassan</span>, <span class="hlFld-ContribAuthor ">Hafiz M.N.  Iqbal</span>. </span><span class="cited-content_cbyCitation_article-title">Tyrosine kinase inhibitors and their unique therapeutic potentialities to combat cancer. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Biological Macromolecules</span><span> <strong>2021,</strong> <em>168 </em>, 22-37. <a href="https://doi.org/10.1016/j.ijbiomac.2020.12.009" title="DOI URL">https://doi.org/10.1016/j.ijbiomac.2020.12.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ijbiomac.2020.12.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ijbiomac.2020.12.009%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Biological%2520Macromolecules%26atitle%3DTyrosine%252Bkinase%252Binhibitors%252Band%252Btheir%252Bunique%252Btherapeutic%252Bpotentialities%252Bto%252Bcombat%252Bcancer%26aulast%3DZhao%26aufirst%3DYuping%26date%3D2021%26volume%3D168%26spage%3D22%26epage%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Wentao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xuesong  Liu</span>, <span class="hlFld-ContribAuthor ">Fengming  Zou</span>, <span class="hlFld-ContribAuthor ">Junjie  Wang</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Zhenquan  Hu</span>, <span class="hlFld-ContribAuthor ">Yongfei  Chen</span>, <span class="hlFld-ContribAuthor ">Shuang  Qi</span>, <span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>207 </em>, 112744. <a href="https://doi.org/10.1016/j.ejmech.2020.112744" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112744</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112744&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112744%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528E%252529-N-%2525284-methyl-5-%2525283-%2525282-%252528pyridin-2-yl%252529vinyl%252529-1H-indazol-6-yl%252529thiazol-2-yl%252529-2-%2525284-methylpiperazin-1-yl%252529acetamide%252B%252528IHMT-TRK-284%252529%252Bas%252Ba%252Bnovel%252Borally%252Bavailable%252Btype%252BII%252BTRK%252Bkinase%252Binhibitor%252Bcapable%252Bof%252Bovercoming%252Bmultiple%252Bresistant%252Bmutants%26aulast%3DWang%26aufirst%3DBeilei%26date%3D2020%26volume%3D207%26spage%3D112744" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Selvaraj  Shyamsivappan</span>, <span class="hlFld-ContribAuthor ">Arjunan  Saravanan</span>, <span class="hlFld-ContribAuthor ">Raju  Vivek</span>, <span class="hlFld-ContribAuthor ">Thangaraj  Suresh</span>, <span class="hlFld-ContribAuthor ">Ramasamy  Shankar</span>, <span class="hlFld-ContribAuthor ">K. M.  Gothandam</span>, <span class="hlFld-ContribAuthor ">Palathurai Subramaniam  Mohan</span>. </span><span class="cited-content_cbyCitation_article-title">Novel phenyl and thiophene dispiro indenoquinoxaline pyrrolidine quinolones induced apoptosis
              via
              G1/S and G2/M phase cell cycle arrest in MCF-7 cells. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2020,</strong> <em>44 </em>
                                    (35)
                                     , 15031-15045. <a href="https://doi.org/10.1039/D0NJ02588G" title="DOI URL">https://doi.org/10.1039/D0NJ02588G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ02588G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ02588G%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DNovel%252Bphenyl%252Band%252Bthiophene%252Bdispiro%252Bindenoquinoxaline%252Bpyrrolidine%252Bquinolones%252Binduced%252Bapoptosis%252Bvia%252BG1%25252FS%252Band%252BG2%25252FM%252Bphase%252Bcell%252Bcycle%252Barrest%252Bin%252BMCF-7%252Bcells%26aulast%3DShyamsivappan%26aufirst%3DSelvaraj%26date%3D2020%26date%3D2020%26volume%3D44%26issue%3D35%26spage%3D15031%26epage%3D15045" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zongru  Jiang</span>, <span class="hlFld-ContribAuthor ">Li  Wang</span>, <span class="hlFld-ContribAuthor ">Xuesong  Liu</span>, <span class="hlFld-ContribAuthor ">Cheng  Chen</span>, <span class="hlFld-ContribAuthor ">Beilei  Wang</span>, <span class="hlFld-ContribAuthor ">Wenliang  Wang</span>, <span class="hlFld-ContribAuthor ">Chen  Hu</span>, <span class="hlFld-ContribAuthor ">Kailin  Yu</span>, <span class="hlFld-ContribAuthor ">Ziping  Qi</span>, <span class="hlFld-ContribAuthor ">Qingwang  Liu</span>, <span class="hlFld-ContribAuthor ">Aoli  Wang</span>, <span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Guangchen  Hong</span>, <span class="hlFld-ContribAuthor ">Wenchao  Wang</span>, <span class="hlFld-ContribAuthor ">Qingsong  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmaceutica Sinica B</span><span> <strong>2020,</strong> <em>10 </em>
                                    (3)
                                     , 488-497. <a href="https://doi.org/10.1016/j.apsb.2019.10.004" title="DOI URL">https://doi.org/10.1016/j.apsb.2019.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.apsb.2019.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.apsb.2019.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmaceutica%2520Sinica%2520B%26atitle%3DDiscovery%252Bof%252Ba%252Bhighly%252Bselective%252BVEGFR2%252Bkinase%252Binhibitor%252BCHMFL-VEGFR2-002%252Bas%252Ba%252Bnovel%252Banti-angiogenesis%252Bagent%26aulast%3DJiang%26aufirst%3DZongru%26date%3D2020%26volume%3D10%26issue%3D3%26spage%3D488%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arduino  Mangoni</span>, <span class="hlFld-ContribAuthor ">Jean  Eynde</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Dimitra  Hadjipavlou-Litina</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">JÃ³hannes  Reynisson</span>, <span class="hlFld-ContribAuthor ">Maria  Sousa</span>, <span class="hlFld-ContribAuthor ">Paula  Gomes</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">F.  Luque</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">M.  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Christopher  Hulme</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Michael  GÃ¼tschow</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Carlo  Siciliano</span>, <span class="hlFld-ContribAuthor ">Raffaele  Capasso</span>, <span class="hlFld-ContribAuthor ">Luigi  Agrofoglio</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">Diego  MuÃ±oz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopesâ5. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (13)
                                     , 2415. <a href="https://doi.org/10.3390/molecules24132415" title="DOI URL">https://doi.org/10.3390/molecules24132415</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24132415&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24132415%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525935%26aulast%3DMangoni%26aufirst%3DArduino%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D13%26spage%3D2415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0019.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of representative inhibitors that bear c-KIT kinase activity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Schematic illustration of discovery of compound <b>18</b> (CHMFL-KIT-64) from <b>9</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Biochemical examination of compound <b>18</b>. (A) Treespot demonstration of selectivity profiling of <b>18</b> with DiscoverX KINOMEscan technology. Measurements were performed at a concentration of 1 Î¼M of the inhibitor. The affinity was defined with respect to a dimethyl sulfoxide (DMSO) control. (B) Biochemical tests of <b>18</b> with Invitrogen SelectScreen platform or Promegaâs ADP-Glo assay (IC<sub>50</sub>) and the antiproliferative effects of <b>18</b> on a panel of transformed BaF3 cells (GI<sub>50</sub>) against the kinase targets that demonstrated strong binding to <b>18</b> with a percent control number less than 1% in the KINOMEscan profiling.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Molecular modeling analysis of the binding modes of c-KIT wt/V654A/T670I with compounds <b>1</b>, <b>2</b>, and <b>18</b>. (A) X-ray of <b>1</b> with c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>); (B) binding mode of <b>1</b> with the c-KIT V654A homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>); (C) binding mode of <b>1</b> with c-KIT T670I homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46">1T46</a>); (D) X-ray of <b>2</b> with c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G0E">3G0E</a>); (E) binding mode of <b>2</b> with the c-KIT V654A homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G0E">3G0E</a>); (F) binding mode of <b>2</b> with the c-KIT T670I homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G0E">3G0E</a>); (G) binding mode of <b>18</b> with c-KIT wt (PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK">6GQK</a>); (H) binding mode of <b>18</b> with the c-KIT V654A homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK">6GQK</a>); (I) binding mode of <b>18</b> with the c-KIT T670I homology model (generated based on the PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK">6GQK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cellular effects of compound <b>18</b> in GIST cell lines GIST-T1, GIST-T1-T670I, and GIST-5R. (A) Effects of <b>18</b> on c-KIT mediated signaling pathways. (B) Effects of <b>18</b> on apoptosis. (C) Effects of <b>18</b> on cell cycle progression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Antiproliferative effects of compounds <b>18</b> and <b>1</b> against primary cells derived from GIST patients upon 6 days of drug treatment with the CellTiter-Glo assay.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. PD effect of <b>18</b> on tumor p-c-KIT, p-ERK, and p-AKT in the GIST-T1-T670I mouse xenograft model with a single dose of 80 mg/kg/day (p.o.).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Antitumor efficacy of <b>18</b> in the BaF3-tel-c-KIT-T670I xenograft mouse model. Female BALB/C-nu mice bearing established BaF3-tel-c-KIT-T670I tumor xenografts were treated with <b>18</b> at 40 and 100 mg/kg/day dosage or vehicle. (B) Antitumor efficacy of <b>18</b> in the BaF3-tel-c-KIT-D820G xenograft mouse model. Female BALB/C-nu mice bearing established BaF3-tel-c-KIT-D820G tumor xenografts were treated with <b>18</b> at 40 and 80 mg/kg/day dosage or vehicle. Daily oral administration was initiated when BaF3-tel-c-KIT-D820G tumors had reached a size of 200â400 mm<sup>3</sup>. (C) Antitumor efficacy of <b>18</b> in the BaF3-tel-c-KIT-Y823D xenograft mouse model. Female BALB/C-nu mice bearing established BaF3-tel-c-KIT-Y823D tumor xenografts were treated with <b>18</b> at 40 and 80 mg/kg/day dosage or vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Antitumor efficacy of <b>18</b> in the GIST-T1 xenograft mouse model. Female BALB/C-nu mice bearing established GIST-T1 tumor xenografts were treated with <b>18</b> at 20 and 40 mg/kg/day dosage or vehicle. (B) Antitumor efficacy of <b>18</b> in the GIST-T1-T670I xenograft mouse model. Female BALB/C-nu mice bearing established GIST-T1-T670I tumor xenografts were treated with <b>18</b> at 20 and 40 mg/kg/day dosage or vehicle. (C) Antitumor efficacy of <b>18</b> in the GIST-5R xenograft mouse model. Female BALB/C-nu mice bearing established GIST-5R tumor xenografts were treated with <b>18</b> at 20 and 40 mg/kg/day dosage or vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds <b>10â30</b>, <b>36â37</b>, and <b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-aminophenol or 4-amino-3-chlorophenol, NaH, DMSO, 110 Â°C, overnight; (b) R<sup>1</sup>CH<sub>2</sub>COOH or 1-phenyl-1-cyclopropanecarboxylic acid, HATU, DIPEA, DMF, rt, overnight; (c) cyclohexylacetyl chloride, DIPEA, DCM, 0 Â°C, 30 min; (d) 2-fluoro-4-nitrophenol or 3-fluoro-4-nitrophenol, Ph<sub>2</sub>O, 140 Â°C, overnight; (e) Fe, NH<sub>4</sub>Cl, EtOH, reflux, 5 h; (f) 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid, HATU, DIPEA, DMF, rt, overnight.</p></p></figure><figure data-id="sch2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compounds <b>31â32</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) methyl 4-hydroxybenzoate, 145 Â°C, overnight; (b) LiOH, CH<sub>3</sub>OH/THF, rt, overnight; (c) R<sup>1</sup>CH<sub>2</sub>NH<sub>2</sub>, EDCI, HOBt, Et<sub>3</sub>N, DMF, rt, overnight.</p></p></figure><figure data-id="sch3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>33â34</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-nitroaniline, TsOH, NMP, 120 Â°C, overnight; (b) Pd/C, MeOH, rt, overnight; (c) 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid, HATU, DIPEA, DMF, rt, overnight; (d) MeI, NaH, anhydrous THF, 0 Â°C-rt, 1 h.</p></p></figure><figure data-id="sch4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compound <b>35</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 4-aminobenzenethiol, rt, overnight; (b) 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid, HATU, DIPEA, DMF, rt, overnight.</p></p></figure><figure data-id="sch5" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/medium/jm-2019-002807_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>38</b> and <b>40â44</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-13/acs.jmedchem.9b00280/20190705/images/large/jm-2019-002807_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00280&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) <i>t</i>BuOK or Cs<sub>2</sub>CO<sub>3</sub>, anhydrous DMSO, rt-100 Â°C, 3 h; (b) Fe, NH<sub>4</sub>Cl, EtOH, reflux, 5 h; (c) 2-(4-chloro-3-(trifluoromethyl)phenyl)acetic acid, HATU, DIPEA, DMF, rt, overnight.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i96">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_78605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_78605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 24 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumour</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>369</i></span>,  <span class="NLM_fpage">1731</span>â <span class="NLM_lpage">1741</span>, <span class="refDoi">Â DOI: 10.1016/s0140-6736(07)60780-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1016%2Fs0140-6736%2807%2960780-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=17512858" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlsFertrk%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=369&publication_year=2007&pages=1731-1741&author=B.+P.+Rubinauthor=M.+C.+Heinrichauthor=C.+L.+Corless&title=Gastrointestinal+stromal+tumour&doi=10.1016%2Fs0140-6736%2807%2960780-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Gastrointestinal stromal tumor</span></div><div class="casAuthors">Rubin, Brian P.; Heinrich, Michael C.; Corless, Christopher L.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">369</span>
        (<span class="NLM_cas:issue">9574</span>),
    <span class="NLM_cas:pages">1731-1741</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumors are the most common mesenchymal neoplasm of the gastrointestinal tract and are highly resistant to conventional chemotherapy and radiotherapy.  Such tumors usually have activating mutations in either KIT (75-80%) or PDGFRA (5-10%), two closely related receptor tyrosine kinases.  These mutations lead to ligand-independent activation and signal transduction mediated by constitutively activated KIT or PDGFRA.  Targeting these activated proteins with imatinib mesylate, a small-mol. kinase inhibitor, has proven useful in the treatment of recurrent or metastatic gastrointestinal stromal tumors and is now being tested as an adjuvant or neoadjuvant.  However, resistance to imatinib is a growing problem and other targeted therapeutics such as sunitinib are available.  The important interplay between the mol. genetics of gastrointestinal stromal tumor and responses to targeted therapeutics serves as a model for the study of targeted therapies in other solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNtDxolv4iBrVg90H21EOLACvtfcHk0li3kbmJz-YhwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlsFertrk%253D&md5=9a9d1fc97239da0bb0cfa8edb925524b</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fs0140-6736%2807%2960780-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fs0140-6736%252807%252960780-6%26sid%3Dliteratum%253Aachs%26aulast%3DRubin%26aufirst%3DB.%2BP.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26atitle%3DGastrointestinal%2520stromal%2520tumour%26jtitle%3DLancet%26date%3D2007%26volume%3D369%26spage%3D1731%26epage%3D1741%26doi%3D10.1016%2Fs0140-6736%2807%2960780-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Steigen, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eide, T. J.</span></span> <span> </span><span class="NLM_article-title">Gastrointestinal stromal tumors (GISTs): a review</span>. <i>APMIS</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>117</i></span>,  <span class="NLM_fpage">73</span>â <span class="NLM_lpage">86</span>, <span class="refDoi">Â DOI: 10.1111/j.1600-0463.2008.00020.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1111%2Fj.1600-0463.2008.00020.x" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=117&publication_year=2010&pages=73-86&author=S.+E.+Steigenauthor=T.+J.+Eide&title=Gastrointestinal+stromal+tumors+%28GISTs%29%3A+a+review&doi=10.1111%2Fj.1600-0463.2008.00020.x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-0463.2008.00020.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-0463.2008.00020.x%26sid%3Dliteratum%253Aachs%26aulast%3DSteigen%26aufirst%3DS.%2BE.%26aulast%3DEide%26aufirst%3DT.%2BJ.%26atitle%3DGastrointestinal%2520stromal%2520tumors%2520%2528GISTs%2529%253A%2520a%2520review%26jtitle%3DAPMIS%26date%3D2010%26volume%3D117%26spage%3D73%26epage%3D86%26doi%3D10.1111%2Fj.1600-0463.2008.00020.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lennartsson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">RÃ¶nnstrand, L.</span></span> <span> </span><span class="NLM_article-title">Stem cell factor receptor/c-Kit: from basic science to clinical implications</span>. <i>Physiol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>92</i></span>,  <span class="NLM_fpage">1619</span>â <span class="NLM_lpage">1649</span>, <span class="refDoi">Â DOI: 10.1152/physrev.00046.2011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1152%2Fphysrev.00046.2011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=23073628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=1619-1649&author=J.+Lennartssonauthor=L.+R%C3%B6nnstrand&title=Stem+cell+factor+receptor%2Fc-Kit%3A+from+basic+science+to+clinical+implications&doi=10.1152%2Fphysrev.00046.2011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Stel cell factor receptor/c-Kit: from basic science to clinical implications</span></div><div class="casAuthors">Lennartsson, Johan; Roennstrand, Lars</div><div class="citationInfo"><span class="NLM_cas:title">Physiological Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1619-1649</span>CODEN:
                <span class="NLM_cas:coden">PHREA7</span>;
        ISSN:<span class="NLM_cas:issn">0031-9333</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">A review.  Stem cell factor (SCF) is a dimeric mol. that exerts its biol. functions by binding to and activating the receptor tyrosine kinase c-Kit.  Activation of c-Kit leads to its autophosphorylation and initiation of signal transduction.  Signaling proteins are recruited to activated c-Kit by certain interaction domains (e.g., SH2 and PTB) that specifically bind to phosphorylated tyrosine residues in the intracellular region of c-Kit.  Activation of c-Kit signaling has been found to mediate cell survival, migration, and proliferation depending on the cell type.  Signaling from c-Kit is crucial for normal hematopoiesis, pigmentation, fertility, gut movement, and some aspects of the nervous system.  Deregulated c-Kit kinase activity has been found in a no. of pathol. conditions, including cancer and allergy.  The observation that gain-of-function mutations in c-Kit can promote tumor formation and progression has stimulated the development of therapeutics agents targeting this receptor, e.g., the clin. used inhibitor imatinib mesylate.  Also other clin. used multiselective kinase inhibitors, for instance, sorafenib and sunitinib, have c-Kit included in their range of targets.  Furthermore, loss-of-function mutations in c-Kit have been obsd. and shown to give rise to a condition called piebaldism.  This review provides a summary of our current knowledge regarding structural and functional aspects of c-Kit signaling both under normal and pathol. conditions, as well as advances in the development of low-mol.-wt. mols. inhibiting c-Kit function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqiAi_V1Wivd7Vg90H21EOLACvtfcHk0li3kbmJz-YhwA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhsl2lsbnK&md5=b874bfb881938c505b6718732950be51</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1152%2Fphysrev.00046.2011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fphysrev.00046.2011%26sid%3Dliteratum%253Aachs%26aulast%3DLennartsson%26aufirst%3DJ.%26aulast%3DR%25C3%25B6nnstrand%26aufirst%3DL.%26atitle%3DStem%2520cell%2520factor%2520receptor%252Fc-Kit%253A%2520from%2520basic%2520science%2520to%2520clinical%2520implications%26jtitle%3DPhysiol.%2520Rev.%26date%3D2012%26volume%3D92%26spage%3D1619%26epage%3D1649%26doi%3D10.1152%2Fphysrev.00046.2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirota, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isozaki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriyama, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hashimoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nishida, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishiguro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawano, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurata, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muhammad
Tunio, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuzawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanakura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shinomura, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kitamura, Y.</span></span> <span> </span><span class="NLM_article-title">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>279</i></span>,  <span class="NLM_fpage">577</span>â <span class="NLM_lpage">580</span>, <span class="refDoi">Â DOI: 10.1126/science.279.5350.577</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1126%2Fscience.279.5350.577" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=9438854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=1998&pages=577-580&author=S.+Hirotaauthor=K.+Isozakiauthor=Y.+Moriyamaauthor=K.+Hashimotoauthor=T.+Nishidaauthor=S.+Ishiguroauthor=K.+Kawanoauthor=M.+Hanadaauthor=A.+Kurataauthor=M.+Takedaauthor=G.+Muhammad%0ATunioauthor=Y.+Matsuzawaauthor=Y.+Kanakuraauthor=Y.+Shinomuraauthor=Y.+Kitamura&title=Gain-of-function+mutations+of+c-kit+in+human+gastrointestinal+stromal+tumors&doi=10.1126%2Fscience.279.5350.577"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors</span></div><div class="casAuthors">Hirota, Seiichi; Isozaki, Koji; Moriyama, Yasuhiro; Hashimoto, Koji; Nishida, Toshirou; Ishiguro, Shingo; Kawano, Kiyoshi; Hanada, Masato; Kurata, Akihiko; Takeda, Masashi; Muhammad Tunio, Ghulam; Matsuzawa, Yuji; Kanakura, Yuzuru; Shinomura, Yasuhisa; Kitamura, Yukihiko</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">279</span>
        (<span class="NLM_cas:issue">5350</span>),
    <span class="NLM_cas:pages">577-580</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their mol. etiol. and cellular origin are unknown.  Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains.  All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF).  Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development.  GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLlGnWQ79KELVg90H21EOLACvtfcHk0lhbz72kAnUgAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXotVyhsw%253D%253D&md5=b66b6b8a389b064f73fba13ca84e8650</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1126%2Fscience.279.5350.577&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.279.5350.577%26sid%3Dliteratum%253Aachs%26aulast%3DHirota%26aufirst%3DS.%26aulast%3DIsozaki%26aufirst%3DK.%26aulast%3DMoriyama%26aufirst%3DY.%26aulast%3DHashimoto%26aufirst%3DK.%26aulast%3DNishida%26aufirst%3DT.%26aulast%3DIshiguro%26aufirst%3DS.%26aulast%3DKawano%26aufirst%3DK.%26aulast%3DHanada%26aufirst%3DM.%26aulast%3DKurata%26aufirst%3DA.%26aulast%3DTakeda%26aufirst%3DM.%26aulast%3DMuhammad%2BTunio%26aufirst%3DG.%26aulast%3DMatsuzawa%26aufirst%3DY.%26aulast%3DKanakura%26aufirst%3DY.%26aulast%3DShinomura%26aufirst%3DY.%26aulast%3DKitamura%26aufirst%3DY.%26atitle%3DGain-of-function%2520mutations%2520of%2520c-kit%2520in%2520human%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DScience%26date%3D1998%26volume%3D279%26spage%3D577%26epage%3D580%26doi%3D10.1126%2Fscience.279.5350.577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blanke, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehren, M. v.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joensuu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGreevey, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbeele, A. D. V. d.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Druker, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiese, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silberman, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dimitrijevic, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span> <span> </span><span class="NLM_article-title">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">4342</span>â <span class="NLM_lpage">4349</span>, <span class="refDoi">Â DOI: 10.1200/jco.2003.04.190</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1200%2Fjco.2003.04.190" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=14645423" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2003&pages=4342-4349&author=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=G.+D.+Demetriauthor=C.+D.+Blankeauthor=M.+v.+Mehrenauthor=H.+Joensuuauthor=L.+S.+McGreeveyauthor=C.-J.+Chenauthor=A.+D.+V.+d.+Abbeeleauthor=B.+J.+Drukerauthor=B.+Kieseauthor=B.+Eisenbergauthor=P.+J.+Robertsauthor=S.+Singerauthor=C.+D.+M.+Fletcherauthor=S.+Silbermanauthor=S.+Dimitrijevicauthor=J.+A.+Fletcher&title=Kinase+mutations+and+imatinib+response+in+patients+with+metastatic+gastrointestinal+stromal+tumor&doi=10.1200%2Fjco.2003.04.190"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Corless, Christopher L.; Demetri, George D.; Blanke, Charles D.; von Mehren, Margaret; Joensuu, Heikki; McGreevey, Laura S.; Chen, Chang-Jie; Van den Abbeele, Annick D.; Druker, Brian J.; Kiese, Beate; Eisenberg, Burton; Roberts, Peter J.; Singer, Samuel; Fletcher, Christopher D. M.; Silberman, Sandra; Dimitrijevic, Sasa; Fletcher, Jonathan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">4342-4349</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Most gastrointestinal stromal tumors (GISTs) express constitutively activated mutant isoforms of KIT or kinase platelet-derived growth factor receptor alpha (PDGFRA) that are potential therapeutic targets for imatinib mesylate.  The relationship between mutations in these kinases and clin. response to imatinib was examd. in a group of patients with advanced GIST.  Patients and Methods: GISTs from 127 patients enrolled onto a phase II clin. study of imatinib were examd. for mutations of KIT or PDGFRA.  Mutation types were correlated with clin. outcome.  Results: Activating mutations of KIT or PDGFRA were found in 112 (88.2%) and six (4.7%) GISTs, resp.  Most KIT mutations involved exon 9 (n = 23) or exon 11 (n = 85).  All KIT mutant isoforms, but only a subset of PDGFRA mutant isoforms, were sensitive to imatinib, in vitro.  In patients with GISTs harboring exon 11 KIT mutations, the partial response rate (PR) was 83.5%, whereas patients with tumors contg. an exon 9 KIT mutation or no detectable mutation of KIT or PDGFRA had PR rates of 47.8% (P = .0006) and 0.0% (P < .0001), resp.  Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.  Conclusion: Activating mutations of KIT or PDGFRA are found in the vast majority of GISTs, and the mutational status of these oncoproteins is predictive of clin. response to imatinib.  PDGFRA mutations can explain response and sensitivity to imatinib in some GISTs lacking KIT mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGquHal4hZZoc7Vg90H21EOLACvtfcHk0lhbz72kAnUgAQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVWqu7Y%253D&md5=cbfd753460bdf0005c3bd93f12df98dc</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1200%2Fjco.2003.04.190&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2003.04.190%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DBlanke%26aufirst%3DC.%2BD.%26aulast%3DMehren%26aufirst%3DM.%2Bv.%26aulast%3DJoensuu%26aufirst%3DH.%26aulast%3DMcGreevey%26aufirst%3DL.%2BS.%26aulast%3DChen%26aufirst%3DC.-J.%26aulast%3DAbbeele%26aufirst%3DA.%2BD.%2BV.%2Bd.%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26aulast%3DKiese%26aufirst%3DB.%26aulast%3DEisenberg%26aufirst%3DB.%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DSinger%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DSilberman%26aufirst%3DS.%26aulast%3DDimitrijevic%26aufirst%3DS.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26atitle%3DKinase%2520mutations%2520and%2520imatinib%2520response%2520in%2520patients%2520with%2520metastatic%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2003%26volume%3D21%26spage%3D4342%26epage%3D4349%26doi%3D10.1200%2Fjco.2003.04.190" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zalcberg, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verweij, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casali, P. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Cesne, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reichardt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blay, J.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlemmer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Glabbeke, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Judson, I. R.</span></span> <span> </span><span class="NLM_article-title">Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">1751</span>â <span class="NLM_lpage">1757</span>, <span class="refDoi">Â DOI: 10.1016/j.ejca.2005.04.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1016%2Fj.ejca.2005.04.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=16098458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2MXns1Wit7g%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2005&pages=1751-1757&author=J.+R.+Zalcbergauthor=J.+Verweijauthor=P.+G.+Casaliauthor=A.+Le+Cesneauthor=P.+Reichardtauthor=J.-Y.+Blayauthor=M.+Schlemmerauthor=M.+Van+Glabbekeauthor=M.+Brownauthor=I.+R.+Judson&title=Outcome+of+patients+with+advanced+gastro-intestinal+stromal+tumours+crossing+over+to+a+daily+imatinib+dose+of+800mg+after+progression+on+400mg&doi=10.1016%2Fj.ejca.2005.04.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg</span></div><div class="casAuthors">Zalcberg, John R.; Verweij, Jaap; Casali, Paolo G.; Le Cesne, Axel; Reichardt, Peter; Blay, Jean-Yves; Schlemmer, Marcus; Van Glabbeke, Martine; Brown, Michelle; Judson, Ian R.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1751-1757</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In the EORTC-ISG-AGITG trial 946 patients with advanced gastro-intestinal stromal tumors (GIST) were randomized to receive 400 or 800 mg of imatinib daily.  An increase in progression free survival (PFS) was demonstrated for patients randomized to the high-dose arm.  Patients randomized to low-dose could cross-over to high-dose upon progression.  We evaluated the feasibility, safety and efficacy of this policy.  Of the 241 patients available for follow-up, 133 patients (55%) crossed over to high-dose imatinib according to the protocol.  Of these patients, 92% had not had a prior dose redn.  The cumulative incidence of subsequent dose redns. after cross-over was 17% after six months with 51% discontinuing therapy without requiring a dose redn.  The extent of anemia and fatigue increased significantly after cross-over, while neutropenia was less severe than during low-dose treatment.  Objective responses after cross-over included three patients (2%) with a partial response and 36 (27%) with stable disease.  The median PFS after cross-over was 81 days, although 18.1% of patients were still alive and progression free one year after cross-over.  We conclude that a cross-over to high-dose imatinib is feasible and safe in GIST patients who progress on low-dose therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVMCGcB-afobVg90H21EOLACvtfcHk0liduucsTC7WuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXns1Wit7g%253D&md5=5d3478838ab344cfaf07ddbbfcc73f03</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.04.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.04.034%26sid%3Dliteratum%253Aachs%26aulast%3DZalcberg%26aufirst%3DJ.%2BR.%26aulast%3DVerweij%26aufirst%3DJ.%26aulast%3DCasali%26aufirst%3DP.%2BG.%26aulast%3DLe%2BCesne%26aufirst%3DA.%26aulast%3DReichardt%26aufirst%3DP.%26aulast%3DBlay%26aufirst%3DJ.-Y.%26aulast%3DSchlemmer%26aufirst%3DM.%26aulast%3DVan%2BGlabbeke%26aufirst%3DM.%26aulast%3DBrown%26aufirst%3DM.%26aulast%3DJudson%26aufirst%3DI.%2BR.%26atitle%3DOutcome%2520of%2520patients%2520with%2520advanced%2520gastro-intestinal%2520stromal%2520tumours%2520crossing%2520over%2520to%2520a%2520daily%2520imatinib%2520dose%2520of%2520800mg%2520after%2520progression%2520on%2520400mg%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2005%26volume%3D41%26spage%3D1751%26epage%3D1757%26doi%3D10.1016%2Fj.ejca.2005.04.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deshmukh, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiNitto, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">English, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, Y.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacques, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lunney, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McTigue, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quenzer, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmett, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marshall, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>106</i></span>,  <span class="NLM_fpage">1542</span>â <span class="NLM_lpage">1547</span>, <span class="refDoi">Â DOI: 10.1073/pnas.0812413106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1073%2Fpnas.0812413106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=19164557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=106&publication_year=2009&pages=1542-1547&author=K.+S.+Gajiwalaauthor=J.+C.+Wuauthor=J.+Christensenauthor=G.+D.+Deshmukhauthor=W.+Diehlauthor=J.+P.+DiNittoauthor=J.+M.+Englishauthor=M.+J.+Greigauthor=Y.-A.+Heauthor=S.+L.+Jacquesauthor=E.+A.+Lunneyauthor=M.+McTigueauthor=D.+Molinaauthor=T.+Quenzerauthor=P.+A.+Wellsauthor=X.+Yuauthor=Y.+Zhangauthor=A.+Zouauthor=M.+R.+Emmettauthor=A.+G.+Marshallauthor=H.-M.+Zhangauthor=G.+D.+Demetri&title=KIT+kinase+mutants+show+unique+mechanisms+of+drug+resistance+to+imatinib+and+sunitinib+in+gastrointestinal+stromal+tumor+patients&doi=10.1073%2Fpnas.0812413106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients</span></div><div class="casAuthors">Gajiwala, Ketan S.; Wu, Joe C.; Christensen, James; Deshmukh, Gayatri D.; Diehl, Wade; DiNitto, Jonathan P.; English, Jessie M.; Greig, Michael J.; He, You-Ai; Jacques, Suzanne L.; Lunney, Elizabeth A.; McTigue, Michele; Molina, Dave; Quenzer, Terri; Wells, Peter A.; Yu, Xiu; Zhang, Yan; Zou, Aihua; Emmett, Mark R.; Marshall, Alan G.; Zhang, Hui-Min; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">106</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1542-1547</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) exhibit aberrant activation of the receptor tyrosine kinase (RTK) KIT.  The efficacy of the inhibitors imatinib mesylate and sunitinib malate in GIST patients has been linked to their inhibition of these mutant KIT proteins.  However, patients on imatinib can acquire secondary KIT mutations that render the protein insensitive to the inhibitor.  Sunitinib has shown efficacy against certain imatinib-resistant mutants, although a subset that resides in the activation loop, including D816H/V, remains resistant.  Biochem. and structural studies were undertaken to det. the mol. basis of sunitinib resistance.  Our results show that sunitinib targets the autoinhibited conformation of WT KIT and that the D816H mutant undergoes a shift in conformational equil. toward the active state.  These findings provide a structural and enzymol. explanation for the resistance profile obsd. with the KIT inhibitors.  Prospectively, they have implications for understanding oncogenic kinase mutants and for circumventing drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkwFxa-p-iWbVg90H21EOLACvtfcHk0liduucsTC7WuA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVOms78%253D&md5=dd226c914c6f9a258426c0f4984a5258</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0812413106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0812413106%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DWu%26aufirst%3DJ.%2BC.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DDeshmukh%26aufirst%3DG.%2BD.%26aulast%3DDiehl%26aufirst%3DW.%26aulast%3DDiNitto%26aufirst%3DJ.%2BP.%26aulast%3DEnglish%26aufirst%3DJ.%2BM.%26aulast%3DGreig%26aufirst%3DM.%2BJ.%26aulast%3DHe%26aufirst%3DY.-A.%26aulast%3DJacques%26aufirst%3DS.%2BL.%26aulast%3DLunney%26aufirst%3DE.%2BA.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DMolina%26aufirst%3DD.%26aulast%3DQuenzer%26aufirst%3DT.%26aulast%3DWells%26aufirst%3DP.%2BA.%26aulast%3DYu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZou%26aufirst%3DA.%26aulast%3DEmmett%26aufirst%3DM.%2BR.%26aulast%3DMarshall%26aufirst%3DA.%2BG.%26aulast%3DZhang%26aufirst%3DH.-M.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DKIT%2520kinase%2520mutants%2520show%2520unique%2520mechanisms%2520of%2520drug%2520resistance%2520to%2520imatinib%2520and%2520sunitinib%2520in%2520gastrointestinal%2520stromal%2520tumor%2520patients%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2009%26volume%3D106%26spage%3D1542%26epage%3D1547%26doi%3D10.1073%2Fpnas.0812413106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maki, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harlow, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Town, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mckinley, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, W.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, C. D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5352</span>â <span class="NLM_lpage">5359</span>, <span class="refDoi">Â DOI: 10.1200/jco.2007.15.7461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1200%2Fjco.2007.15.7461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=18955458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslCmtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5352-5359&author=M.+C.+Heinrichauthor=R.+G.+Makiauthor=C.+L.+Corlessauthor=C.+R.+Antonescuauthor=A.+Harlowauthor=D.+Griffithauthor=A.+Townauthor=A.+Mckinleyauthor=W.-B.+Ouauthor=J.+A.+Fletcherauthor=C.+D.+M.+Fletcherauthor=X.+Huangauthor=D.+P.+Cohenauthor=C.+M.+Baumauthor=G.+D.+Demetri&title=Primary+and+secondary+kinase+genotypes+correlate+with+the+biological+and+clinical+activity+of+sunitinib+in+imatinib-resistant+gastrointestinal+stromal+tumor&doi=10.1200%2Fjco.2007.15.7461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor</span></div><div class="casAuthors">Heinrich, Michael C.; Maki, Robert G.; Corless, Christopher L.; Antonescu, Cristina R.; Harlow, Amy; Griffith, Diana; Town, Ajia; McKinley, Arin; Ou, Wen-Bin; Fletcher, Jonathan A.; Fletcher, Christopher D. M.; Huang, Xin; Cohen, Darrel P.; Baum, Charles M.; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5352-5359</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Most gastrointestinal stromal tumors (GISTs) harbor mutant KIT or platelet-derived growth factor receptor Î± (PDGFRA) kinases, which are imatinib targets.  Sunitinib, which targets KIT, PDGFRs, and several other kinases, has demonstrated efficacy in patients with GIST after they experience imatinib failure.  We evaluated the impact of primary and secondary kinase genotype on sunitinib activity.  Tumor responses were assessed radiol. in a phase I/II trial of sunitinib in 97 patients with metastatic, imatinib-resistant/intolerant GIST.  KIT/PDGFRA mutational status was detd. for 78 patients by using tumor specimens obtained before and after prior imatinib therapy.  Kinase mutants were biochem. profiled for sunitinib and imatinib sensitivity.  Clin. benefit (partial response or stable disease for â¥ 6 mo) with sunitinib was obsd. for the three most common primary GIST genotypes: KIT exon 9 (58%), KIT exon 11 (34%), and wild-type KIT/PDGFRA (56%).  Progression-free survival (PFS) was significantly longer for patients with primary KIT exon 9 mutations (P = .0005) or with a wild-type genotype (P = .0356) than for those with KIT exon 11 mutations.  The same pattern was obsd. for overall survival (OS).  PFS and OS were longer for patients with secondary KIT exon 13 or 14 mutations (which involve the KIT-ATP binding pocket) than for those with exon 17 or 18 mutations (which involve the KIT activation loop).  Biochem. profiling studies confirmed the clin. results.  The clin. activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases, which has implications for optimization of the treatment of patients with GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqC-Yvw1bbDYrVg90H21EOLACvtfcHk0lijidcIWOOm_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslCmtQ%253D%253D&md5=b84e19da0589f0ba6b12d8ed6b0da2c6</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1200%2Fjco.2007.15.7461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2007.15.7461%26sid%3Dliteratum%253Aachs%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DHarlow%26aufirst%3DA.%26aulast%3DGriffith%26aufirst%3DD.%26aulast%3DTown%26aufirst%3DA.%26aulast%3DMckinley%26aufirst%3DA.%26aulast%3DOu%26aufirst%3DW.-B.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DFletcher%26aufirst%3DC.%2BD.%2BM.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DCohen%26aufirst%3DD.%2BP.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DPrimary%2520and%2520secondary%2520kinase%2520genotypes%2520correlate%2520with%2520the%2520biological%2520and%2520clinical%2520activity%2520of%2520sunitinib%2520in%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumor%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5352%26epage%3D5359%26doi%3D10.1200%2Fjco.2007.15.7461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corless, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butrynski, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tap, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van den Abbeele, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manola, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solomon, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Mehren, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span> <span> </span><span class="NLM_article-title">Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: A multicenter phase II trial</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">2401</span>â <span class="NLM_lpage">2407</span>, <span class="refDoi">Â DOI: 10.1200/jco.2011.39.9394</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1200%2Fjco.2011.39.9394" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=22614970" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1aisbbM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2012&pages=2401-2407&author=S.+Georgeauthor=Q.+Wangauthor=M.+C.+Heinrichauthor=C.+L.+Corlessauthor=M.+Zhuauthor=J.+E.+Butrynskiauthor=J.+A.+Morganauthor=A.+J.+Wagnerauthor=E.+Choyauthor=W.+D.+Tapauthor=J.+T.+Yapauthor=A.+D.+Van+den+Abbeeleauthor=J.+B.+Manolaauthor=S.+M.+Solomonauthor=J.+A.+Fletcherauthor=M.+von+Mehrenauthor=G.+D.+Demetri&title=Efficacy+and+safety+of+regorafenib+in+patients+with+metastatic+and%2For+unresectable+GI+stromal+tumor+after+failure+of+imatinib+and+sunitinib%3A+A+multicenter+phase+II+trial&doi=10.1200%2Fjco.2011.39.9394"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial</span></div><div class="casAuthors">George, Suzanne; Wang, Qian; Heinrich, Michael C.; Corless, Christopher L.; Zhu, Meijun; Butrynski, James E.; Morgan, Jeffrey A.; Wagner, Andrew J.; Choy, Edwin; Tap, William D.; Yap, Jeffrey T.; Van den Abbeele, Annick D.; Manola, Judith B.; Solomon, Sarah M.; Fletcher, Jonathan A.; von Mehren, Margaret; Demetri, George D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">2401-2407</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Metastatic GI stromal tumor (GIST) is a life-threatening disease with no therapy of proven efficacy after failure of imatinib and sunitinib.  Regorafenib is a structurally unique inhibitor of multiple cancer-assocd. kinases, including KIT and platelet-derived growth factor receptor (PDGFR), with broad-spectrum anticancer activity in preclin. and early-phase trials.  Because KIT and PDGFR-Î± remain drivers of GIST after resistance to imatinib and sunitinib, we performed a multicenter single-stage phase II trial of regorafenib in patients with advanced GIST after failure of at least imatinib and sunitinib.  Patients and Methods: Patients received regorafenib orally, 160 mg daily, on days 1 to 21 of a 28-day cycle.  Disease assessment was performed every two cycles per RECIST 1.1.  Primary end point was clin. benefit rate (CBR), defined as objective responses (ie, complete or partial response [PR] as well as stable disease [SD] â¥ 16 wk).  Serial tumor biopsies were obtained from consenting patients whenever possible.  Results From Feb. to Dec. 2010, 34 patients were enrolled at four US centers.  As of July 28, 2011, 33 patients had received at least two cycles of regorafenib (range, two to 17 cycles).  CBR was 79% (95% CI, 61% to 91%).  Four patients achieved PR, and 22 exhibited SD â¥ 16 wk.  Median progression-free survival was 10.0 mo.  The most common grade 3 toxicities were hypertension and hand-foot-skin reaction.  Conclusion: Regorafenib has significant activity in patients with advanced GIST after failure of both imatinib and sunitinib.  A phase III trial of regorafenib vs. placebo is ongoing to define more fully the safety and efficacy of regorafenib in this setting.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4RtWuSuSFcbVg90H21EOLACvtfcHk0lijidcIWOOm_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1aisbbM&md5=54875f152708a1020a429f24cf398b30</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2Fjco.2011.39.9394&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252Fjco.2011.39.9394%26sid%3Dliteratum%253Aachs%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DCorless%26aufirst%3DC.%2BL.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DButrynski%26aufirst%3DJ.%2BE.%26aulast%3DMorgan%26aufirst%3DJ.%2BA.%26aulast%3DWagner%26aufirst%3DA.%2BJ.%26aulast%3DChoy%26aufirst%3DE.%26aulast%3DTap%26aufirst%3DW.%2BD.%26aulast%3DYap%26aufirst%3DJ.%2BT.%26aulast%3DVan%2Bden%2BAbbeele%26aufirst%3DA.%2BD.%26aulast%3DManola%26aufirst%3DJ.%2BB.%26aulast%3DSolomon%26aufirst%3DS.%2BM.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3Dvon%2BMehren%26aufirst%3DM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26atitle%3DEfficacy%2520and%2520safety%2520of%2520regorafenib%2520in%2520patients%2520with%2520metastatic%2520and%252For%2520unresectable%2520GI%2520stromal%2520tumor%2520after%2520failure%2520of%2520imatinib%2520and%2520sunitinib%253A%2520A%2520multicenter%2520phase%2520II%2520trial%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2012%26volume%3D30%26spage%3D2401%26epage%3D2407%26doi%3D10.1200%2Fjco.2011.39.9394" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valverde, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivares, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">GarcÃ­a-Valverde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SuÃ¡rez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morales-Barrera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carles, J.</span></span> <span> </span><span class="NLM_article-title">Novel insights into the treatment of imatinib-resistant gastrointestinal stromal tumors</span>. <i>Targeted Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">277</span>â <span class="NLM_lpage">288</span>, <span class="refDoi">Â DOI: 10.1007/s11523-017-0490-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1007%2Fs11523-017-0490-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=28478525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A280%3ADC%252BC1crkslWgtQ%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=277-288&author=C.+Serranoauthor=S.+Georgeauthor=C.+Valverdeauthor=D.+Olivaresauthor=A.+Garc%C3%ADa-Valverdeauthor=C.+Su%C3%A1rezauthor=R.+Morales-Barreraauthor=J.+Carles&title=Novel+insights+into+the+treatment+of+imatinib-resistant+gastrointestinal+stromal+tumors&doi=10.1007%2Fs11523-017-0490-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Serrano Cesar; Valverde Claudia; Suarez Cristina; Morales-Barrera Rafael; Carles Joan; Serrano Cesar; Olivares David; Garcia-Valverde Alfonso; George Suzanne; George Suzanne; Carles Joan</div><div class="citationInfo"><span class="NLM_cas:title">Targeted oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">277-288</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Gastrointestinal stromal tumors (GIST) have emerged as a compelling clinical and biological model for the rational development of therapeutic strategies targeting critical oncogenic events over the past two decades.  Oncogenic activation of KIT or PDGFRA receptor tyrosine kinases is the crucial driver for GIST tumor initiation, transformation, and cancer cell proliferation.  Three tyrosine kinase inhibitors (TKIs) with KIT inhibitory activity - imatinib, sunitinib, and regorafenib - are approved to treat advanced GIST and have successfully exploited this addiction to KIT oncogenic signaling, demonstrating remarkable activity in a disease that historically had no successful systemic therapy options.  However, GIST refractory to approved TKIs remain an unmet clinical need, as virtually all patients with metastatic GIST eventually progress on any given therapy.  The main and best-established mechanism of resistance is the polyclonal expansion of multiple subpopulations harboring different secondary KIT mutations.  The present review aims at summarizing current and forthcoming treatment directions in advanced imatinib-resistant GIST supported by a strong biological rationale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTOQAvzbjNN2pdYoSR9eyvsfW6udTcc2ebYGlGEaRp1ILntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1crkslWgtQ%253D%253D&md5=071c98b43a1d806ee1fe9393957e6ab2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2Fs11523-017-0490-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11523-017-0490-9%26sid%3Dliteratum%253Aachs%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DGeorge%26aufirst%3DS.%26aulast%3DValverde%26aufirst%3DC.%26aulast%3DOlivares%26aufirst%3DD.%26aulast%3DGarc%25C3%25ADa-Valverde%26aufirst%3DA.%26aulast%3DSu%25C3%25A1rez%26aufirst%3DC.%26aulast%3DMorales-Barrera%26aufirst%3DR.%26aulast%3DCarles%26aufirst%3DJ.%26atitle%3DNovel%2520insights%2520into%2520the%2520treatment%2520of%2520imatinib-resistant%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DTargeted%2520Oncol.%26date%3D2017%26volume%3D12%26spage%3D277%26epage%3D288%26doi%3D10.1007%2Fs11523-017-0490-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garner, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gozgit, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vodala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Serrano, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eilers, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ketzer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wardwell, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohlmann, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clackson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heinrich, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivera, V. M.</span></span> <span> </span><span class="NLM_article-title">Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">5745</span>â <span class="NLM_lpage">5755</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-14-1397</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1078-0432.ccr-14-1397" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=25239608" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2014&pages=5745-5755&author=A.+P.+Garnerauthor=J.+M.+Gozgitauthor=R.+Anjumauthor=S.+Vodalaauthor=A.+Schrockauthor=T.+Zhouauthor=C.+Serranoauthor=G.+Eilersauthor=M.+Zhuauthor=J.+Ketzerauthor=S.+Wardwellauthor=Y.+Ningauthor=Y.+Songauthor=A.+Kohlmannauthor=F.+Wangauthor=T.+Clacksonauthor=M.+C.+Heinrichauthor=J.+A.+Fletcherauthor=S.+Bauerauthor=V.+M.+Rivera&title=Ponatinib+inhibits+polyclonal+drug-resistant+KIT+oncoproteins+and+shows+therapeutic+potential+in+heavily+pretreated+gastrointestinal+stromal+tumor+%28GIST%29+patients&doi=10.1158%2F1078-0432.ccr-14-1397"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Ponatinib Inhibits Polyclonal Drug-Resistant KIT Oncoproteins and Shows Therapeutic Potential in Heavily Pretreated Gastrointestinal Stromal Tumor (GIST) Patients</span></div><div class="casAuthors">Garner, Andrew P.; Gozgit, Joseph M.; Anjum, Rana; Vodala, Sadanand; Schrock, Alexa; Zhou, Tianjun; Serrano, Cesar; Eilers, Grant; Zhu, Meijun; Ketzer, Julia; Wardwell, Scott; Ning, Yaoyu; Song, Youngchul; Kohlmann, Anna; Wang, Frank; Clackson, Tim; Heinrich, Michael C.; Fletcher, Jonathan A.; Bauer, Sebastian; Rivera, Victor M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5745-5755</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: KIT is the major oncogenic driver of gastrointestinal stromal tumors (GIST).  Imatinib, sunitinib, and regorafenib are approved therapies; however, efficacy is often limited by the acquisition of polyclonal secondary resistance mutations in KIT, with those located in the activation (A) loop (exons 17/18) being particularly problematic.  Here, we explore the KIT-inhibitory activity of ponatinib in preclin. models and describe initial characterization of its activity in patients with GIST.  Exptl. Design: The cellular and in vivo activities of ponatinib, imatinib, sunitinib, and regorafenib against mutant KIT were evaluated using an accelerated mutagenesis assay and a panel of engineered and GIST-derived cell lines.  The ponatinib-KIT costructure was also detd.  The clin. activity of ponatinib was examd. in three patients with GIST previously treated with all three FDA-approved agents.  Results: In engineered and GIST-derived cell lines, ponatinib potently inhibited KIT exon 11 primary mutants and a range of secondary mutants, including those within the A-loop.  Ponatinib also induced regression in engineered and GIST-derived tumor models contg. these secondary mutations.  In a mutagenesis screen, 40 nmol/L ponatinib was sufficient to suppress outgrowth of all secondary mutants except V654A, which was suppressed at 80 nmol/L.  This inhibitory profile could be rationalized on the basis of structural analyses.  Ponatinib (30 mg daily) displayed encouraging clin. activity in two of three patients with GIST.  Conclusion:Ponatinib possesses potent activity against most major clin. relevant KIT mutants and has demonstrated preliminary evidence of activity in patients with refractory GIST.  These data strongly support further evaluation of ponatinib in patients with GIST.  Clin Cancer Res; 20(22); 5745-55. Â©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTGG18CSl3XLVg90H21EOLACvtfcHk0liIYB0eSSyIbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFGgsL7E&md5=7537e45f37546f9e0cb799bdf05ed847</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-14-1397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-14-1397%26sid%3Dliteratum%253Aachs%26aulast%3DGarner%26aufirst%3DA.%2BP.%26aulast%3DGozgit%26aufirst%3DJ.%2BM.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DVodala%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DT.%26aulast%3DSerrano%26aufirst%3DC.%26aulast%3DEilers%26aufirst%3DG.%26aulast%3DZhu%26aufirst%3DM.%26aulast%3DKetzer%26aufirst%3DJ.%26aulast%3DWardwell%26aufirst%3DS.%26aulast%3DNing%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DKohlmann%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DClackson%26aufirst%3DT.%26aulast%3DHeinrich%26aufirst%3DM.%2BC.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DBauer%26aufirst%3DS.%26aulast%3DRivera%26aufirst%3DV.%2BM.%26atitle%3DPonatinib%2520inhibits%2520polyclonal%2520drug-resistant%2520KIT%2520oncoproteins%2520and%2520shows%2520therapeutic%2520potential%2520in%2520heavily%2520pretreated%2520gastrointestinal%2520stromal%2520tumor%2520%2528GIST%2529%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2014%26volume%3D20%26spage%3D5745%26epage%3D5755%26doi%3D10.1158%2F1078-0432.ccr-14-1397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebreyohannes, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¶ffski, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Looy, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vreys, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornillie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanleeuw, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aftab, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debiec-Rychter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A.</span></span> <span> </span><span class="NLM_article-title">Cabozantinib is active against human gastrointestinal stromal tumor xenografts carrying different KIT mutations</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2845</span>â <span class="NLM_lpage">2852</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-16-0224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1535-7163.mct-16-0224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=27777285" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvFynt7jM" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2845-2852&author=Y.+K.+Gebreyohannesauthor=P.+Sch%C3%B6ffskiauthor=T.+Van+Looyauthor=J.+Wellensauthor=L.+Vreysauthor=J.+Cornillieauthor=U.+Vanleeuwauthor=D.+T.+Aftabauthor=M.+Debiec-Rychterauthor=R.+Sciotauthor=A.+Wozniak&title=Cabozantinib+is+active+against+human+gastrointestinal+stromal+tumor+xenografts+carrying+different+KIT+mutations&doi=10.1158%2F1535-7163.mct-16-0224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations</span></div><div class="casAuthors">Gebreyohannes, Yemarshet K.; Schoffski, Patrick; Van Looy, Thomas; Wellens, Jasmien; Vreys, Lise; Cornillie, Jasmien; Vanleeuw, Ulla; Aftab, Dana T.; Debiec-Rychter, Maria; Sciot, Raf; Wozniak, Agnieszka</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2845-2852</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In the majority of gastrointestinal stromal tumors (GIST), oncogenic signaling is driven by KIT mutations.  Advanced GIST is treated with tyrosine kinase inhibitors (TKI) such as imatinib.  Acquired resistance to TKI is mainly caused by secondary KIT mutations, but can also be attributed to a switch of KIT dependency to another receptor tyrosine kinase (RTK).  We tested the efficacy of cabozantinib, a novel TKI targeting KIT, MET, AXL, and vascular endothelial growth factor receptors (VEGFR), in patient-derived xenograft (PDX) models of GIST, carrying different KIT mutations.  NMRI nu/nu mice (n = 52) were bilaterally transplanted with human GIST: UZLX-GIST4 (KIT exon 11 mutation, imatinib sensitive), UZLX-GIST2 (KIT exon 9, imatinib dose-dependent resistance), or UZLX-GIST9 (KIT exon 11 and 17 mutations, imatinib resistant).  Mice were grouped as control (untreated), imatinib (50 mg/kg/bid), and cabozantinib (30 mg/kg/qd) and treated orally for 15 days.  Cabozantinib resulted in significant tumor regression in UZLX-GIST4 and -GIST2 and delayed tumor growth in -GIST9.  In all three models, cabozantinib inhibited the proliferative activity, which was completely absent in UZLX-GIST4 and significantly reduced in -GIST2 and -GIST9.  Increased apoptotic activity was obsd. only in UZLX-GIST4.  Cabozantinib inhibited the KIT signaling pathway in UZLX-GIST4 and -GIST2.  In addn., compared with both control and imatinib, cabozantinib significantly reduced microvessel d. in all models.  In conclusion, cabozantinib showed antitumor activity in GIST PDX models through inhibition of tumor growth, proliferation, and angiogenesis, in both imatinib-sensitive and imatinib-resistant models.  Mol Cancer Ther; 15(12); 2845-52. Â©2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGOXU3S6aJ0rVg90H21EOLACvtfcHk0liIYB0eSSyIbg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvFynt7jM&md5=7c8970124406fefac29156d3eb4d0e63</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-16-0224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-16-0224%26sid%3Dliteratum%253Aachs%26aulast%3DGebreyohannes%26aufirst%3DY.%2BK.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DVan%2BLooy%26aufirst%3DT.%26aulast%3DWellens%26aufirst%3DJ.%26aulast%3DVreys%26aufirst%3DL.%26aulast%3DCornillie%26aufirst%3DJ.%26aulast%3DVanleeuw%26aufirst%3DU.%26aulast%3DAftab%26aufirst%3DD.%2BT.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DWozniak%26aufirst%3DA.%26atitle%3DCabozantinib%2520is%2520active%2520against%2520human%2520gastrointestinal%2520stromal%2520tumor%2520xenografts%2520carrying%2520different%2520KIT%2520mutations%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2016%26volume%3D15%26spage%3D2845%26epage%3D2852%26doi%3D10.1158%2F1535-7163.mct-16-0224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gebreyohannes, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wozniak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhai, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wellens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornillie, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vanleeuw, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardino, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lengauer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debiec-Rychter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sciot, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">SchÃ¶ffski, P.</span></span> <span> </span><span class="NLM_article-title">Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">609</span>â <span class="NLM_lpage">618</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-18-1858</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1078-0432.ccr-18-1858" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=30274985" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A280%3ADC%252BB3czkslClsg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=609-618&author=Y.+K.+Gebreyohannesauthor=A.+Wozniakauthor=M.-E.+Zhaiauthor=J.+Wellensauthor=J.+Cornillieauthor=U.+Vanleeuwauthor=E.+Evansauthor=A.+K.+Gardinoauthor=C.+Lengauerauthor=M.+Debiec-Rychterauthor=R.+Sciotauthor=P.+Sch%C3%B6ffski&title=Robust+Activity+of+Avapritinib%2C+Potent+and+Highly+Selective+Inhibitor+of+Mutated+KIT%2C+in+Patient-derived+Xenograft+Models+of+Gastrointestinal+Stromal+Tumors&doi=10.1158%2F1078-0432.ccr-18-1858"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Gebreyohannes Yemarshet K; Wozniak Agnieszka; Zhai Madalina-Elena; Wellens Jasmien; Cornillie Jasmien; Vanleeuw Ulla; Schoffski Patrick; Evans Erica; Gardino Alexandra K; Lengauer Christoph; Debiec-Rychter Maria; Sciot Raf</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">609-618</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  Gastrointestinal stromal tumors (GIST) are commonly treated with tyrosine kinase inhibitors (TKI).  The majority of patients with advanced GIST ultimately become resistant to TKI due to acquisition of secondary KIT mutations, whereas primary resistance is mainly caused by PDGFRA p.D842V mutation.  We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations, with differential sensitivity to standard TKI.Experimental Design: NMRI nu/nu mice (n = 93) were transplanted with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9 (KIT 11+17) ), exon 11 (UZLX-GIST3 (KIT 11) ), or exon 9 (UZLX-GIST2B (KIT9) ) mutations, respectively.  We compared avapritinib (10 and 30 mg/kg/once daily) versus vehicle, imatinib (50 mg/kg/bid) or regorafenib (30 mg/kg/once daily; UZLX-GIST9 (KIT11+17) ); avapritinib (10, 30, 100 mg/kg/once daily) versus vehicle or imatinib [UZLX-GIST3 (KIT11) ]; and avapritinib (10, 30, 60 mg/kg/once daily) versus vehicle, imatinib (50, 100 mg/kg/twice daily), or sunitinib (40 mg/kg/once daily; UZLX-GIST2B (KIT9) ).  RESULTS:  In all models, avapritinib resulted in reduction of tumor volume, significant inhibition of proliferation, and reduced KIT signaling.  In two models, avapritinib led to remarkable histologic responses, increase in apoptosis, and inhibition of MAPK-phosphorylation.  Avapritinib showed superior (UZLX-GIST9 (KIT 11+17) and -GIST2B (KIT 9) ) or equal (UZLX-GIST3 (KIT 11) ) antitumor activity to the standard dose of imatinib.  In UZLX-GIST9 (KIT 11+17) , the antitumor effects of avapritinib were significantly better than with imatinib or regorafenib.  CONCLUSIONS:  Avapritinib has significant antitumor activity in GIST PDX models characterized by different KIT mutations and sensitivity to established TKI.  These data provide strong support for the ongoing clinical trials with avapritinib in patients with GIST (NCT02508532, NCT03465722).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQPWswagAFJBOb6AVA-44PTfW6udTcc2eY_qf3qrFCyr7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czkslClsg%253D%253D&md5=cb62624c4777c7be59e1fd08a39a584f</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-18-1858&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-18-1858%26sid%3Dliteratum%253Aachs%26aulast%3DGebreyohannes%26aufirst%3DY.%2BK.%26aulast%3DWozniak%26aufirst%3DA.%26aulast%3DZhai%26aufirst%3DM.-E.%26aulast%3DWellens%26aufirst%3DJ.%26aulast%3DCornillie%26aufirst%3DJ.%26aulast%3DVanleeuw%26aufirst%3DU.%26aulast%3DEvans%26aufirst%3DE.%26aulast%3DGardino%26aufirst%3DA.%2BK.%26aulast%3DLengauer%26aufirst%3DC.%26aulast%3DDebiec-Rychter%26aufirst%3DM.%26aulast%3DSciot%26aufirst%3DR.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26atitle%3DRobust%2520Activity%2520of%2520Avapritinib%252C%2520Potent%2520and%2520Highly%2520Selective%2520Inhibitor%2520of%2520Mutated%2520KIT%252C%2520in%2520Patient-derived%2520Xenograft%2520Models%2520of%2520Gastrointestinal%2520Stromal%2520Tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D609%26epage%3D618%26doi%3D10.1158%2F1078-0432.ccr-18-1858" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kettle, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anjum, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barry, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhavsar, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyd, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grondine, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guichard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hardy, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moleva, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogg, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overman, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Packer, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pearson, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schimpl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stead, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stokes, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tucker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, Y.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-(4-{[5-fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8797</span>â <span class="NLM_lpage">8810</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.8b00938</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00938" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhs12isrzI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8797-8810&author=J.+G.+Kettleauthor=R.+Anjumauthor=E.+Barryauthor=D.+Bhavsarauthor=C.+Brownauthor=S.+Boydauthor=A.+Campbellauthor=K.+Goldbergauthor=M.+Grondineauthor=S.+Guichardauthor=C.+J.+Hardyauthor=T.+Huntauthor=R.+D.+O.+Jonesauthor=X.+Liauthor=O.+Molevaauthor=D.+Oggauthor=R.+C.+Overmanauthor=M.+J.+Packerauthor=S.+Pearsonauthor=M.+Schimplauthor=W.+Shaoauthor=A.+Smithauthor=J.+M.+Smithauthor=D.+Steadauthor=S.+Stokesauthor=M.+Tuckerauthor=Y.+Ye&title=Discovery+of+N-%284-%7B%5B5-fluoro-7-%282-methoxyethoxy%29quinazolin-4-yl%5Damino%7Dphenyl%29-2-%5B4-%28propan-2-yl%29-1H-1%2C2%2C3-triazol-1-yl%5Dacetamide+%28AZD3229%29%2C+a+potent+pan-KIT+mutant+inhibitor+for+the+treatment+of+gastrointestinal+stromal+tumors&doi=10.1021%2Facs.jmedchem.8b00938"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-{[5-Fluoro-7-(2-methoxyethoxy)quinazolin-4-yl]amino}phenyl)-2-[4-(propan-2-yl)-1H-1,2,3-triazol-1-yl]acetamide (AZD3229), a Potent Pan-KIT Mutant Inhibitor for the Treatment of Gastrointestinal Stromal Tumors</span></div><div class="casAuthors">Kettle, Jason G.; Anjum, Rana; Barry, Evan; Bhavsar, Deepa; Brown, Crystal; Boyd, Scott; Campbell, Andrew; Goldberg, Kristin; Grondine, Michael; Guichard, Sylvie; Hardy, Christopher J.; Hunt, Tom; Jones, Rhys D. O.; Li, Xiuwei; Moleva, Olga; Ogg, Derek; Overman, Ross C.; Packer, Martin J.; Pearson, Stuart; Schimpl, Marianne; Shao, Wenlin; Smith, Aaron; Smith, James M.; Stead, Darren; Stokes, Steve; Tucker, Michael; Ye, Yang</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8797-8810</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">While the treatment of gastrointestinal stromal tumors (GISTs) has been revolutionized by the application of targeted tyrosine kinase inhibitors capable of inhibiting KIT-driven proliferation, diverse mutations to this kinase drive resistance to established therapies.  Here we describe the identification of potent pan-KIT mutant kinase inhibitors that can be dosed without being limited by the tolerability issues seen with multitargeted agents.  This effort focused on identification and optimization of an existing kinase scaffold through the use of structure-based design.  Starting from a series of previously reported phenoxyquinazoline and quinoline based inhibitors of the tyrosine kinase PDGFRÎ±, potency against a diverse panel of mutant KIT driven Ba/F3 cell lines was optimized, with a particular focus on reducing activity against a KDR driven cell model in order to limit the potential for hypertension commonly seen in second and third line GIST therapies.  AZD3229 demonstrates potent single digit nM growth inhibition across a broad cell panel, with good margin to KDR-driven effects.  Selectivity over KDR can be rationalized predominantly by the interaction of water mols. with the protein and ligand in the active site, and its kinome selectivity is similar to the best of the approved GIST agents.  This compd. demonstrates excellent cross-species pharmacokinetics, shows strong pharmacodynamic inhibition of target, and is active in several in vivo models of GIST.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoa2ACsIdMk2bVg90H21EOLACvtfcHk0lilZM5tOJB-1Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhs12isrzI&md5=c258e7b529e8c029804278526a6b2ee1</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00938&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00938%26sid%3Dliteratum%253Aachs%26aulast%3DKettle%26aufirst%3DJ.%2BG.%26aulast%3DAnjum%26aufirst%3DR.%26aulast%3DBarry%26aufirst%3DE.%26aulast%3DBhavsar%26aufirst%3DD.%26aulast%3DBrown%26aufirst%3DC.%26aulast%3DBoyd%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DGoldberg%26aufirst%3DK.%26aulast%3DGrondine%26aufirst%3DM.%26aulast%3DGuichard%26aufirst%3DS.%26aulast%3DHardy%26aufirst%3DC.%2BJ.%26aulast%3DHunt%26aufirst%3DT.%26aulast%3DJones%26aufirst%3DR.%2BD.%2BO.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DMoleva%26aufirst%3DO.%26aulast%3DOgg%26aufirst%3DD.%26aulast%3DOverman%26aufirst%3DR.%2BC.%26aulast%3DPacker%26aufirst%3DM.%2BJ.%26aulast%3DPearson%26aufirst%3DS.%26aulast%3DSchimpl%26aufirst%3DM.%26aulast%3DShao%26aufirst%3DW.%26aulast%3DSmith%26aufirst%3DA.%26aulast%3DSmith%26aufirst%3DJ.%2BM.%26aulast%3DStead%26aufirst%3DD.%26aulast%3DStokes%26aufirst%3DS.%26aulast%3DTucker%26aufirst%3DM.%26aulast%3DYe%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520N-%25284-%257B%255B5-fluoro-7-%25282-methoxyethoxy%2529quinazolin-4-yl%255Damino%257Dphenyl%2529-2-%255B4-%2528propan-2-yl%2529-1H-1%252C2%252C3-triazol-1-yl%255Dacetamide%2520%2528AZD3229%2529%252C%2520a%2520potent%2520pan-KIT%2520mutant%2520inhibitor%2520for%2520the%2520treatment%2520of%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8797%26epage%3D8810%26doi%3D10.1021%2Facs.jmedchem.8b00938" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schneeweiss, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peter, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bibi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eisenwort, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smiljkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jawhar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berger, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanzl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herndlhofer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greiner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoermann, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hadzijusufovic, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gleixner, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bettelheim, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geissler, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperr, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reiter, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arock, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span> <span> </span><span class="NLM_article-title">The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis</span>. <i>Haematologica</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>103</i></span>,  <span class="NLM_fpage">799</span>â <span class="NLM_lpage">809</span>, <span class="refDoi">Â DOI: 10.3324/haematol.2017.179895</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.3324%2Fhaematol.2017.179895" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=29439183" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFCnu78%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2018&pages=799-809&author=M.+Schneeweissauthor=B.+Peterauthor=S.+Bibiauthor=G.+Eisenwortauthor=D.+Smiljkovicauthor=K.+Blattauthor=M.+Jawharauthor=D.+Bergerauthor=G.+Stefanzlauthor=S.+Herndlhoferauthor=G.+Greinerauthor=G.+Hoermannauthor=E.+Hadzijusufovicauthor=K.+V.+Gleixnerauthor=P.+Bettelheimauthor=K.+Geisslerauthor=W.+R.+Sperrauthor=A.+Reiterauthor=M.+Arockauthor=P.+Valent&title=The+KIT+and+PDGFRA+switch-control+inhibitor+DCC-2618+blocks+growth+and+survival+of+multiple+neoplastic+cell+types+in+advanced+mastocytosis&doi=10.3324%2Fhaematol.2017.179895"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis</span></div><div class="casAuthors">Schneeweiss, Mathias; Peter, Barbara; Bibi, Siham; Eisenwort, Gregor; Smiljkovic, Dubravka; Blatt, Katharina; Jawhar, Mohamad; Berger, Daniela; Stefanzl, Gabriele; Herndlhofer, Susanne; Greiner, Georg; Hoermann, Gregor; Hadzijusufovic, Emir; Gleixner, Karoline V.; Bettelheim, Peter; Geissler, Klaus; Sperr, Wolfgang R.; Reiter, Andreas; Arock, Michel; Valent, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Haematologica</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">799-809</span>CODEN:
                <span class="NLM_cas:coden">HAEMAX</span>;
        ISSN:<span class="NLM_cas:issn">1592-8721</span>.
    
            (<span class="NLM_cas:orgname">Ferrata Storti Foundation</span>)
        </div><div class="casAbstract">Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs.  Most patients exhibit a D816V-mutated variant of KIT, which confers resistance against imatinib.  Clin. problems in systemic mastocytosis arise from mediator-related symptoms and/or organ destruction caused by malignant expansion of neoplastic mast cells and/or other myeloid cells in various organ systems.  DCC-2618 is a spectrum-selective pan KIT and PDGFRA inhibitor which blocks KIT D816V and multiple other kinase targets relevant to systemic mastocytosis.  We found that DCC-2618 inhibits the proliferation and survival of various human mast cell lines (HMC-1, ROSA, MCPV-1) as well as primary neoplastic mast cells obtained from patients with advanced systemic mastocytosis (IC50 <1 Î¼M).  Moreover, DCC-2618 decreased growth and survival of primary neoplastic eosinophils obtained from patients with systemic mastocytosis or eosinophilic leukemia, leukemic monocytes obtained from patients with chronic myelomonocytic leukemia with or without concomitant systemic mastocytosis, and blast cells obtained from patients with acute myeloid leukemia.  Furthermore, DCC-2618 was found to suppress the proliferation of endothelial cells, suggesting addnl. drug effects on systemic mastocytosis-related angiogenesis.  Finally, DCC-2618 was found to downregulate IgE-mediated histamine release from basophils and tryptase release from mast cells.  Together, DCC-2618 inhibits growth, survival and activation of multiple cell types relevant to advanced systemic mastocytosis.  Whether DCC-2618 is effective in vivo in patients with advanced systemic mastocytosis is currently under investigation in clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGYf2PuUqSe7Vg90H21EOLACvtfcHk0liYp9U0xiHkrA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFCnu78%253D&md5=7db381be140adfbbe321d97bd31f2069</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.3324%2Fhaematol.2017.179895&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3324%252Fhaematol.2017.179895%26sid%3Dliteratum%253Aachs%26aulast%3DSchneeweiss%26aufirst%3DM.%26aulast%3DPeter%26aufirst%3DB.%26aulast%3DBibi%26aufirst%3DS.%26aulast%3DEisenwort%26aufirst%3DG.%26aulast%3DSmiljkovic%26aufirst%3DD.%26aulast%3DBlatt%26aufirst%3DK.%26aulast%3DJawhar%26aufirst%3DM.%26aulast%3DBerger%26aufirst%3DD.%26aulast%3DStefanzl%26aufirst%3DG.%26aulast%3DHerndlhofer%26aufirst%3DS.%26aulast%3DGreiner%26aufirst%3DG.%26aulast%3DHoermann%26aufirst%3DG.%26aulast%3DHadzijusufovic%26aufirst%3DE.%26aulast%3DGleixner%26aufirst%3DK.%2BV.%26aulast%3DBettelheim%26aufirst%3DP.%26aulast%3DGeissler%26aufirst%3DK.%26aulast%3DSperr%26aufirst%3DW.%2BR.%26aulast%3DReiter%26aufirst%3DA.%26aulast%3DArock%26aufirst%3DM.%26aulast%3DValent%26aufirst%3DP.%26atitle%3DThe%2520KIT%2520and%2520PDGFRA%2520switch-control%2520inhibitor%2520DCC-2618%2520blocks%2520growth%2520and%2520survival%2520of%2520multiple%2520neoplastic%2520cell%2520types%2520in%2520advanced%2520mastocytosis%26jtitle%3DHaematologica%26date%3D2018%26volume%3D103%26spage%3D799%26epage%3D809%26doi%3D10.3324%2Fhaematol.2017.179895" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span> <span> </span><span class="NLM_article-title">Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I âGatekeeperâ Mutant of cKIT Kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8456</span>â <span class="NLM_lpage">8472</span>, <span class="refDoi">Â DOI: 10.1021/acs.jmedchem.6b00902</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00902" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7vK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8456-8472&author=B.+Liauthor=A.+Wangauthor=J.+Liuauthor=Z.+Qiauthor=X.+Liuauthor=K.+Yuauthor=H.+Wuauthor=C.+Chenauthor=C.+Huauthor=W.+Wangauthor=J.+Wuauthor=Z.+Huauthor=L.+Yeauthor=F.+Zouauthor=F.+Liuauthor=B.+Wangauthor=L.+Wangauthor=T.+Renauthor=S.+Zhangauthor=M.+Baiauthor=S.+Zhangauthor=J.+Liuauthor=Q.+Liu&title=Discovery+of+N-%28%281-%284-%283-%283-%28%286%2C7-Dimethoxyquinolin-3-yl%29oxy%29phenyl%29ureido%29-2-%28trifluoromethyl%29phenyl%29piperidin-4-yl%29methyl%29propionamide+%28CHMFL-KIT-8140%29+as+a+Highly+Potent+Type+II+Inhibitor+Capable+of+Inhibiting+the+T670I+%E2%80%9CGatekeeper%E2%80%9D+Mutant+of+cKIT+Kinase&doi=10.1021%2Facs.jmedchem.6b00902"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase</span></div><div class="casAuthors">Li, Binhua; Wang, Aoli; Liu, Juan; Qi, Ziping; Liu, Xiaochuan; Yu, Kailin; Wu, Hong; Chen, Cheng; Hu, Chen; Wang, Wenchao; Wu, Jiaxin; Hu, Zhenquan; Ye, Ling; Zou, Fengming; Liu, Feiyang; Wang, Beilei; Wang, Li; Ren, Tao; Zhang, Shaojuan; Bai, Mingfeng; Zhang, Shanchun; Liu, Jing; Liu, Qingsong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">8456-8472</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CKIT kinase inhibitors, e.g., imatinib could induce drug-acquired mutations such as cKIT T670I that rendered drug resistance after chronic treatment.  Through a type II kinase inhibitor design approach the authors discovered a highly potent type II cKIT kinase inhibitor compd. 35 (CHMFL-KIT-8140), which potently inhibited both cKIT wt (IC50: 33 nM) and cKIT gatekeeper T670I mutant (IC50: 99 nM).  Compd. 35 displayed strong anti-proliferative effect against GISTs cancer cell lines GIST-T1 (cKIT wt, GI50: 4 nM) and GIST-5R (cKIT T670I, GI50: 26 nM).  In the cellular context it strongly inhibited c-KIT mediated signaling pathways and induced apoptosis.  In the BaF3-TEL-cKIT-T670I isogenic cell inoculated xenograft mouse model, 35 exhibited dose dependent tumor growth suppression efficacy and 100 mg/kg dosage provided 47.7% tumor growth inhibition (TGI) without obvious toxicity.  The authors believe compd. 35 would be a good pharmacol. tool for exploration of the cKIT-T670I mutant mediated pathol. in GISTs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqj62D00P-jObVg90H21EOLACvtfcHk0lgLI39dAqvtgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xhtlyls7vK&md5=8911a8de7d377ab485504d493a0dd846</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00902&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00902%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DYu%26aufirst%3DK.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DYe%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DBai%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520N-%2528%25281-%25284-%25283-%25283-%2528%25286%252C7-Dimethoxyquinolin-3-yl%2529oxy%2529phenyl%2529ureido%2529-2-%2528trifluoromethyl%2529phenyl%2529piperidin-4-yl%2529methyl%2529propionamide%2520%2528CHMFL-KIT-8140%2529%2520as%2520a%2520Highly%2520Potent%2520Type%2520II%2520Inhibitor%2520Capable%2520of%2520Inhibiting%2520the%2520T670I%2520%25E2%2580%259CGatekeeper%25E2%2580%259D%2520Mutant%2520of%2520cKIT%2520Kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8456%26epage%3D8472%26doi%3D10.1021%2Facs.jmedchem.6b00902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1230</span>â <span class="NLM_lpage">1241</span>, <span class="refDoi">Â DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+A+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lgLI39dAqvtgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520A%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fabian, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Biggs, W. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azimioara, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benedetti, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ford, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galvin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grotzfeld, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Insko, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">LÃ©lias, J.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Velasco, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span> <span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">329</span>â <span class="NLM_lpage">336</span>, <span class="refDoi">Â DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.-M.+L%C3%A9liasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lgLI39dAqvtgA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DL%25C3%25A9lias%26aufirst%3DJ.-M.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, K. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Odell, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrnes, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baleato, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffith, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lyons, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashman, L. K.</span></span> <span> </span><span class="NLM_article-title">Resistance to c-KIT kinase inhibitors conferred by V654A mutation</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">1159</span>â <span class="NLM_lpage">1166</span>, <span class="refDoi">Â DOI: 10.1158/1535-7163.mct-06-0641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1535-7163.mct-06-0641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=17363509" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BD2sXivV2ntLg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=1159-1166&author=K.+G.+Robertsauthor=A.+F.+Odellauthor=E.+M.+Byrnesauthor=R.+M.+Baleatoauthor=R.+Griffithauthor=A.+B.+Lyonsauthor=L.+K.+Ashman&title=Resistance+to+c-KIT+kinase+inhibitors+conferred+by+V654A+mutation&doi=10.1158%2F1535-7163.mct-06-0641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Resistance to c-KIT kinase inhibitors conferred by V654A mutation</span></div><div class="casAuthors">Roberts, Kathryn G.; Odell, Adam F.; Byrnes, Ellen M.; Baleato, Rosa M.; Griffith, Renate; Lyons, Alan Bruce; Ashman, Leonie K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1159-1166</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Certain mutations within c-KIT cause constitutive activation of the receptor and have been assocd. with several human malignancies.  These include gastrointestinal stromal tumors (GIST), mastocytosis, acute myelogenous leukemia, and germ cell tumors.  The kinase inhibitor imatinib potently inhibits c-KIT and is approved for treatment of GIST.  However, secondary point mutations can develop within the kinase domain to confer resistance to imatinib and cause drug-resistant relapse.  A common mutation, which results in a V654A substitution, has been documented in imatinib-resistant GIST patients.  We expressed c-KIT cDNA constructs encoding the V654A substitution alone and in combination with a typical activating exon 11 mutation characteristic of GIST, V560G, in factor-dependent FDC-P1 cells.  The V654A substitution alone resulted in enhanced proliferation in c-KIT ligand (stem cell factor) but not factor independence.  Cells expressing the double mutant were, like those expressing single V560G mutant c-KIT, factor independent.  Anal. of cellular proliferation in the presence of imatinib showed that the V654A substitution alone conferred resistance.  The difference in sensitivity was esp. pronounced for cells expressing single mutant V560G c-KIT compared with double mutant V560G/V654A c-KIT.  The findings were supported by studies of c-KIT phosphorylation.  Anal. of the crystal structure of imatinib in complex with the kinase domain of c-KIT predicts that the V654A substitution directly affects the binding of imatinib to the receptor.  Alternative c-KIT inhibitors, nilotinib (AMN107) and PKC412, were also less active on V560G/V654A c-KIT than on the V560G single mutant; however, nilotinib, like imatinib, potently inhibited the V560G mutant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCNgmeMfhnN7Vg90H21EOLACvtfcHk0lj9OpT8yng5nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXivV2ntLg%253D&md5=fbfc887ea53992caf668f89baf70a380</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.mct-06-0641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.mct-06-0641%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DK.%2BG.%26aulast%3DOdell%26aufirst%3DA.%2BF.%26aulast%3DByrnes%26aufirst%3DE.%2BM.%26aulast%3DBaleato%26aufirst%3DR.%2BM.%26aulast%3DGriffith%26aufirst%3DR.%26aulast%3DLyons%26aufirst%3DA.%2BB.%26aulast%3DAshman%26aufirst%3DL.%2BK.%26atitle%3DResistance%2520to%2520c-KIT%2520kinase%2520inhibitors%2520conferred%2520by%2520V654A%2520mutation%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2007%26volume%3D6%26spage%3D1159%26epage%3D1166%26doi%3D10.1158%2F1535-7163.mct-06-0641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wilcken, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmermann, M. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joerger, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boeckler, F. M.</span></span> <span> </span><span class="NLM_article-title">Principles and applications of halogen bonding in medicinal chemistry and chemical biology</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">1363</span>â <span class="NLM_lpage">1388</span>, <span class="refDoi">Â DOI: 10.1021/jm3012068</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3012068" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=1363-1388&author=R.+Wilckenauthor=M.+O.+Zimmermannauthor=A.+Langeauthor=A.+C.+Joergerauthor=F.+M.+Boeckler&title=Principles+and+applications+of+halogen+bonding+in+medicinal+chemistry+and+chemical+biology&doi=10.1021%2Fjm3012068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Principles and Applications of Halogen Bonding in Medicinal Chemistry and Chemical Biology</span></div><div class="casAuthors">Wilcken, Rainer; Zimmermann, Markus O.; Lange, Andreas; Joerger, Andreas C.; Boeckler, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1363-1388</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Halogen bonding has been known in material science for decades, but until recently, halogen bonds in protein-ligand interactions were largely the result of serendipitous discovery rather than rational design.  In this Perspective, we provide insights into the phenomenon of halogen bonding, with special focus on its role in drug discovery.  We summarize the theor. background defining its strength and directionality, provide a systematic anal. of its occurrence and interaction geometries in protein-ligand complexes, and give recent examples where halogen bonding has been successfully harnessed for lead identification and optimization.  In light of these data, we discuss the potential and limitations of exploiting halogen bonds for mol. recognition and rational drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjholHfNZ9kbVg90H21EOLACvtfcHk0lj9OpT8yng5nw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhs1GrurfJ&md5=81ba024e4427fac3e7af0a4cd330909c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm3012068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3012068%26sid%3Dliteratum%253Aachs%26aulast%3DWilcken%26aufirst%3DR.%26aulast%3DZimmermann%26aufirst%3DM.%2BO.%26aulast%3DLange%26aufirst%3DA.%26aulast%3DJoerger%26aufirst%3DA.%2BC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26atitle%3DPrinciples%2520and%2520applications%2520of%2520halogen%2520bonding%2520in%2520medicinal%2520chemistry%2520and%2520chemical%2520biology%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D1363%26epage%3D1388%26doi%3D10.1021%2Fjm3012068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRÎ± kinase inhibitor for PDGFRÎ± driving chronic eosinophilic leukemia</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">366</span>â <span class="NLM_lpage">384</span>, <span class="refDoi">Â DOI: 10.1016/j.ejmech.2018.03.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1016%2Fj.ejmech.2018.03.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=29544149" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslajtrc%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2018&pages=366-384&author=Q.+Wangauthor=F.+Liuauthor=S.+Qiauthor=Z.+Qiauthor=X.-E.+Yanauthor=B.+Wangauthor=A.+Wangauthor=W.+Wangauthor=C.+Chenauthor=X.+Liuauthor=Z.+Jiangauthor=Z.+Huauthor=L.+Wangauthor=W.+Wangauthor=T.+Renauthor=S.+Zhangauthor=C.-H.+Yunauthor=Q.+Liuauthor=J.+Liu&title=Discovery+of+4-%28%28N-%282-%28dimethylamino%29ethyl%29acrylamido%29methyl%29-N-%284-methyl-3-%28%284-%28pyridin-3-yl%29pyrimidin-2-yl%29amino%29phenyl%29benzamide+%28CHMFL-PDGFR-159%29+as+a+highly+selective+type+II+PDGFR%CE%B1+kinase+inhibitor+for+PDGFR%CE%B1+driving+chronic+eosinophilic+leukemia&doi=10.1016%2Fj.ejmech.2018.03.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRÎ± kinase inhibitor for PDGFRÎ± driving chronic eosinophilic leukemia</span></div><div class="casAuthors">Wang, Qiang; Liu, Feiyang; Qi, Shuang; Qi, Ziping; Yan, Xiao-E.; Wang, Beilei; Wang, Aoli; Wang, Wei; Chen, Cheng; Liu, Xiaochuan; Jiang, Zongru; Hu, Zhenquan; Wang, Li; Wang, Wenchao; Ren, Tao; Zhang, Shanchun; Yun, Cai-Hong; Liu, Qingsong; Liu, Jing</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">366-384</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Through exploration of the non-highly conserved allosteric hydrophobic pocket generated by DFG-out shifting in the inactive conformation, we discovered a highly selective type II PDGFRÎ± kinase inhibitor 15i (CHMFL-PDGFRÎ±-159), which exhibited strong potency against purified PDGFRÎ± (IC50: 132 nM) but not structurally similar PDGFRÎ², ABL, c-KIT and VEGFR2 kinases.  In addn., it displayed a high selectivity profile (S score (10) = 0.02) at the concn. of 1 Î¼M among 468 kinases/mutants in the KINOMEscan profiling.  X-ray crystal structure of 15i in complex with PDGFRÎ± revealed a distinct binding feature in the allosteric hydrophobic pocket which might help to expand the diversity of type II kinase inhibitors.  Compd. 15i potently inhibited the proliferation of PDGFRÎ± driving Chronic Eosinophilic Leukemia (CEL) cell line EOL-1 through strong blockage of PDGFRÎ± mediated signaling pathways, arresting cell cycle progression, and induction of apoptosis.  Furthermore, compd. 15i effectively suppressed the EOL-1 tumor progression in the xenograft model and increased the survival rate in the engraftment tumor model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAbce2hA0OhLVg90H21EOLACvtfcHk0likNLXmAUP3_Q"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslajtrc%253D&md5=f256eddd3292193495c2f236e885304a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.003%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DQi%26aufirst%3DS.%26aulast%3DQi%26aufirst%3DZ.%26aulast%3DYan%26aufirst%3DX.-E.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DWang%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DZ.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DRen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%25204-%2528%2528N-%25282-%2528dimethylamino%2529ethyl%2529acrylamido%2529methyl%2529-N-%25284-methyl-3-%2528%25284-%2528pyridin-3-yl%2529pyrimidin-2-yl%2529amino%2529phenyl%2529benzamide%2520%2528CHMFL-PDGFR-159%2529%2520as%2520a%2520highly%2520selective%2520type%2520II%2520PDGFR%25CE%25B1%2520kinase%2520inhibitor%2520for%2520PDGFR%25CE%25B1%2520driving%2520chronic%2520eosinophilic%2520leukemia%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D150%26spage%3D366%26epage%3D384%26doi%3D10.1016%2Fj.ejmech.2018.03.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Abrams, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanton, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huber, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kline, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ison-Dugenny, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krauser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galimi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghoddusi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mansfield, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee-Hoeflich, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holash, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pryer, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kluwe, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ettenberg, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lees, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schleyer, S. C.</span></span> <span> </span><span class="NLM_article-title">Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">4297</span>â <span class="NLM_lpage">4308</span>, <span class="refDoi">Â DOI: 10.1158/1078-0432.ccr-17-3795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1158%2F1078-0432.ccr-17-3795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=29764854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjtFSgurg%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=4297-4308&author=T.+Abramsauthor=A.+Connorauthor=C.+Fantonauthor=S.+B.+Cohenauthor=T.+Huberauthor=E.+E.+Hongauthor=X.+Niuauthor=J.+Klineauthor=M.+Ison-Dugennyauthor=S.+Harrisauthor=D.+Walkerauthor=K.+Krauserauthor=F.+Galimiauthor=Z.+Wangauthor=M.+Ghoddusiauthor=K.+Mansfieldauthor=S.+T.+Lee-Hoeflichauthor=J.+Holashauthor=N.+Pryerauthor=W.+Kluweauthor=S.+A.+Ettenbergauthor=W.+R.+Sellersauthor=E.+Leesauthor=P.+Kwonauthor=J.+A.+Abrahamauthor=S.+C.+Schleyer&title=Preclinical+antitumor+activity+of+a+novel+anti-c-KIT+antibody-drug+conjugate+against+mutant+and+wild-type+c-KIT-positive+solid+tumors&doi=10.1158%2F1078-0432.ccr-17-3795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors</span></div><div class="casAuthors">Abrams, Tinya; Connor, Anu; Fanton, Christie; Cohen, Steven B.; Huber, Thomas; Miller, Kathy; Hong, E. Erica; Niu, Xiaohong; Kline, Janine; Ison-Dugenny, Marjorie; Harris, Sarah; Walker, Dana; Krauser, Klaus; Galimi, Francesco; Wang, Zhen; Ghoddusil, Majid; Mansfield, Keith; Lee-Hoeflich, Si Tuen; Holash, Jocelyn; Pryer, Nancy; Kluwe, William; Ettenberg, Seth A.; Sellers, William R.; Lees, Emma; Kwon, Paul; Abraham, Judith A.; Schleyer, Slew C.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">4297-4308</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: c-KIT overexpression is well recognized in cancers such as gastrointestinal stromal tumors (GIST), small cell lung cancer (SCLC), melanoma, non-small cell lung cancer (NSCLC), and acute myelogenous leukemia (AML).  Treatment with the small-mol. inhibitors imatinib, sunitinib, and regorafenib resulted in resistance (c-KIT mutant tumors) or limited activity (c-KIT wild-type tumors).  We selected an anti-c-K1T ADC approach to evaluate the anticancer activity in multiple disease models.  Exptl. Design: A humanized anti-c-KIT antibody LMJ729 was conjugated to the microtubule destabilizing maytansinoid, DM I, via a nondeavable linker (SMCC).  The activity of the resulting ADC, LOP628, was evaluated in vitro against GIST, SCLC, and AML models and in vivo against GIST and SCLC models.  Results: 10P628 exhibited potent antiproliferative activity on c-KIT-pos. cell lines, whereas LMJ729 dis- played little to no effect.  At exposures predicted to be clin. achievable, LOP628 demonstrated single admin- istration regressions or stasis in GIST and SCLC xenograft models in mice.  LOP628 also displayed superior efficacy in an imatinib-resistant GIST model.  Further, LOP628 was well tolerated in monkeys with an adequate therapeutic index several fold above efficacious exposures.  Safety findings were consistent with the pharmacodynamic effect of neutropenia due to c-KIT-directed targeting.  Addnl. toxicities were considered off-target and were consistent with DM1, such as effects in the liver and hematopoietic/ lymphatic system.  Conclusions: The predinical findings suggest that the c-KIT-directed ADC may be a promising therapeutic for the treatment of mutant and wild-type c-KIT-pos. cancers and supported the clin. evaluation of LOP628 in GIST, AML and SCLC patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUgbz5hjaoObVg90H21EOLACvtfcHk0lh1GnkpkJyu9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjtFSgurg%253D&md5=d421d5fcb4b9a18d6c53c5a90d480a66</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.ccr-17-3795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.ccr-17-3795%26sid%3Dliteratum%253Aachs%26aulast%3DAbrams%26aufirst%3DT.%26aulast%3DConnor%26aufirst%3DA.%26aulast%3DFanton%26aufirst%3DC.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DHuber%26aufirst%3DT.%26aulast%3DHong%26aufirst%3DE.%2BE.%26aulast%3DNiu%26aufirst%3DX.%26aulast%3DKline%26aufirst%3DJ.%26aulast%3DIson-Dugenny%26aufirst%3DM.%26aulast%3DHarris%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DKrauser%26aufirst%3DK.%26aulast%3DGalimi%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DGhoddusi%26aufirst%3DM.%26aulast%3DMansfield%26aufirst%3DK.%26aulast%3DLee-Hoeflich%26aufirst%3DS.%2BT.%26aulast%3DHolash%26aufirst%3DJ.%26aulast%3DPryer%26aufirst%3DN.%26aulast%3DKluwe%26aufirst%3DW.%26aulast%3DEttenberg%26aufirst%3DS.%2BA.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DLees%26aufirst%3DE.%26aulast%3DKwon%26aufirst%3DP.%26aulast%3DAbraham%26aufirst%3DJ.%2BA.%26aulast%3DSchleyer%26aufirst%3DS.%2BC.%26atitle%3DPreclinical%2520antitumor%2520activity%2520of%2520a%2520novel%2520anti-c-KIT%2520antibody-drug%2520conjugate%2520against%2520mutant%2520and%2520wild-type%2520c-KIT-positive%2520solid%2520tumors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D4297%26epage%3D4308%26doi%3D10.1158%2F1078-0432.ccr-17-3795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janeway, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lodish, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nose, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rustin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaal, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahia, P. L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liegl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ball, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raygada, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelly, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hornick, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">OâSullivan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Krijger, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dinjens, W. N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Demetri, G. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antonescu, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fletcher, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stratakis, C. A.</span></span> <span> </span><span class="NLM_article-title">Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">314</span>â <span class="NLM_lpage">318</span>, <span class="refDoi">Â DOI: 10.1073/pnas.1009199108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1073%2Fpnas.1009199108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=21173220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC3MXms1Khug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2011&pages=314-318&author=K.+A.+Janewayauthor=S.+Y.+Kimauthor=M.+Lodishauthor=V.+Noseauthor=P.+Rustinauthor=J.+Gaalauthor=P.+L.+M.+Dahiaauthor=B.+Lieglauthor=E.+R.+Ballauthor=M.+Raygadaauthor=A.+H.+Laiauthor=L.+Kellyauthor=J.+L.+Hornickauthor=M.+O%E2%80%99Sullivanauthor=R.+R.+de+Krijgerauthor=W.+N.+M.+Dinjensauthor=G.+D.+Demetriauthor=C.+R.+Antonescuauthor=J.+A.+Fletcherauthor=L.+Helmanauthor=C.+A.+Stratakis&title=Defects+in+succinate+dehydrogenase+in+gastrointestinal+stromal+tumors+lacking+KIT+and+PDGFRA+mutations&doi=10.1073%2Fpnas.1009199108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations</span></div><div class="casAuthors">Janeway, Katherine A.; Kim, Su Young; Lodish, Maya; Nose, Vania; Rustin, Pierre; Gaal, Jose; Dahia, Patricia L. M.; Liegl, Bernadette; Ball, Evan R.; Rayga, Margarita; Lai, Angela H.; Kelly, Lorna; Hornick, Jason L.; O'Sullivan, Maureen; de Krijger, Ronald R.; Dinjens, Winand N. M.; Demetri, George D.; Antonescu, Cristina R.; Fletcher, Jonathan A.; Helman, Lee; Stratakis, Constantine A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">314-318, S314/1-S314/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Carney-Stratakis syndrome, an inherited condition predisposing affected individuals to gastrointestinal stromal tumor (GIST) and paraganglioma, is caused by germline mutations in succinate dehydrogenase (SDH) subunits B, C, or D, leading to dysfunction of complex II of the electron transport chain.  We evaluated the role of defective cellular respiration in sporadic GIST lacking mutations in KIT or PDGFRA (WT).  Thirty-four patients with WT GIST without a personal or family history of paraganglioma were tested for SDH germline mutations.  WT GISTs lacking demonstrable SDH genetic inactivation were evaluated for SDHB expression by immunohistochem. and Western blotting and for complex II activity.  For comparison, SDHB expression was also detd. in KIT mutant and neurofibromatosis-1-assocd. GIST, and complex II activity was also measured in SDH-deficient paraganglioma and KIT mutant GIST; 4 of 34 patients (12%) with WT GIST without a personal or family history of paraganglioma had germline mutations in SDHB or SDHC.  WT GISTs lacking somatic mutations or deletions in SDH subunits had either complete loss of or substantial redn. in SDHB protein expression, whereas most KIT mutant GISTs had strong SDHB expression.  Complex II activity was substantially decreased in WT GISTs.  WT GISTs, particularly those in younger patients, have defects in SDH mitochondrial complex II, and in a subset of these patients, GIST seems to arise from germline-inactivating SDH mutations.  Testing for germline mutations in SDH is recommended in patients with WT GIST.  These findings highlight a potential central role of SDH dysregulation in WT GIST oncogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnKFZ6J_MtWLVg90H21EOLACvtfcHk0lh1GnkpkJyu9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXms1Khug%253D%253D&md5=596ca3d096cb80d88bb2a67cfbf080a7</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1009199108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1009199108%26sid%3Dliteratum%253Aachs%26aulast%3DJaneway%26aufirst%3DK.%2BA.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DLodish%26aufirst%3DM.%26aulast%3DNose%26aufirst%3DV.%26aulast%3DRustin%26aufirst%3DP.%26aulast%3DGaal%26aufirst%3DJ.%26aulast%3DDahia%26aufirst%3DP.%2BL.%2BM.%26aulast%3DLiegl%26aufirst%3DB.%26aulast%3DBall%26aufirst%3DE.%2BR.%26aulast%3DRaygada%26aufirst%3DM.%26aulast%3DLai%26aufirst%3DA.%2BH.%26aulast%3DKelly%26aufirst%3DL.%26aulast%3DHornick%26aufirst%3DJ.%2BL.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DM.%26aulast%3Dde%2BKrijger%26aufirst%3DR.%2BR.%26aulast%3DDinjens%26aufirst%3DW.%2BN.%2BM.%26aulast%3DDemetri%26aufirst%3DG.%2BD.%26aulast%3DAntonescu%26aufirst%3DC.%2BR.%26aulast%3DFletcher%26aufirst%3DJ.%2BA.%26aulast%3DHelman%26aufirst%3DL.%26aulast%3DStratakis%26aufirst%3DC.%2BA.%26atitle%3DDefects%2520in%2520succinate%2520dehydrogenase%2520in%2520gastrointestinal%2520stromal%2520tumors%2520lacking%2520KIT%2520and%2520PDGFRA%2520mutations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2011%26volume%3D108%26spage%3D314%26epage%3D318%26doi%3D10.1073%2Fpnas.1009199108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Janeway, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pappo, A.</span></span> <span> </span><span class="NLM_article-title">Treatment guidelines for gastrointestinal stromal tumors in children and young adults</span>. <i>J. Pediatr. Hematol./Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">S69</span>â <span class="NLM_lpage">S72</span>, <span class="refDoi">Â DOI: 10.1097/mph.0b013e31824e3899</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=10.1097%2Fmph.0b013e31824e3899" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=22525410" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVShtL7N" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2012&pages=S69-S72&author=K.+A.+Janewayauthor=A.+Pappo&title=Treatment+guidelines+for+gastrointestinal+stromal+tumors+in+children+and+young+adults&doi=10.1097%2Fmph.0b013e31824e3899"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Treatment guidelines for gastrointestinal stromal tumors in children and young adults</span></div><div class="casAuthors">Janeway, Katherine A.; Pappo, Alberto</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pediatric Hematology/Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">Suppl. 2</span>),
    <span class="NLM_cas:pages">S69-S72</span>CODEN:
                <span class="NLM_cas:coden">JPHOFG</span>;
        ISSN:<span class="NLM_cas:issn">1077-4114</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review.  Gastrointestinal stromal tumor (GIST) occurring in the pediatric population has a unique biol. and natural history when compared to GIST occurring in adults.  As a result of these unique features, management of GIST in children may need to differ from management of GIST in adults.  GIST is a very rare disease in children.  Consequently prospective clin. trials have not been performed.  A review of the biol., clin. presentation and natural history of GIST in children is presented.  Guidelines for diagnostic evaluation and management of GIST in children are presented.  The presented guidelines are based on clin. experience and data from case reports and case series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNqM5QsNCKwrVg90H21EOLACvtfcHk0lh1GnkpkJyu9w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVShtL7N&md5=7091fba633742ba310acf94095cb9bf5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1097%2Fmph.0b013e31824e3899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252Fmph.0b013e31824e3899%26sid%3Dliteratum%253Aachs%26aulast%3DJaneway%26aufirst%3DK.%2BA.%26aulast%3DPappo%26aufirst%3DA.%26atitle%3DTreatment%2520guidelines%2520for%2520gastrointestinal%2520stromal%2520tumors%2520in%2520children%2520and%2520young%2520adults%26jtitle%3DJ.%2520Pediatr.%2520Hematol.%252FOncol.%26date%3D2012%26volume%3D34%26spage%3DS69%26epage%3DS72%26doi%3D10.1097%2Fmph.0b013e31824e3899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6GQK','PDB','6GQK'); return false;">PDB: 6GQK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1T46','PDB','1T46'); return false;">PDB: 1T46</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G0E" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3G0E','PDB','3G0E'); return false;">PDB: 3G0E</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i92"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00280">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_24278"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00280">10.1021/acs.jmedchem.9b00280</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">DiscoverXâs KINOMEScan selectivity profiling data of <b>18</b>, expression and autophosphorylation inhibition of PDGFRÎ±, PDGFRÎ², and CSF1R in GIST-T1 cells, effects of selective PDGFRÎ± inhibitor CHMFL-PDGFR-159 on PDGFR-mediated signaling pathways in GIST-T1 cells and antiproliferation against GIST-T1 cells, PK profiles of <b>18</b> in mice, rats, and beagle dogs, and PD effect of <b>18</b> on tumor p-c-KIT, p-ERK, and p-AKT in the GIST-T1-T670I mouse xenograft model from a single dose of 80 mg/kg/day (p.o.) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_002.csv">CSV</a>)</p></li><li><p class="inline">Docking poses for <b>1</b>, <b>2</b>, and <b>18</b> with c-KIT wt, c-KIT V654A, and c-KIT T670I (PDB) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_003.zip">ZIP</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_001.pdf">jm9b00280_si_001.pdf (733.28 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_002.csv">jm9b00280_si_002.csv (5.56 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00280/suppl_file/jm9b00280_si_003.zip">jm9b00280_si_003.zip (0.98 MB)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00280&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-13%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00280" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00280" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66e0d744ad88a30c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
